docetaxel anhydrous has been researched along with Benign Neoplasms in 614 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 74 (12.05) | 18.2507 |
| 2000's | 182 (29.64) | 29.6817 |
| 2010's | 282 (45.93) | 24.3611 |
| 2020's | 76 (12.38) | 2.80 |
| Authors | Studies |
|---|---|
| Capuano, B; DeBono, A; Scammells, PJ | 1 |
| Dong, Y; Li, L; Liu, L; Lou, H; Sun, B; Yuan, H; Zheng, H | 1 |
| Ding, N; Gao, D; Li, Y; Ren, S; Wang, J; Wang, Y; Zhang, M | 1 |
| Abbas Bukhari, SN; Abdel-Aziz, M; Abdel-Rahman, HM; Abdelazeem, AH; El-Sherief, HAM; Youssif, BGM | 1 |
| Cai, B; Cui, CB; Li, CW; Wang, N; Xu, LL; Zhu, HJ | 1 |
| Ding, Z; Li, W; Li, Z; Ma, L; Ma, M; Wang, S; Wang, Y; Yang, J; Zhong, L | 1 |
| Anderton, M; Bailey, A; Boyd, S; Brookfield, J; Cairnduff, C; Charles, M; Cheasty, A; Critchlow, SE; Culshaw, J; Ekwuru, T; Finlay, MRV; Hollingsworth, I; Jones, N; Leroux, F; Littleson, M; McCarron, H; McKelvie, J; Mooney, L; Nissink, JWM; Perkins, D; Powell, S; Quesada, MJ; Raubo, P; Sabin, V; Smith, J; Smith, PD; Stark, A; Ting, A; Wang, P; Wilson, Z; Winter-Holt, JJ; Wood, JM; Wrigley, GL; Yu, G; Zhang, P | 1 |
| Lee, CS; Li, F; Lv, H; Wan, Y; Zhang, R | 1 |
| Al-Nemrawi, NK; Altawabeyeh, RM; Darweesh, RS | 1 |
| Gu, Y; Li, J; Li, Q; Shi, Y; Wang, D; Wang, X; Wang, Z; Xia, M; Xu, Y | 1 |
| Chang, LS; Chiou, JT; Lee, YC; Wang, LJ | 1 |
| Cao, Y; Cheng, J; He, L; Hu, Y; Liu, W; Luo, W; Ran, H; Yang, L; Ye, X; Zhang, W; Zheng, M | 1 |
| Cao, Y; Chen, Q; Li, L; Liu, S; Liu, W; Ran, H; Shang, T; Tan, M; Wang, Z; Xie, Z; Zhang, L; Zhang, W | 1 |
| Avitabile, C; Conte, C; Dal Poggetto, G; Esposito, D; Laurienzo, P; Moret, F; Quaglia, F; Reddi, E; Romanelli, A; Tiso, N; Ungaro, F | 1 |
| Fan, X; Jia, Y; Jiang, L; Liu, Y; Lv, X; Si, H; Wang, X; Wang, Z; Xia, Y; Yan, M; Yin, H | 1 |
| Adamchuk, H; Blayney, DW; Chen, M; Du, L; Ginn, G; Huang, L; Kirtbaya, DV; Mohanlal, R; Ogenstad, S; Zhang, Q | 1 |
| Chu, Q; Fang, Y; Fu, S; Gao, T; Guan, L; Liang, S; Liu, Y; Mu, W; Zhang, N; Zhang, Z | 1 |
| Dai, C; Fang, Y; Wang, L; Wu, J; You, X | 1 |
| Cao, D; Du, Q; Jia, Q; Liang, C; Ma, Z; Qi, J; Qi, X; Shen, H; Xiang, B; Xue, X; Yang, S; Zhang, H; Zhang, J; Zhao, T; Zhao, Y | 1 |
| Li, Y; Liang, M; Liu, S; Yang, W; Zhang, L; Zhao, H | 1 |
| Huang, J; Lai, W; Li, G; Wang, F; Wang, J; Xie, D; Xu, R; Zhang, R; Zhou, M | 1 |
| Farhoudi, L; Jaafari, MR; Kharrazi, S; Mashreghi, M; Mehrabian, A; Mirzavi, F; Rezayat, SM; Sadri, K; Vakili-Ghartavol, R | 1 |
| Ge, C; He, J; Lin, X; Liu, J; Lu, W; Lu, X; Qin, J; Sun, G; Tang, X; Wang, J; Yang, Y; Zhang, W; Zhang, Y; Zhao, Y | 1 |
| Li, H; Liu, T; Zhao, Y; Zheng, Y; Zhu, H; Zhu, Y | 1 |
| Daa, T; Etoh, T; Fuchino, T; Fumoto, S; Hanada, T; Hijiya, N; Hirashita, Y; Hironaka, S; Inomata, M; Kinoshita, K; Kurogi, S; Mieno, F; Mizukami, K; Moriyama, M; Murakami, K; Nakada, C; Shibata, T; Shirao, K; Suzuki, K; Takekawa, M; Tsukamoto, Y; Uchida, T; Ueda, Y; Yanagihara, K; Yano, S | 1 |
| Atrafi, F; Biancacci, I; De Lorenzi, F; Hanssen, RGJM; Hennink, WE; Hu, Q; Lammers, T; Liskamp, RMJ; Mathijssen, RHJ; Menke-van der Houven van Oordt, CW; Miedema, IHC; Rijcken, CJF; Thewissen, M; Timmers, M; van Dongen, GAMS; Vugts, DJ | 1 |
| El-Aneed, A; Haddadi, A; Khajavinia, A; Yarahmadi, M | 1 |
| Smith, ER; Wang, JQ; Xu, XX; Yang, DH | 1 |
| Chen, G; Dai, J; Huang, B; Li, Y; Liu, J; Nie, J; Ren, L; Yin, J | 1 |
| Gordon Steel, G; Tannock, IF | 1 |
| Li, M; Su, Z; Xie, J; Zhao, D; Zhao, J; Zhao, X | 1 |
| Fan, Y; Han, W; Jiang, X; Lee, MJ; Lin, W; Liu, J; Luo, T; Mao, J; Xia, J | 1 |
| Chen, Y; Luo, Y; Ou, J; Sun, Y; Wang, C; Ye, Y; Zhang, C | 1 |
| Baum, J; Charette, L; Choi, JE; Cremasco, V; Diwanji, R; Dranoff, G; Grauel, AL; Jayaraman, P; Laszewski, T; Martin, AM; Millholland, JM; Nguyen, B; O'Brien, NA; Pelletier, MR; Piquet, M; Pruteanu-Malinici, I; Rodrik-Outmezguine, V; Ruddy, DA; Sabatos-Peyton, C; Savchenko, A; Wong, CC; Wu, J; Xu, X; Yan, Z | 1 |
| Heibloem, RE; Ilozumba, OUC; Komen, MMC; van den Hurk, CJG | 1 |
| Jiang, Y; Li, X; Liu, C; Wang, J; Xing, H; Zhang, H; Zhang, Y | 1 |
| Alexis Ramírez-Coronel, A; Alsaikhan, F; Gupta, R; Hassan Jawhar, Z; Kadhim, MM; Khalimovna Mukhamedova, N; Najafi, M; Qasim Alasheqi, M; Ramaiah, P; Turki Jalil, A | 1 |
| Chariou, PL; Fabian, KP; Franks, SE; Gameiro, SR; Hamilton, DH; Hodge, JW; Kowalczyk, JT; Padget, MR; Santiago-Sanchez, GS; Schlom, J; Solocinski, K | 1 |
| Cao, P; Chen, W; Chen, X; Gong, Y; Guo, H; Wang, L; Wang, Z; Wei, C; Wu, D; Xiao, F; Xu, J; Xu, R | 1 |
| Cao, F; Fan, Y; Fang, Q; Li, D; Liu, X; Wu, D; Xu, P; Yang, X; Zhao, Z; Zhu, Y | 1 |
| Amant, FCH; Beijnen, JH; Damoiseaux, D; Dorlo, TPC; Huitema, ADR; Janssen, JM; van Calsteren, K; van Hasselt, JGC | 1 |
| Cao, X; Gao, Y; Guo, R; Li, L; Ouyang, Z; Shi, X; Yang, R; Yu, H; Zhang, Y | 1 |
| Dai, Q; Huang, R; Qi, X; Sun, F; Wang, Q; Wang, X; Wang, Y; Xia, P; Yang, J; Yang, M; Yao, P; Zhang, D; Zhang, X | 1 |
| Lee, JY; Lee, S; Park, JS; Son, HY; Tangchang, W; Tran, NP; Tran, P; Yoo, SY | 1 |
| Bakhtiary, M; Bhasin, MK; Bhasin, SS; Cheemarla, NR; Ganesan, R; Krishnan, U; Sukhatme, VP; Thomas, BE | 1 |
| Cooper, TT; Postovit, LM | 1 |
| Bae, YH; Kim, KS; Youn, YS | 1 |
| Ballestri, M; Columbaro, M; Ferroni, C; Gaio, E; Guerrini, A; Martella, E; Moret, F; Reddi, E; Varchi, G | 1 |
| Guillerm, S; Hennequin, C; Quero, L | 1 |
| Cheng, H; Huang, X; Lang, T; Li, Y; Liu, Y; Wang, G; Yin, Q; Zheng, Z | 1 |
| Amiri Kordestani, L; Bersoff-Matcha, SJ; Christopher Jones, S; Fedenko, K; Nayernama, A; Prowell, T; Singh, P | 1 |
| Beijnen, JH; de Weger, VA; Huitema, ADR; Janssen, JM; Nuijen, B; Sawicki, E; Schellens, JHM; van Hasselt, JGC; Yu, H | 1 |
| Beijnen, JH; Bergman, AM; Crombag, MBS; Dorlo, TPC; Huitema, ADR; van der Pan, E; van Erp, NP; van Straten, A | 1 |
| Chen, L; Cong, Z; Guo, L; Huai, C; Jia, L; Li, G; Li, M; Liu, Y; Ma, J; Niu, X; Qin, S; Ren, W; Shen, L; Su, K; Sun, X; Zhang, D; Zhang, S; Zhou, C; Zhou, W | 1 |
| Ang, E; Ang, S; Bandla, A; Chan, A; Chan, G; Hairom, Z; Huang, Y; Kumarakulasinghe, NB; Lee, SC; Lee, YM; Lim, JSJ; Magarajah, G; Ngoi, N; Sundar, R; Tan, S; Thakor, N; Wilder-Smith, E; Wong, A | 1 |
| Abasi, S; Ahmadi, Z; Ashrafizadeh, M; Dehghannoudeh, G; Khanbabaei, H; Mohamadi, N; Mohammadinejad, R; Tamaddondoust, RN; Thakur, VK; Zarrabi, A | 1 |
| Jang, SJ; Jo, SY; Lee, A; Lee, B; Lee, CH; Lee, SH; Mun, H; Oh, JH; Suh, YA | 1 |
| Beijers, AJM; Bonhof, CS; de Vos-Geelen, J; Jacobs, EMG; Mols, F; Ophorst, J; van de Poll-Franse, LV; Vreugdenhil, G | 1 |
| Jiang, M; Jiang, X; Jin, Z; Li, C; Li, Q; Li, X; Luo, L; Luo, Z; Qiu, W; Qiu, Y; Shen, T; You, J; Zhu, C | 1 |
| Kharkar, PB; Patravale, VB; Talkar, SS | 1 |
| Alonso-González, C; Cos, S; González, A; González-González, A; Martínez-Campa, C; Menéndez, JM; Mitola, S; Rueda, N | 1 |
| de Vries, P; Forero-Torres, A; Kulukian, A; Lee, P; Peterson, S; Rosler, R; Taylor, J; Watson, D | 1 |
| Cao, Z; Gong, YH; Jiang, ZZ; Liu, J; Shu, M; Xie, JH; Zhang, C | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Du, Q; Li, W; Li, X; Liu, S; Pan, F; Xi, X; Yang, J | 1 |
| Liang, G; Lu, J; Shen, B; Sun, N; Yang, D; Zhang, X; Zhang, Y; Zhu, H; Zhu, J | 1 |
| Goyal, AK; Misra, C; Raza, K | 1 |
| He, C; Hou, T; Liang, S; Liu, Y; Pang, X; Wang, T; Yang, R; Yu, S; Zhang, N | 1 |
| Andersen, NT; Bennedsgaard, K; Bennett, DL; Finnerup, NB; Jensen, TS; Tankisi, H; Themistocleous, AC; Ventzel, L | 1 |
| Emami, J; Hasanzadeh, F; Kazemi, M; Lavasanifar, A; Minaiyan, M; Mirian, M; Mokhtari, M | 1 |
| Ang, YLE; Chong, WQ; Goh, BC; Ho, GF; Lee, SC; Lim, JSJ; Ow, SGW; Soe, PP; Soo, RA; Sundar, R; Tai, BC; Tan, SH; Wang, L; Yong, WP | 1 |
| Becerra, CHR; Boyd, TE; Casero, RA; Conkling, PR; Fitzgerald, M; Garbo, LE; Jotte, RM; Marton, LJ; Murray Stewart, T; Richards, DA; Smith, DA; Stephenson, JJ; Vogelzang, NJ; Von Hoff, D; Wu, HH | 1 |
| Bajaj, A; Dasgupta, U; Kar, A; Komalla, V; Kumar, S; Mukhopadhyay, A; Pal, S; Sengupta, S; Sharma, H; Sharma, RD; Sharma, Y; Shyam, R; Sreekanth, V; Yadav, P | 1 |
| Beijnen, JH; de Weger, VA; Huitema, ADR; Janssen, JM; Keessen, M; Lopez-Yurda, MI; Marchetti, S; Rosing, H; Thijssen, B; Vermunt, MAC | 1 |
| Amant, FCH; Beijnen, JH; Bekkers, R; Boere, I; Dorlo, TPC; Drochytek, V; Fruscio, R; Halaska, MJ; Huitema, ADR; Janssen, JM; Ottevanger, P; Painter, RC; Schröder, CP; Van Calsteren, K; Witteveen, PO | 1 |
| Huang, J; Liu, G; Liu, J; Wu, J; Xin, P | 1 |
| De Souza, P; Dees, CE; Gangadhar, T; Kefford, R; Markman, B; Piha-Paul, SA; Schuster, S; Smith, C; Thein, KZ; Zamboni, WC | 1 |
| Casazza, G; Cheli, S; Clementi, E; Cona, MS; Dalu, D; Demurtas, S; Fasola, C; Ferrario, S; Filipazzi, V; Gambaro, A; La Verde, N; Montrasio, C; Rota, S; Tosca, N | 1 |
| Chen, H; Hao, Y; Nan, W; Song, Q; Wang, L; Zhang, Y; Zhang, Z; Zheng, C | 1 |
| Dalbah, MI; Jaddoua, SM; Khalil, HZ; Mashni, OK; Nazer, LH; Rumman, AT; Tuffaha, HW | 1 |
| Bellet, MM; Castelli, M; Costantini, C; Della-Fazia, MA; Gargaro, M; Pieroni, S; Piobbico, D; Romani, L; Sassone-Corsi, P; Servillo, G; Stincardini, C | 1 |
| Aoi, J; Aoki, M; Fujii, K; Fukushima, S; Kajihara, I; Kanekura, T; Matsushita, S; Tada, K; Yamamura, K | 1 |
| Gui, S; He, Z; Li, Z; Peng, C; Sun, J; Wang, Y; Zhang, W; Zhang, Y; Zhou, M; Zhu, J | 1 |
| Grynkiewicz, G; Gubernator, J; Hrynyk, R; Machowska, M; Rzepecki, R; Wisniewski, K; Zawilska, P | 1 |
| Cathcart-Rake, EJ; Friday, BB; Lacouture, M; Loprinzi, CL; McCue, S; O'Connor, A; Piens, J; Register, T; Smith, D; Thomé, S; Young, S; Zahrieh, D | 1 |
| Gao, J; Gao, S; Xu, M; Yao, C; Zhang, W; Zou, H | 1 |
| Banerjee, SK; Bhargavi, N; Chaudhari, D; Date, T; Ghadi, R; Jain, S; Katare, PB; Kuche, K; Malavia, N; Swami, R | 1 |
| Goebel, S; Hoelzer, D; Leovsky, C; Meyer, FB; Spangel, SB; Thierbach, R | 1 |
| Aref, AR; Ashrafizadeh, M; Daneshi, S; Hashemi, F; Hushmandi, K; Khan, H; Kumar, AP; Mirzaei, S; Saleki, H; Samarghandian, S; Sharifzadeh, SO; Soleymani, L; Zabolian, A; Zarrabi, A | 1 |
| Cathcart, N; Kitaev, V; Maleki, A; Radmanesh, M; Taheri-Ledari, R; Zhang, W | 1 |
| Choi, YW; Jang, MH; Kang, MH; Kang, MJ; Kim, CH; Kim, SR; Kwak, SS; Sung, SW; Yeom, DW; Yoon, HY | 1 |
| Du, B; Jia, S; Su, X; Wang, Y; Yan, X; Zhao, F; Zhou, J | 1 |
| Cao, Y; Dong, M; Hao, Y; Jia, Y; Peng, J; Qian, Z; Zhang, T | 1 |
| Bharadwaj, G; Lam, KS; Li, X; Li, Y; Macarenco, AC; Narayanan, A; Nhan, V; Shi, Y; Vieira, LS; Xiao, W; Yang, D; Yang, S | 1 |
| Jang, EJ; Jin Hyung, W; Kim, H; Kyu Choi, D; Kyum Kim, S; Lim, SJ; Seok Lim, J | 1 |
| Blaydorn, L; Coats, J; Farley, JH; Khemka, V; Lynch, CA; McGahey, K; Niu, J; Sangal, A; Waypa, J; Weiss, GJ | 1 |
| Andriguetti, NB; Antunes, MV; Linden, R; Perassolo, MS; Raymundo, S; Suyenaga, ES; Verza, SG | 1 |
| Friberg, LE; Karlsson, MO; Netterberg, I; Nielsen, EI | 1 |
| Avaji, PG; Jun, YJ; Lee, HJ; Lee, KE; Park, JH; Park, KS; Sohn, YS | 1 |
| Fan, L; Song, C; Tan, J; Wu, H; Yang, Q; Zhao, S | 1 |
| Boudreau, J; Edwardson, DW; Kovala, AT; Lanner, C; Mapletoft, J; Parissenti, AM | 1 |
| Hsu, CW; Huang, R; Li, S; Sakamuru, S; Xia, M; Zou, C | 1 |
| Chang, M; Fan, Y; Gu, Z; Lin, G; Shi, Y | 1 |
| Claggett, B; Fu, H; Kane, RC; Kim, DH; Pak, K; Takeuchi, M; Tian, L; Uno, H; Wei, LJ | 1 |
| Beijnen, JH; de Weger, VA; Hendrikx, JJMA; Huitema, ADR; Keessen, M; Marchetti, S; Mergui-Roelvink, M; Moes, JJ; Nuijen, B; Rosing, H; Sawicki, E; Schellens, JHM; Stuurman, FE; Thijssen, B | 1 |
| Bai, Y; Cao, Y; Chen, H; Hu, W; Yang, Q; Zhang, L | 1 |
| Leandersson, K; Mehmeti, M; Millrud, CR | 1 |
| Baldassari, F; Bergamini, CM; Bianchi, N; Galasso, M; Minotti, L; Volinia, S | 1 |
| Battogtokh, G; Chimed, G; Cho, J; Gotov, O; Jeong, TH; Kang, JH; Ko, YT | 1 |
| Bei, X; Cai, Y; Cheng, W; Hu, C; Huang, W; Jin, J; Li, H; Li, S; Lin, R; Liu, G; Liu, S; Ma, Y; Ou, Y; Pan, T; Rao, J; Wan, L; Wang, Z; Wen, X; Wu, N; Wu, W; Yan, J; Zhang, Q; Zhang, X; Zheng, P | 1 |
| Choi, E; Han, J; Jin, Z; Kim, CS; Kim, KP; Park, JO; Park, S; Zheng, S | 1 |
| Jing, Y; Ojima, I; Wang, C; Wang, X | 1 |
| Cao, QR; Chen, LQ; Cui, JH; Huang, HY; Jin, H; Lee, BJ; Li, B; Liu, Y; Zhang, XX | 1 |
| Baumann, A; Benhamida, S; Fiteni, F; Houédé, N; Lefebvre, L; Nadjafizadeh, S; Orillard, E; Paillard, MJ; Pivot, X; Roland, A; Selmani, Z; Vienot, A | 1 |
| Chorilli, M; da Silva, GH; de Lima, FT; Eloy, JO; Fernandes, MA; Trevizan, LNF | 1 |
| Boon, U; Huijbers, IJ; Jonkers, J; Linder, S; Maia, ARR; Medema, RH; Pritchard, CEJ; Song, JY; Vaarting, C; van Tellingen, O; Velds, A | 1 |
| Binger, K; Bruce, JY; Carmichael, L; Dukart, G; Eickhoff, J; Harrow, K; Heideman, J; Jeraj, R; Kolesar, J; Liang, C; Liu, G; Perlman, S; Rampurwala, M; Scarpelli, M | 1 |
| Bloomfield, A; Dircksen, C; Dorton, R; Kleindl, P; Leamon, CP; Nelson, M; Reddy, JA; Santhapuram, H; Vetzel, M; Vlahov, IR | 1 |
| Fukutomi, A; Hamauchi, S; Kawahira, M; Kawai, S; Machida, N; Onozawa, Y; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T; Yoshida, Y | 1 |
| Atrafi, F; Braal, CL; de Bruijn, P; Koolen, SLW; Mathijssen, RHJ; Rijcken, CJF; van Geijn, M | 1 |
| Bieblová, J; Hodný, Z; Mikyšková, R; Mrázková, B; Reiniš, M; Sapega, O | 1 |
| Beckford Vera, DR; Benhabbour, SR; Glatt, DM; Luft, JC; Mumper, RJ; Parrott, MC; Prabhu, SS | 1 |
| Belov, AV; Faustova, MR; Mollaev, MD; Nikolskaya, ED; Severin, ES; Sokol, MB; Tereshchenko, OG; Yabbarov, NG; Zabolotsky, AI; Zenin, VA; Zhunina, OA | 1 |
| Bavbek, S; Bonadonna, P; Caralli, M; Castells, M; Cernadas, J; Cortellini, G; Costantino, MT; Dursun, AB; Gelincik, A; Lucchini, G; Pagani, M | 1 |
| Cheng, S; Li, J; Pang, N; Qi, XR; Sun, A; Yang, Z | 1 |
| Friedman, A; Lai, X | 1 |
| Li, J; Liu, Y; Pang, N; Qi, XR; Su, H; Zhang, L | 1 |
| Cheng, Y; Tian, H; Wang, X; Xia, X; Zhang, W | 1 |
| Li, P; Liu, S; Xing, R; Zhang, E | 1 |
| Beijnen, JH; Bergman, AM; Crombag, MBS; de Vries Schultink, AHM; Huitema, ADR; Otten, HM; Schellens, JHM; van Werkhoven, E | 1 |
| Bauer, TM; Faessel, H; Faller, DV; Harvey, RD; Lockhart, AC; Nemunaitis, J; Sedarati, F; Venkatakrishnan, K; Zhou, X | 1 |
| Ohyama, K | 1 |
| Higuchi, K; Yanagawa, T | 1 |
| Savitsky, K; Yu, X | 1 |
| Chang, SF; Godec, A; Hawkins, WG; Hirbe, AC; Prudner, BC; Rathore, R; Robinson, AM; Van Tine, BA | 1 |
| Baş, E; Nazıroğlu, M | 1 |
| Hua, YM; Huang, KL; Huang, TW; Lin, KY; Loh, EW; Su, HC; Tam, KW | 1 |
| Chauhan, AS; Kumar, MJM; Kuncha, M; Nayak, VL; Sarma, AVS; Singh, MK; Sistla, R | 1 |
| Cao, J; Chi, J; Ge, R; Han, S; Liang, M; Liang, Y; Sun, Y; Xu, L | 1 |
| Fujiwara, M; Furuse, J; Goto, H; Goya, T; Hiraoka, S; Ishii, H; Saraya, T; Takizawa, H; Tamura, M; Yano, K; Yokoyama, T | 1 |
| Gordon, MS; Marshall, J; Ould-Kaci, M; Shapiro, GI; Stopfer, P; Uttenreuther-Fischer, M | 1 |
| Agarwala, S; Boelle, E; Cascinu, S; Clemens, M; Daugaard, G; Demir, G; Eniu, A; Goksel, T; Grecea, D; Guthrie, T; Jäger, E; Machiels, JP; Magherini, E; Maison-Blanche, P; Meiri, E; Nardi, M; Pinotti, G; Rottey, S; Scheulen, M; Sengeløv, L; Strumberg, D; Vermorken, JB; Volovat, C | 1 |
| Gao, W; Liu, F; Meng, TT; Qi, XR; Xiang, B | 1 |
| Bai, F; Ban, FQ; Chen, HZ; Fang, C; Guan, YY; Liu, YR; Lovell, JF; Lu, Q; Luan, X; Wang, C; Yu, DH; Zhao, M | 1 |
| Deslandes, A; Lazar, V; Massard, C; Mery-Mignard, D; Ozoux, ML; Soria, JC; Tolcher, AW | 1 |
| Choi, HG; Kim, DW; Kim, JA; Kim, JK; Kim, JO; Ku, SK; Oh, DH; Oh, YK; Park, YJ; Ramasamy, T; Seo, YG; Yeo, WH; Yong, CS | 1 |
| Hertz, DL; Krens, SD; McLeod, HL | 1 |
| Bissery, MC; Bouchard, H; Calvet, L; Combeau, C; Commerçon, A; Lavelle, F; Lejeune, P; Riou, JF; Sémiond, D; Vrignaud, P | 1 |
| Frazier, N; Ghandehari, H; Gormley, A; Larson, N | 1 |
| Chen, X; Chu, B; Long, C; Luo, F; Qian, Z; Wang, C; Wang, Y; Xie, C; Zhang, L | 1 |
| Anchisi, S; Betticher, DC; Bodenmann, S; Breitenstein, U; Bühler, V; Delmore, G; Hügli-Dayer, AM; Müller, A; Schefer, H; Trueb, RR; von Moos, R; Zimmerli-Schwab, B | 1 |
| Accolla, ML; Castelli, F; Celia, C; Ferrari, M; Fresta, M; Grattoni, A; Paolino, D; Sarpietro, MG | 1 |
| Cho, KJ; Khatun, Z; Lee, YK; Nurunnabi, M; Reeck, GR | 1 |
| Chen, W; Deng, R; Hu, L; Lei, M; Liu, J; Liu, P; Wang, X | 1 |
| Nicolaou, KC; Valiulin, RA | 1 |
| Beijnen, JH; Burgers, JA; Goey, AK; Keessen, M; Marchetti, S; Meijerman, I; Mergui-Roelvink, M; Rosing, H; Schellens, JH | 1 |
| Choi, HG; Kim, DH; Kim, DW; Kim, JH; Kim, JK; Kim, JO; Marasini, N; Oh, YK; Ramasamy, T; Seo, YG; Yong, CS | 1 |
| Gandara, DR; Groshen, S; Iqbal, S; Lenz, HJ; Newman, EM; Shibata, SI; Synold, TW | 1 |
| Kudlowitz, D; Muggia, F | 1 |
| Adjei, AA; Bowles, DW; Brahmer, JR; Davies, M; Hausman, D; Jimeno, A; Lazar, AJ; Ma, WW; Peterson, S; Rudin, CM; Senzer, N; Vo, A; Walker, L | 1 |
| Dimelow, RJ; Evans, ND; Yates, JW | 1 |
| Zhang, L; Zhang, N | 1 |
| Lopes, Gde L | 1 |
| Culine, S; Cupissol, D; Droz, JP; Fabbro, M; Gourgou, S; Pouessel, D; Romieu, G; Terret, C | 1 |
| Hadjiandreou, MM; Mitsis, GD | 1 |
| Hall, RG; Jean, GW; Shah, S; Sigler, M | 1 |
| Adams, S; Baum, J; Fitzgerald, JB; Harms, BD; Iadevaia, S; Jiao, Y; Johnson, BW; Kohli, N; Lugovskoy, AA; Nielsen, UB; Olivier, KJ; Razlog, M; Rennard, R; Rimkunas, V; Schoeberl, B; Tang, J; Xu, L | 1 |
| Cho, EK; Kang, JH; Kim, YH; Lee, KH; Min, YJ; Park, JY; Song, HS | 1 |
| Gillespie, K; McCarthy, AL; Shaban, RZ; Vick, J | 1 |
| Biondo, A; Cassier, PA; Chen, E; de Bono, JS; Minton, S; Molife, LR; Papadopoulos, KP; Patnaik, A; Siu, LL; Sullivan, DM; Tetteh, E; Tolcher, AW; Vitfell-Rasmussen, J; Yan, L; Zernhelt, AM | 1 |
| Baumgartner, S; Kunz, M; Urech, K; Weissenstein, U | 1 |
| Bloomfield, A; Dorton, R; Guan, J; Leamon, CP; Nelson, M; Reddy, JA; Vetzel, M | 1 |
| Chen, W; Deng, H; Xie, F; Xu, Q; Yu, J; Zhu, B | 1 |
| Eckhoff, L; Gaist, D; Krøigård, T; Pfeiffer, P; Qvortrup, C; Schrøder, HD; Sindrup, SH | 1 |
| Choi, M; Jon, S; Kim, D; Kim, H; Kim, S; Kim, YC; Lee, IH; Lee, J; Lee, Y; Saw, PE | 1 |
| Ke, B; Liu, T; Ma, D; Xie, MQ; Xue, W | 1 |
| Pala, N; Sanna, V; Sechi, M | 1 |
| Bowerman, CJ; Chu, KS; DeSimone, JM; Finniss, MC; Haroon, ZA; Kuijer, JL; Luft, JC; Napier, ME; Schorzman, AN; Zamboni, WC | 1 |
| Feng, LX; Li, M; Liu, YJ; Yang, SM; Zhang, N | 1 |
| Beijnen, JH; de Weger, VA; Schellens, JH | 1 |
| Gao, H; He, Q; Hu, G; Jiang, X; Zhang, Q; Zhang, S | 1 |
| Muggia, FM | 1 |
| Amant, F; Beijnen, JH; Han, S; Heyns, L; Huitema, ADR; Mhallem Gziri, M; Schellens, JHM; van Calsteren, K; van Hasselt, JGC | 1 |
| Dieras, V; Eskens, FA; Fontaine, H; Hospitel, M; Oprea, C; Tosi, D; Tresca, P; Van der Gaast, A; Van Doorn, L; Veyrat-Follet, C | 1 |
| Byagari, K; Kundu, GC; Rengan, AK; Shanavas, A; Srivastava, R | 1 |
| Aguirre, E; Benhadji, KA; Callies, S; Garcia, M; Gil-Martín, M; Llombart, A; Morales, S; Oaknin, A; Salazar, R; Wickremsinhe, ER | 1 |
| da Silva Simão, DA; de Paula Lima, ED; Souza, RS; Teixeira, AL | 1 |
| Lammertsma, AA; van der Veldt, AA | 1 |
| Bahleda, R; Capri, G; Daglish, B; Del Conte, G; Gianni, L; Hospitel, M; Oprea, C; Sessa, C; Soria, JC; Varga, A | 1 |
| Brana, I; Calles, A; Calvo, E; de Boer, CJ; LoRusso, PM; Puchalski, TA; Seetharam, S; Tabernero, J; Yee, LK; Zhong, B | 1 |
| Berveiller, P; Mir, O; Selleret, L | 1 |
| Becerra, CR; Braiteh, F; Chen, J; Chow, KH; Conkling, PR; Garbo, L; Ilaria, R; Jotte, RM; Richards, DA; Robert-Vizcarrondo, F; Smith, DA; Stephenson, J; Tai, DF; Turner, PK; Von Hoff, DD | 1 |
| Hashimoto, S; Hayashi, S; Maruoka, S; Takahashi, N | 1 |
| Allcott, K; Pettengell, R; Pfeil, AM; Schwenkglenks, M; Szabo, Z; von Minckwitz, G | 1 |
| Anderson, G; Charles, J; Gallegos, NS; Hart, J; Kousba, A; Mahalingam, D; Malik, L; Mita, AC; Nemunaitis, JJ; Rogers, JM; Sankhala, K; Sarantopoulos, J; Senzer, NN; Weitman, S | 1 |
| Antonia, S; Dees, EC; Han, H; Harvey, RD; Ismail-Khan, R; Jackson, E; Link, C; Minton, S; Neuger, T; Soliman, HH; Sullivan, DM; Vahanian, NN | 1 |
| Eppler, S; Gordon, M; Lum, BL; Redfern, CH; Trudeau, C; Xu, N | 1 |
| Joerger, M | 2 |
| Gao, H; He, Q; Jiang, X; Yang, Y; Zhang, Q | 1 |
| de Bruijn, P; de Jonge, MJ; Eskens, FA; Hamberg, P; Leonowens, C; Mathijssen, RH; Sleijfer, S; van der Biessen, D; Verweij, J | 1 |
| Eppler, S; Gordon, MS; Han, K; Lum, BL; Redfern, CH; Trudeau, C; Xu, N | 1 |
| Chen, X; Joshua, AM; Kanga, N; Saggar, JK; Tan, Q; Tannock, IF; Wang, M; Wouters, BG; Yu, M; Zhang, JY | 1 |
| Qin, S; Wang, W; Zhao, L | 1 |
| Babacan, NA; Deveci, K; Kacan, T; Sancakdar, E; Seker, A; Seker, MM; Turesin, AK; Yilmaz, A | 1 |
| Belum, VR; Capriotti, JA; Capriotti, K; Goldfarb, S; Lacouture, ME; Lessin, S; Wu, S | 1 |
| Akande, T; Bomalaski, JS; Diaz, M; Dutia, MP; Gandara, DR; Gong, IY; Kelly, K; Lara, PN; Li, T; Mahaffey, N; Pan, CX; Semrad, T; Thomson, JA; Tomlinson, BK | 1 |
| Al-Batran, SE; Burmester, M; Hinke, A; Hofheinz, RD; Hozaeel, W; Hübner, A; Koenigsmann, M; Kuhl, R; Linsse, B; Pauligk, C; Tauchert, FK; Wiegand, J; Windemuth-Kieselbach, C; Zur Hausen, G | 1 |
| Moawad, EY | 1 |
| Albert, DH; Belmont, LD; Boghaert, ER; Chen, J; Diaz, D; Elmore, SW; Fairbrother, WJ; Huang, DC; Jin, S; Kovar, P; La, N; Leverson, JD; Lowes, KN; Ma, XM; Magoc, TJ; Mitten, MJ; Nimmer, P; Oleksijew, A; Phillips, DC; Rosenberg, SH; Sampath, D; Smith, M; Souers, AJ; Tahir, SK; Tao, ZF; Tarrant, JM; Tse, C; Vaidya, KS; Wang, L; Wendt, MD; Xiao, Y; Xue, J; Zhang, H | 1 |
| Bookman, M; Cohen, RB; Knoblauch, R; Li, J; Meropol, NJ; Parekh, T; Sherman, E; von Mehren, M; Weiner, LM | 1 |
| Cui, J; Cui, Q; Li, S; Meng, Q; Zhang, X; Zhou, W | 1 |
| Huang, L; Liu, D; Liu, G; Liu, Y; Mei, L; Tao, W; Yu, Q; Zeng, X; Zhang, J; Zhu, X | 1 |
| Jeengar, MK; Khan, W; Naidu, VG; Singh, I; Sistla, R; Swami, R | 1 |
| de Graan, AJ; de Morrée, ES; de Wit, R; Mathijssen, RH; Nieuweboer, AJ; Sparreboom, A | 1 |
| Chafeeva, I; Khan, MK; Kizhakkedathu, JN; Lum, CM; Misri, R; Rustum, Y; Shenoi, RA; Toth, K; Wong, NK | 1 |
| Huang, Z; Liu, P; Qian, J; Shu, Y; Wu, Y; Zhou, X; Zhu, W | 1 |
| Cartot-Cotton, S; Mazuir, F; Thai, HT; Veyrat-Follet, C | 1 |
| Bertrand, N; Choi, WI; Farokhzad, OC; MacLean, JL; Mulvale, M; Shah, V; Shi, J; Wu, J; Xu, X; Yameen, B; Zhao, L | 1 |
| de Bruijn, P; de Graan, AJ; de Jonge, E; Mathijssen, RH; Sparreboom, A; van der Holt, B; van Schaik, RH; Verweij, J; Wiemer, EA | 1 |
| Logie, J; McLaughlin, CK; Shoichet, MS; Tam, RY | 1 |
| Aneja, R; Knudsen, BS; Kucuk, O; Ogden, A; Rida, PC | 1 |
| Fujita, K; Ishida, H; Kaneta, T; Kawara, K; Kusuhara, H; Maeda, K; Sasaki, Y; Sugiyama, Y; Yokoyama, T; Yoshino, E | 1 |
| Balakrishnan, P; Cho, HJ; Jahn, A; Song, CK | 1 |
| Chen, K; Gong, H; Guo, J; Han, S; Li, X; Wei, Y; Zhang, D; Zhang, J | 1 |
| Balis, FM; Chen, CC; Cole, D; Fox, E; Pastakia, D; Widemann, BC; Yang, SX | 1 |
| Ajani, JA; Assadourian, S; Bahleda, R; Baker, J; Boelle, E; Deutsch, E; Gadgeel, SM; Garris, JL; Izzedine, H; Khan, A; Massard, C; Rogers, JE; Soria, JC | 1 |
| Cai, Y; Chen, M; Fang, X; He, C; Li, P; Wang, Y; Xiao, F | 1 |
| Hu, Y; Qin, F; Shou, D; Xu, B; Xu, J; Xu, Y | 1 |
| Xianwei, M | 1 |
| Chen, Z; Lu, T; Shi, J; Wang, B; Wang, L; Zhang, Z | 1 |
| Chu, M; Mu, X; Shi, W; Song, Q; Xu, S; Yang, K; Yuan, Y; Zhang, Z; Zhao, S | 1 |
| Amin, M; Hille, D; Krishnamurthi, SS; Lockhart, AC; LoRusso, PM; Lunceford, J; Mauro, D; Minton, SE; Pickett, CA; Stein, MN; Trull, L; Wang-Gillam, A | 1 |
| Guo, Y; Luan, Y; Wang, K; Zhang, P; Zhao, Q | 1 |
| Lee, S; Lichtenthal, B; Ojima, I; Wang, C; Wang, X | 1 |
| Chan, D; Chuah, B; Goh, BC; Lee, SC; Soe, MY; Soo, RA; Syn, NL; Tan, SH; Wang, L; Wong, AL; Yong, WP | 1 |
| Breed, WP; Goey, SH; Komen, MM; Nortier, JW; Smorenburg, CH; van den Hurk, CJ; van der Hoeven, JJ; van der Ploeg, T | 1 |
| Arai, Y; Dmuchowski, C; Fakhoury, A; Infante, JR; Krivoshik, A; LoRusso, P; Luke, JJ; Schuster, R; Shapiro, GI; Yamazaki, T | 1 |
| Burris, HA; Hart, LL; LoRusso, PM; Low, SC; Mita, AC; Mita, MM; Parsons, DM; Ramanathan, RK; Sachdev, JC; Summa, JM; Von Hoff, DD; Weiss, GJ; Youssoufian, H; Zale, SE | 1 |
| Hamada, H; Kasai, T; Mandai, T; Masuda, J; Mikuni, K; Mizutani, A; Murakami, H; Salomon, DS; Seno, M; Seno, Y; Shigehiro, T; Vaidyanath, A; Zhai, W | 1 |
| Chen, XX; Gao, F; Qu, XX; Tian, XC; Wang, D; Wen, G; Zhou, XL | 1 |
| Kanwar, JR; Kanwar, RK; Roy, K; Singh, N | 1 |
| Chen, G; Li, Q; Liu, Y; Ma, H; Wang, T | 1 |
| Huang, Y; Li, L; Sun, W; Zhang, Z | 1 |
| Amadori, D; Bianchini, E; Casadei Gardini, A; Frassineti, GL; Gallani, ML; Masini, C; Maugeri, A; Menozzi, S; Minguzzi, M; Nanni, O; Palazzini, S; Restuccia, S; Scarpi, E; Tenti, E; Valgiusti, M | 1 |
| Kirk, TB; Ma, D; Wang, C; Wu, JP; Xu, J; Xue, W; Zheng, Q; Zhou, X | 1 |
| Graff, JN; Hahn, NM; Higano, CS; Leonard, EJ; Sarantopoulos, J; Taylor, MH; Venkatakrishnan, K; Zhang, B; Zhou, X | 1 |
| Almouzni, G; Cottu, P; Gentien, D; Gurard-Levin, ZA; Marangoni, E; Pancaldi, V; Pommier, Y; Postel-Vinay, S; Reyes, C; Sousa, FG; Valencia, A; Wilson, LO | 1 |
| Fang, X; Ren, X; Sha, X; Wang, X; Zhang, X; Zhong, W | 1 |
| Cui, H; Fu, R; Hu, M; Li, C; Li, M; Li, X; Li, Z; Lu, L; Luo, M; Sheng, F; Shi, S; Wu, G; Xiang, M; Xu, J; Zhang, Q; Zhou, M | 1 |
| Hong, SS; Kim, CW; Kim, SJ; Lee, JS; Oh, ET; Park, HJ | 1 |
| Cun, X; Gao, H; He, Q; Hu, C; Hu, G; Kuang, Q; Ruan, S; Shi, K; Wang, Y; Xiao, W | 1 |
| Adams, J; Chang, EH; Leung, PK; Nemunaitis, J; Nunan, R; Pirollo, KF | 1 |
| Chekerov, R; Darvin, ME; Eucker, J; Fuss, H; Jung, S; Kühnhardt, D; Lademann, J; Lee, BN; Patzelt, A; Sehouli, J; Yu, RX | 1 |
| Arnold, RD; Cummings, BS; Glenn, TC; Kolli, RT; Moore, M; Scholpa, NE | 1 |
| Chen, S; Chowbay, B; Khor, CC; Lam, S; Sutiman, N; Yu, Y; Zhang, CZ | 1 |
| Li, Y; Zhai, GX; Zhang, H | 1 |
| Choi, EK; Chung, HK; Jeong, SY; Jung, J; Jung, KH; Kim, KP; Lee, JS; Lee, SW; Park, J; Seo, MH; Song, SY | 1 |
| Biswas, A; Ghosh, S; Jana, B; Mohapatra, S; Mondal, P; Saha, A | 1 |
| Guan, Q; Ji, D; Sun, C; Sun, D; Wang, M; Yang, W; Zhang, G | 1 |
| Chytil, P; Etrych, T; Lidický, O; Říhová, B; Šírová, M; Strohalm, J; Tomala, J | 1 |
| Adena, SK; Mishra, B; Mittal, P; Vardhan, H | 1 |
| Huang, Y; Li, L; Wu, L; Yang, Q; Zhou, Z | 1 |
| Aldonza, MB; Hong, JY; Lee, SK | 1 |
| McKeage, K | 1 |
| Capek, I | 1 |
| Arya, N; Burris, HA; Fleming, RA; Gadgeel, S; Jones, SF; Koch, KM; Loftiss, J; LoRusso, PM; Pandite, L; Weber, BL | 1 |
| Strother, RM; Sweeney, C | 1 |
| Bukowski, RM; Dreicer, R; Elson, P; Mekhail, T; Olencki, T; Roman, S; Tamaskar, I | 1 |
| Alonso, MJ; Domínguez, F; Lozano, MV; Torrecilla, D; Torres, D; Vidal, A | 1 |
| Chew, L; Chuen, VS | 1 |
| Biganzoli, L; Di Leo, A; Licitra, S; Moretti, E; Pestrin, M; Zafarana, E | 1 |
| Bako, J; Bokar, JA; Brell, JM; Cooney, MM; Dowlati, A; Gibbons, J; Horvath, N; Krishnamurthi, S; Nock, C; Remick, SC; Sanborn, SL | 1 |
| Fujii, H; Igarashi, T; Itoh, K; Kawada, K; Minami, H; Ozawa, K; Saeki, T; Sasaki, Y; Sato, H; Tahara, M | 1 |
| Aapro, MS; Ajani, J; Baker, J; Martin, M; Scotté, F; von Minckwitz, G; Winther, D | 1 |
| Chen, L; Huang, X; Liu, P | 1 |
| Anitha, P; Feng, SS; Gan, CW; Mei, L; Zhou, W | 1 |
| Aoun, N; Baz, W; Burton, J; El-Soueidi, R; Forte, F; Lowry, J; Nakhl, F | 1 |
| Elson, P; Peereboom, D; Thomas Budd, G; Weiss, P; Wesolowski, R | 1 |
| Lee, LJ; Lee, RJ; Li, H; Mao, W; Piao, L; Wu, J; Xiang, G; Yu, B; Zhai, G | 1 |
| Huang, L; Mei, L; Song, C; Sun, H; Tang, L; Yan, F; Zhang, C; Zheng, Y | 1 |
| Beijnen, JH; Huitema, A; Jansen, RS; Keessen, M; Oostendorp, RL; Rosing, H; Schellens, JH; Ter Heine, R | 1 |
| Anderson, AR; Ayati, BP; Ciobanu, M; Claridge, J; Gerlee, P; Graham, JM; Hinow, P; Loveless, M; McCawley, LJ; Quaranta, V; Swanson, KR; Wang, S | 1 |
| Anderes, K; Arango, ME; Buckman, D; Chen, E; Christensen, JG; Hallin, J; Hallin, M; Kuszpit, K; Painter, CL; Qiu, M; Sun, G; Wong, A; Yan, Z; Zasadny, K; Zhang, C; Zhang, Q | 1 |
| Gillis, A; Leyssens, B; Lobelle, JP; Mombaerts, I; Paridaens, R; Wildiers, H | 1 |
| Chiuri, VE; Lorusso, V; Silvestris, N; Tinelli, A | 1 |
| Friberg, LE; Hansson, EK; Karlsson, MO; Lindman, H; Sandström, M; Wallin, JE | 1 |
| Aono, H; Hirazawa, H; Horiuchi, A; Kawachi, K; Maehara, T; Nakagawa, H; Naohara, T; Sato, K; Sato, M; Sugishita, H; Watanabe, Y; Yamamoto, Y; Yoshida, M; Yukumi, S | 1 |
| Fridley, BL; Jenkins, GD; Kalari, KR; Li, L; Lingle, W; Lou, Z; Pei, H; Petersen, G; Wang, L | 1 |
| Alamara, C; Chatzidarellis, E; Georgiadis, E; Giza, L; Makrilia, N; Syrigos, KN | 1 |
| Halldén, G | 1 |
| Amarantidis, K; Chatzaki, E; Chelis, L; Chiotis, A; Kakolyris, S; Karakitsos, P; Kortsaris, A; Polychronidis, A; Tentes, A; Xenidis, N | 1 |
| Chen, ZD; Pan, YY; Zhang, MJ | 1 |
| Bazan, F; Dixit, VM; Dornan, D; Eastham-Anderson, J; Ferrando, R; French, DM; Huang, DC; Huang, X; Lill, JR; Liu, J; Maecker, H; O'Rourke, K; Schwickart, M; Yue, P | 1 |
| Abacioglu, U; Basaran, G; Cabuk, D; Ceyhan, B; Dane, F; Eroglu, BT; Gumus, M; Kefeli, U; Turhal, NS; Yumuk, PF | 1 |
| Chao, R; Harper, K; Huang, X; Ilagan, J; Liu, G; Robert, F; Sandler, A; Schiller, JH; Traynor, AM; Tye, L; Verkh, L | 1 |
| Ackler, S; Bouska, J; Ellis, P; Foster, K; Frost, D; Hickson, J; Klaubert, D; Oleksijew, A; Rodriguez, L; Schlessinger, S; Wang, B | 1 |
| Blackburn, WH; Dickerson, EB; Kapa, LB; Lyon, LA; McDonald, JF; Smith, MH | 1 |
| Dyck, J; Huizing, MT; Rasschaert, M; Schrijvers, D; Specenier, P; Van den Brande, J; Vermorken, JB | 1 |
| Aparicio, A; El-Khoueiry, A; Garcia, AA; Gitlitz, BJ; Groshen, S; Iqbal, S; Lenz, HJ; Pinski, J; Quinn, DI; Tsao-Wei, DD | 1 |
| Twelves, C; Woodward, EJ | 1 |
| Davis, TH; Dragnev, KH; Hardin, SB; Pipas, JM; Rigas, JR | 1 |
| Gerritsen, WR; Hendrikse, NH; Lammertsma, AA; Lubberink, M; Mooijer, MP; Rijnders, AY; Smit, EF; van der Hoeven, JJ; van der Veldt, AA; Windhorst, AD | 1 |
| Adams, LM; Bauman, J; Dandamudi, UB; Gartner, E; Hohl, R; Johnson, B; Lewis, LD; Morris, S; Murray, S; Webb, RT | 1 |
| Brumnik, T; Czejka, M; Farkouh, A; Greil, R; Kienesberger, K; Schierholz, J; Schnait, H; Ulsperger, E | 1 |
| Beijnen, JH; Huitema, AD; Koolen, SL; Oostendorp, RL; Schellens, JH | 1 |
| Ahmad, A; Azmi, AS; Banerjee, S; Kong, D; Li, Y; Sarkar, FH; Wang, Z | 1 |
| Arkenau, HT; de Bono, JS; Demers, L; Fong, PC; Gualberto, A; Karavasilis, V; Leitzel, K; Lipton, A; Molife, LR; Olmos, D; Paccagnella, L; Postel-Vinay, S; Reid, AH; Shaw, HM; Spicer, J; Vidal, L; Yap, TA; Yin, D | 1 |
| Baker, LH; Chenevert, T; Chugh, R; Karantza, V; Mehnert, J; Moss, RA; Poplin, EA; Saraiya, B; Savkina, N; Stein, MN | 1 |
| Djeu, JY; Gilvary, DL; Kodumudi, KN; Sahakian, E; Wei, S; Woan, K | 1 |
| Feng, SS; Li, K; Liu, B; Liu, Y | 1 |
| Coffey, MC; Cohn, DE; Comins, C; Harrington, KJ; Melcher, A; Mettinger, KL; Nuovo, G; Pandha, HS; Phelps, M; Protheroe, A; Roulstone, V; Spicer, J; Twigger, K; Vile, R; White, CM | 1 |
| Guo, F; Khamly, K; Michael, M; Olszanski, AJ; Pierce, KJ; Vlahovic, G | 1 |
| Gwoździński, K; Koceva-Chyła, A; Matczak, K; Tabaczar, S | 1 |
| Azrak, RG; Rempinski, DR; Rustum, YM; Saifo, MS | 1 |
| Huang, XE; Jiang, Y; Li, Y; Xiang, J; Yan, PW | 1 |
| Friberg, LE; Karlsson, MO; Quartino, AL | 1 |
| Nagykálnai, T | 1 |
| Wang, J; Wang, X; Zhang, Q; Zhang, X; Zhang, Y | 1 |
| Beck, SL; Cohen, JA; Lavoie Smith, EM; Pett, MA | 1 |
| Bicknell, R; Cotton, G; Dyer, H; Harrison, T; Hirst, DG; Hookham, M; James, I; McCallum, L; McCarthy, HO; McClelland, K; McGregor, J; McKeen, H; O'Rourke, M; Roberts, J; Robson, T; Valentine, A; Waugh, DJ; Worthington, J; Yakkundi, A | 1 |
| Bender, L; Chanel-Vos, C; Escuin, D; Fanucchi, MP; Gal, A; Giannakakou, P; Harvey, RD; Kauh, J; Khuri, FR; Kutner, M; Marcus, A; Pan, L; Ramalingam, SS; Saba, N; Shin, DM | 1 |
| Kip, K; Overcash, J; Tofthagen, C | 1 |
| Fanti, PA; Misciali, C; Miteva, M; Romanelli, P; Tosti, A; Vincenzi, C | 1 |
| Battista, A; Beuselinck, B; Brega, N; Courtney, R; de Jonge, MJ; Dumez, H; Kitzen, JJ; Schöffski, P; Verweij, J | 1 |
| Cetnar, J; Eickhoff, J; Liu, G; LoConte, NK; McFarland, TA; McNeel, D; Wilding, G | 1 |
| Juan, Z; Liu, C; Liu, D; Liu, Z; Wang, L; Zhang, N | 1 |
| Binder, D; Hübner, RH; Schlattmann, P; Temmesfeld-Wollbrück, B | 1 |
| Ducros, C; Montana, M; Rathelot, P; Terme, T; Vanelle, P; Verhaeghe, P | 1 |
| Chen, C; Huang, XX; Ren, Y; Wang, H; Xu, Q; Yu, SQ; Zhou, CL; Zhu, YY | 1 |
| Bartal, A; Liszkay, G; Mátrai, Z; Szûcs, A | 1 |
| Collins, B; Hwang, J; Malik, SM; Marshall, J; Pishvaian, M; Ramzi, P | 1 |
| Gao, X; Ling, Y; Luo, Y; Wei, K; Zhong, S | 1 |
| Cho, HJ; Kim, DD; Kim, K; Ko, SH; Koo, H; Kwon, IC; Lee, JH; Shim, JS; Yoon, HY | 1 |
| Daga, H; Hida, T; Horio, Y; Ishikawa, S; Kobayashi, K; Shimizu, J; Takeda, K; Tokunaga, S | 1 |
| Honda, K; Imaishi, H; Kamura, T; Takemoto, S; Terada, A; Ushijima, K; Wada, H | 1 |
| Kim, JK; Kim, YH; Lim, KS; Won, YW | 1 |
| Beijnen, JH; Hendrikx, JJ; Hillebrand, MJ; Rosing, H; Schellens, JH; Schinkel, AH; Thijssen, B | 1 |
| Charles, KA; Chua, W; Clarke, SJ | 1 |
| Ernsting, MJ; Li, SD; MacCallum, N; Tang, WL | 1 |
| Ernsting, MJ; Li, SD; MacCallum, NW; Tang, WL | 1 |
| Goto, N; Kayano, Y; Konno, A; Masada, M; Nakamura, T; Ohnaka, H; Tsukamoto, H; Watanabe, K; Yano, R | 1 |
| Curley, T; DeLaCruz, A; Egorin, MJ; Heller, G; Ivy, SP; Iyer, G; Larson, SM; Morris, MJ; Rathkopf, D; Rosen, N; Scher, HI; Schwartz, LH; Slovin, SF; Solit, DB; Steers, M; Ye, Q | 1 |
| Cho, SH; Jeong, SY; Kim, K; Koo, AN; Kwon, IC; Lee, HJ; Lee, SC; Lee, SU; Min, KH | 1 |
| Haanpää, ML; Haapasalo, HK; Hietaharju, AJ; Kautio, AL; Kellokumpu-Lehtinen, PL; Koskinen, MJ; Saarto, T | 1 |
| Bessonov, AA; Dashian, GA; Kolar'kova, VV; Paltuev, RM; Pen'kov, KD; Remizov, AS; Semiglazov, VF; Semiglazov, VV; Semiglazova, TIu; Vasil'ev, AG | 1 |
| Assadourian, S; Falandry, C; Favier, L; Freyer, G; Fumoleau, P; Isambert, N; Soussan-Lazard, K; Trillet-Lenoir, V; You, B; Zanetta, S; Ziti-Ljajic, S | 2 |
| Awada, A; Bartholomeus, S; Brendel, E; Christensen, O; de Valeriola, D; Delaunoit, T; Gil, T; Hendlisz, A; Lathia, CD; Lebrun, F; Piccart-Gebhart, M; Radtke, M | 1 |
| Hassali, MA; Hassan, BA; Othman, SB; Yusoff, ZB | 1 |
| Ernsting, MJ; Foltz, WD; Li, SD; Tagami, T; Undzys, E | 1 |
| Koroleva, IA; Mochalova, AS | 1 |
| Chuang, JC; Huang, CF; Liao, FT; Liu, WS; Sheu, GT; Tseng, MH; Wang, PC; Wu, MF | 1 |
| Astruc, D; Zhao, P | 1 |
| Breed, WP; Nortier, JW; van den Hurk, CJ | 1 |
| Baker, SD; de Graan, AJ; Friberg, LE; Loos, WJ; Mathijssen, RH; van der Bol, JM; van der Holt, B; van Doorn, L; Verweij, J; Wiemer, EA | 1 |
| Baker, SD; Bruun, GH; Corydon, TJ; de Bruijn, P; de Graan, AJ; Du, G; Elens, L; Friberg, LE; Gibson, AA; Hagenbuch, B; Hu, S; Lancaster, CS; Loos, WJ; Mathijssen, RH; Mikkelsen, TS; Obaidat, A; Sparreboom, A; van Schaik, RH; Walker, AL | 1 |
| Ahn, S; Chen, J; Costello, TA; Dalton, JT; Dalton, MN; Li, CM; Li, W; Lu, Y; Miller, DD; Narayanan, R; Snyder, LM | 1 |
| Ding, J; Feng, SS; Liu, X; Mi, Y; Zhao, J | 1 |
| Agur, Z; Amir, O; Ariad, S; Ben-Av, R; Chan, S; Inbar, O; Kleiman, M; Mermershtain, W; Mukherjee, A; Vainas, O; Vainstein, V | 1 |
| McBride, D | 1 |
| Asano, K; Ito, Y; Kim, S; Matsukawa, N; Yamamoto, K; Yamatodani, A | 1 |
| Aman, A; Ernsting, MJ; Li, SD; Murakami, M; Press, B; Undzys, E | 1 |
| Chen, Y; Cohen, RB; Herbst, RS; Kim, S; Kozloff, MF; Martin, LP; Olszanski, AJ; Rado, T; Rosbrook, B; Samuel, TA; Starr, A; Tarazi, J; Tortorici, M | 1 |
| Chen, C; Hou, L; Li, L; Li, Z; Shi, J; Wang, H; Wang, L; Wang, Z; Zhang, C; Zhang, H; Zhang, Z | 1 |
| Alonso, MJ; Brea, J; Esteban, H; Loza, MI; Lozano, MV; Torres, D | 1 |
| Gu, Y; Jameson, MB; McKeage, MJ; Melink, TJ; Rajendran, J; Ramanathan, RK; Tchekmedyian, NS; Wilson, WR | 1 |
| Kim, JY; Kim, K; Kim, SY; Koo, EJ; Kwon, IC; Lee, EH; Lee, H; Oh, KS; Park, JH; Yuk, SH | 1 |
| Awada, AH; Besse-Hammer, T; Dumez, H; Fleischer, F; Hendlisz, A; Piccart, M; Schöffski, P; Stopfer, P; Uttenreuther-Fischer, M; Wolter, P | 1 |
| Fraga, J; Gallo, E; García-Diez, A; Llamas-Velasco, M; Navarro, R | 1 |
| Berveiller, P; Broutin, S; Camps, S; Deroussent, A; Gil, S; Mir, O; Paci, A; Seck, A; Tréluyer, JM; Vinot, C | 1 |
| Bies, RR; Egorin, MJ; Jiang, C; Kroetz, DL; Lewis, LD; Markova, S; McLeod, HL; Miller, AA; Owzar, K; Ratain, MJ | 1 |
| Chiorean, EG; Dipaola, RS; Jung, DT; Kroll, S; Kurtoglu, M; Lampidis, TJ; Langmuir, VK; Papadopoulos, K; Raez, LE; Ricart, AD; Rocha Lima, CM; Rosenblatt, J; Schlesselman, JJ; Stein, MN; Tolba, K | 1 |
| Tkaczuk, KH; Yared, JA | 1 |
| Cotarla, I; Deeken, JF; He, AR; Hwang, J; Lewandowski, K; Marshall, JL; Pishvaian, MJ; Rahman, A; Ramanathan, RK; Slack, R; Subramaniam, D; Weiss, GJ | 1 |
| Chen, Y; He, G; He, J; He, Y; He, Z; Song, X; Xie, Y; Xu, B; Yang, Y; Yu, Y; Zhang, Y; Zheng, Y | 1 |
| Bocklitz, T; Bräutigam, K; Popp, J; Rösch, P; Schmitt, M | 1 |
| Cai, L; Deng, J; Gong, P; Liu, P; Ma, Y; Yi, H; Zhang, P; Zhang, Y; Zheng, C; Zheng, M | 1 |
| Hong, WK | 1 |
| Fife, K; Ganjoo, KN; Gordon, MS; Loehrer, PJ; Poirier, S; Sandler, AB; Seshadri, R; Warner, RE | 1 |
| Tsukuda, M | 1 |
| de Boeck, G; de Bruijn, E; de Jonge, MJ; Dumez, H; Guetens, G; Highley, M; Louwerens, M; Mantel, M; Pawinsky, A; Planting, AS; Van Oosterom, AT; Verweij, J | 1 |
| Agelaki, S; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kotsakis, A; Kouroussis, C; Mavroudis, D; Samonis, G; Souglakos, J; Vlachonikolis, J | 1 |
| Ashley, DM; Baum, CM; Caruso, DA; Koina, C; Radcliff, FJ; Riordan, MJ; Roberts, AW; Tang, ML; Woulfe, SL | 1 |
| Ackland, S; Hall, K; Levi, J; Lewis, C; Marx, G | 1 |
| Ackland, SP; Clarke, S; Garg, MB; Millward, MJ; Rischin, D; Smith, J; Toner, GC; Zalcberg, J | 1 |
| Budd, GT; Bukowski, RM; Elson, P; Hutson, TE; Mekhail, T; Olencki, T; Peereboom, D; Pelley, R; Srkalovic, G | 1 |
| Colowick, AB; Fleishman, A; Glaspy, JA; Jadeja, JS; Justice, G; Rossi, G | 1 |
| Baick, CH; Chiou, JY; Fruehauf, JP; Mehta, RS; Nalcioglu, O; Su, MY; Wang, J; Yu, H | 1 |
| Brockstein, BE; Mani, S; Masters, GA; Ratain, MJ | 1 |
| Appia, F; Basser, R; Cebon, J; Chipman, M; Davis, ID; Green, M; Grigg, A; Mitchell, PL; Ng, S; Zalcberg, J | 1 |
| Duncan, MW; Eckhardt, SG; Gustafson, DL; Holden, SN; Long, ME; Pierson, AS; Zirrolli, JA | 1 |
| Choy, H; Saha, D | 1 |
| Booser, DJ; Cristofanilli, M; David, CL; Esparza-Guerra, LT; Hortobagyi, GN; Ibrahim, N; Murray, JL; Patel, S; Rahman, Z; Trent, JC; Valero, V; Vernillet, L | 1 |
| Arquette, MA; Fears, CL; Fracasso, PM; Goodner, SA; Govindan, R; Herzog, TJ; Picus, J; Rader, JS; Rodriguez, LC; Tan, BR | 1 |
| Behrns, K; Bernard, SA; Calvo, B; Cance, W; Churchel, MA; Detterbeck, FC; Koruda, M; Ollila, D; Poole, ME; Weissler, MC | 1 |
| Markman, M | 1 |
| Brenton, JD; Caldas, C | 1 |
| Fu, LN; Gao, Y; Guo, XL; Lin, GJ; Qian, LP; Wang, JJ; Xu, Q; Xu, SR; Zhao, H | 1 |
| Herbst, RS; Khuri, FR | 1 |
| Baker, SD; Boonstra, JG; Loos, WJ; Sparreboom, A; Verweij, J | 1 |
| Blair, EY; Clarke, SJ; McLachlan, AJ; Rivory, LP; Slaviero, KA | 1 |
| Baker, SD; Brahmer, JR; Carducci, MA; Lee, CK; Sparreboom, A; Verweij, J; Wolff, AC; Zabelina, Y; Zhao, M | 1 |
| Chodkiewicz, C; Downey, A; Hamilton, A; Hochster, H; Liebes, L; Muggia, F; Pavlick, AC; Phillips, Z; Sorich, J; Speyer, J; Wasserheit, C | 1 |
| Azéma, J; Busi, F; Chatelut, E; Chevreau, C; Cresteil, T; Dalenc, F; Hennebelle, I; Lafont, T; Poublanc, M; Puisset, F; Roché, H | 1 |
| Glisson, BS; Lee, JS; Palmer, JL; Shin, DM; Tsao, AS | 1 |
| Gligorov, J; Lotz, JP | 1 |
| Ayers, D; Chi, KN; Chia, S; Cripps, C; Fry, D; Gelmon, KA; Huan, S; Janke, S; McIntosh, L; Seymour, LK; Shabbits, JA; Stewart, D; Walsh, W | 1 |
| Ang, KK; Fan, Z; Hunter, N; Mason, K; Milas, L; Nakata, E | 1 |
| Argiris, A; Kut, V; Patel, JD | 1 |
| Bouker, KB; Chen, H; Figueira, M; Frankel, SR; Hayes, DF; Ling, Y; Lippman, M; Marshall, J; Yang, D | 1 |
| Garrison, M; Jones, CB; McCreery, H; Patnaik, A; Rowinsky, EK; Schwartz, GH; Skinner, M; Takimoto, C; Tolcher, AW | 1 |
| Beijnen, JH; Bosch, TM; Fitzpatrick, A; Kuppens, IE; Rosing, H; Schellens, JH; van Maanen, MJ | 1 |
| Devries, A; Haidenberger, A; Lukas, P; Nevinny-Stickel, M; Saurer, M; Seppi, T; Skvortsov, S; Skvortsova, I | 1 |
| Hainsworth, JD | 1 |
| Andre, VA; Arquette, MA; Burgess, MF; de Alwis, DP; Fears, CL; Fracasso, PM; Gazak, RJ; Goldstein, LJ; Goodner, SA; Rader, JS; Schellens, JH; Slapak, CA; Wright, LP | 1 |
| Baker, SD; Figg, WD; Graveland, W; Li, J; Sparreboom, A; ten Tije, AJ; Verweij, J | 1 |
| Dees, EC; Watkins, PB | 1 |
| Hennequin, C | 1 |
| Baker, SD; Carducci, MA; Dawkins, F; Graveland, W; Pronk, T; Rogers, T; ten Tije, AJ; Verbruggen, MP; Verweij, J | 1 |
| Ahmed, T; Cocquyt, V; de Smet, M; Fedgchin, M; Gottesdiener, KM; Hande, K; Majumdar, A; Murphy, MG; Nygren, P; Panebianco, D; Petty, KJ; van Belle, S; van Dyck, K | 1 |
| Belani, CP; Chatta, GS; Egorin, MJ; Fakih, M; Friedland, DM; Jacobs, SA; Jung, LL; Potter, DM; Ramalingam, S; Ramanathan, RK; Shin, DM; Strychor, S; Tutchko, S; Zamboni, WC | 1 |
| Katano, M; Kubo, M; Kuroki, H; Matsumoto, K; Morisaki, T; Nakamura, M; Nakashima, H; Tanaka, M; Tasaki, A | 1 |
| Baumann, K | 1 |
| Dietrich, ES | 1 |
| Bokemeyer, C; Lipp, HP | 1 |
| Beringer, P; Garcia, AA; Iqbal, S; Jeffers, S; Lenz, HJ; Louie, S; Pujari, M | 1 |
| Fossella, F; Hortobagyi, G; Montero, A; Valero, V | 1 |
| Epstein, AL; Hu, P; Khawli, LA | 1 |
| Delgrosso, A; Freda, T; Hamilton, J; Posey, JA; Wang, H; Zamboni, WC; Zhang, R | 1 |
| Adjei, AA; Croghan, GC; Dy, GK; Furth, A; Hanson, LJ; Mandrekar, S; Okuno, SH; Peethambaram, PP | 1 |
| Ahmed, F; Ali, S; Kucuk, O; Li, Y; Philip, PA; Sarkar, FH | 1 |
| Creaven, PJ; Fakih, MG; French, RA; Javle, M; Ramnath, N; Repinski, TV; Schwarz, JK; Strychor, S; Trump, D; Zamboni, BA; Zamboni, WC | 1 |
| Androulakis, N; Georgoulias, V; Kalykaki, A; Kentepozidis, N; Kouroussis, Ch; Saridaki, Z; Spiridonakou, S; Vamvakas, L; Xiropoulou, E | 1 |
| Bonneterre, J; Bonneterre, ME; Degardin, M; Diéras, V; Fumoleau, P; Lacombe, D; Laurence, V; Marreaud, S; Pierga, JY | 1 |
| Ballard, EE; Dowell, JE; Hunt, WC; Jumper, CA; Krieger, JA; Rabinowitz, I; Shah, SR; Stanford, BL | 1 |
| Bakker, WH; Buijs, D; Engels, FK; Krenning, EP; Loos, WJ; Verweij, J | 1 |
| Edwards, S; Garcia, AA; Iqbal, S; Lenz, HJ; Quinn, D; Weber, J | 1 |
| Fujimura, M; Inoue, K; Isobe, K; Komagata, H; Sakai, H; Shirai, T; Tabei, T; Yoneda, S | 1 |
| Endo, Y; Fujiwara, T; Hioki, M; Ikeda, Y; Kagawa, S; Kishimoto, H; Sakai, R; Tanaka, N; Urata, Y | 1 |
| Almuete, VI; Armstrong, DK; Baker, SD; Carducci, MA; Dinh, K; Donehower, RC; Lassiter, L; Messersmith, WA; Sullivan, RA; Wright, JJ | 1 |
| André, N; Meille, C | 1 |
| Fujii, H; Igarashi, T; Itoh, K; Kawada, K; Minami, H; Saeki, T; Sasaki, Y; Tahara, M | 1 |
| Cirillo, I; de Bruijn, P; de Jonge, MJ; Felici, A; Loos, WJ; Mathijssen, RH; Nooter, K; Verweij, J | 1 |
| Alberti, D; Arzoomanian, R; Binger, K; Dubey, S; Feierabend, C; Hutson, P; Schiller, JH; Volkman, J; Wilding, G | 1 |
| Caligiuri, MA; Criswell, T; Guttridge, D; Kuhn, J; Monk, JP; Otterson, GA; Phillips, G; Rhoades, C; Schaaf, LJ; Shah, M; Villalona-Calero, MA; Waite, R | 1 |
| Desai, K; Einstein, M; Fields, A; Goel, S; Goldberg, G; Macapinlac, M; Mani, S; Martin, R; Volterra, F; Wadler, S; Wong, B | 1 |
| Beale, P; Beith, J; Boyer, M; Charles, KA; Clarke, SJ; Rivory, LP; Stockler, MR | 1 |
| Balkman, CE; Beaulieu, BB; Lewis, LD; McEntee, MC; Page, RL; Rassnick, KM; Zgola, MM | 1 |
| Cardenal, F; García, M; Germà-Lluch, JR; Gil, M; Izquierdo, MA; Martínez, M; Mesía, R; Navarro, M; Pérez, X; Pontón, JL; Salazar, R; Valentí, V | 1 |
| Engels, FK; Loos, WJ; Mathot, RA; van Schaik, RH; Verweij, J | 2 |
| Arun, BK; Eder, JP; Eiseman, IA; Garland, LL; Hidalgo, M; Lenehan, PF; Lovalvo, JL; Mendelson, DS; Olson, SC; Ryan, DP | 1 |
| Azzoli, CG; Fury, MG; Gomez, JE; Henry, R; Kris, MG; Miller, VA; Pfister, DG; Pizzo, BA; Rizvi, NA; Rosen, N; Sirotnak, FM; Smith, RP; Solit, DB; Su, YB | 1 |
| Asakura, H; Fuji, H; Harada, H; Mizumoto, M; Murayama, S; Nishimura, T; Zenda, S | 1 |
| Agrawal, S; Cherton-Horvat, GG; Durkin, JP; Gillard, JW; Hewitt, KE; Jerome, LJ; Kandimalla, ER; LaCasse, EC; Morris, SJ; Wang, H; Wang, W; Yu, D; Zhang, R | 1 |
| Bisonni, R; Calvani, M; D'Iddio, S; Graziano, F; Lippe, P; Mancinelli, A | 1 |
| Beijnen, JH; Bosch, TM; Doodeman, VD; Huitema, AD; Jansen, R; Jansen, RL; Schellens, JH; Smit, WM; Soesan, M; van Herpen, CM; Witteveen, E | 1 |
| Alexandre, J; Dieras, V; Girre, V; Goldwasser, F; Grabar, S; Hérait, P; Jullien, V; Montheil, V; Pons, G; Rabillon, F; Rey, E; Tran, A; Treluyer, JM | 1 |
| Borden, E; Bukowski, R; Cline-Burkhardt, M; Davis, M; Dowlati, A; Dreicer, R; Kalmadi, S; Mekhail, T; O'Keefe, S; Pelley, RJ | 1 |
| Berchery, D; Chatelut, E; Delord, JP; Lafont, T; Lochon, I; Puisset, F; Roché, H; Sparreboom, A | 1 |
| Engels, FK; Mathot, RA; Verweij, J | 1 |
| Ideguchi, H; Ishigatsubo, Y; Ohno, S; Ueda, A | 1 |
| Assayag, F; Garbay, C; Gril, B; Liu, WQ; Poupon, MF; Vidal, M | 1 |
| Belani, CP; Egorin, MJ; Eiseman, JL; Guo, J; Ivy, SP; Ramanathan, RK; Scher, HI; Solit, DB; Zuhowski, EG | 1 |
| de Bruijn, P; de Jong, FA; Engels, FK; Kitzen, JJ; Loos, WJ; Mathijssen, RH; Mathot, RA; Sparreboom, A; Verweij, J | 1 |
| Berg, R; Koropatnick, J; Pandyra, AA; Vincent, M | 1 |
| Azzoli, CG; Dunne, M; Farmer, A; Ginsberg, MS; Gomez, J; Henry, R; Jones, J; Kris, MG; Krug, LM; Miller, VA; Pizzo, B; Sirotnak, FM; Steffen, R; Tyson, L; Venkatraman, E | 1 |
| Huxham, LA; Kyle, AH; Minchinton, AI; Yeoman, DM | 1 |
| Amarantidis, K; Chatzaki, E; Houhouli, K; Kakolyris, S; Lyrantzopoulos, N; Matthaios, D; Miloussis, A; Papatheodorou, K; Tentes, A; Tsaroucha, A | 1 |
| Burnstein, K; de Las Pozas, A; Gomez, LA; Perez-Stable, C; Reiner, T | 1 |
| Awada, A; De Porre, P; de Valeriola, D; Gil, T; Lalami, Y; Piccart-Gebhart, MJ; Zhang, S | 1 |
| Bies, RR; Dowell, JE; Egorin, MJ; Hollis, DR; Levine, EG; Lewis, LD; Millard, F; Miller, AA; Otterson, GA; Ratain, MJ; Relling, MV; Rosner, GL; Valdivieso, M | 1 |
| Cheng, KD; Kong, JQ; Wang, W; Zhu, P | 1 |
| Benhadji, K; Calvo, F; Chiao, J; Cvitkovic, E; Faivre, S; Galmarini, CM; Ghoul, A; Green, SR; Le Tourneau, C; Raymond, E; Serova, M | 1 |
| Fojo, T; Menefee, M | 1 |
| Gassner, B; Gekle, M; Kelleher, DK; Schwerdt, G; Thews, O | 1 |
| Minami, H; Ozawa, K; Sato, H | 2 |
| Fornier, MN; Hudis, C; Kelsen, DP; Lefkowitz, R; O'Reilly, E; Patil, S; Rathkopf, D; Schwartz, GK; Shah, M; Tse, AN | 1 |
| Goh, BC; Lee, HS; Lee, SC; Soo, R; Sukri, N; Tham, LS; Wang, LZ; Wong, CI; Yong, WP | 1 |
| Aldaz, A; Aramendía, JM; Aristu, J; Centeno, C; Hernández, M; Moreno, M; Nieto, Y; Pérez-Calvo, J; Rifón, J; Sayar, O; Viteri, S; Viúdez, A; Zafra, A; Zufia, L | 1 |
| Attard, G; Blagden, SP; de Bono, JS; de Jonge, M; Fong, PC; Kitzen, J; Pronk, LC; Verweij, J; Zhi, J; Zugmaier, G | 1 |
| Ernst, T; Gnad-Vogt, U; Hochhaus, A; Hofheinz, RD; Kripp, M; Lukan, N; Merx, K; Schultheis, B | 1 |
| Burgess, TL; Coxon, A; Jun, HT; Kendall, R; Radinsky, R; Rex, K; Sun, J | 1 |
| Chi, KN; Eisenhauer, E; Gleave, M; Guns, E; Hirte, H; Hotte, SJ; Knox, J; Kollmansberger, C; Powers, J; Siu, LL; Tu, D; Walsh, W | 1 |
| Al Omari, AS; Chiorean, EG; Fife, KL; Foster, AE; Jones, DR; Murry, DJ; Porter, JM; Strother, RM; Sweeney, CJ; Yoder, CA; Yu, M | 1 |
| Andrieu, JM; Banu, A; Banu, E; Ebenezer, C; Levy, E; Marsan, S; Medioni, J; Oudard, S; Scotté, F; Tourani, JM | 1 |
| Blagden, SP; Bowen, C; Dar, MM; de Bono, JS; Hodge, JP; Kathman, SJ; Middleton, MR; Molife, LR; Payne, M; Protheroe, AS; Reid, AH; Seebaran, A; Vasist, LS; Williams, DD | 1 |
| Addison, R; Basche, M; Chow, LQ; Creese, BR; Davis, K; Eckhardt, SG; Gore, L; Grolnic, S; Gustafson, DL; Holden, SN; Morrow, MC; O'Bryant, CL; Roberts, KL | 1 |
| Baggstrom, MQ; Fracasso, PM; Govindan, R; Read, W; Suresh, R; Wildi, JD | 1 |
| Hwang, HY; Kim, IS; Kim, YH; Kwon, IC | 1 |
| Böhme, C; Cerny, T; Demmer, R; Gillessen, S; Schmitz, SF; Strasser, F; Thuerlimann, B | 1 |
| Liu, B; Qian, X; Wang, L; Wang, T; Wei, J; Yin, H; Yu, L; Zhao, Y | 1 |
| Fumoleau, P; Lemevel, B; Maugard-Louboutin, C; Perrocheau, G | 1 |
| Aamdal, S; Catimel, G; Sternberg, C; Sulkes, A; van Hoesel, Q; Verweij, J; Wolff, I | 1 |
| Aapro, M; Bruno, R | 1 |
| Cortes, JE; Pazdur, R | 1 |
| Beijnen, JH; Huizing, MT; Misser, VH; Pieters, RC; Pinedo, HM; ten Bokkel Huinink, WW; Veenhof, CH; Vermorken, JB | 1 |
| Shparik, IV | 1 |
| Bissery, MC; Lavelle, F; Nohynek, G; Sanderink, GJ | 1 |
| Schriivers D [corrected to Schrijvers, D]; Schrijvers, D; van Oosterom, AT | 1 |
| McNeil, C | 1 |
| Kaye, SB | 1 |
| Bruno, R; Sanderink, GJ | 1 |
| Cuvier, C; Espie, M; Extra, JM; Giacchetti, S; Marty, M | 1 |
| Foa, R; Norton, L; Seidman, AD | 1 |
| Auzannet, V; Awada, A; de Valeriola, D; Kerger, J; Lips, S; Lossignol, D; Piccart, MJ; Ravoet, C; Sculier, JP; Tomiak, E | 1 |
| Verweij, J | 1 |
| Ariyoshi, Y; Fukuoka, M; Furue, H; Furuse, K; Hasegawa, K; Ishitani, K; Kanamaru, R; Niitani, H; Noda, K; Taguchi, T | 1 |
| Bruno, R; Clavel, M; Extra, JM; Le Bail, N; Marty, M; Rousseau, F | 1 |
| Burris, H; Eckardt, J; Fields, S; Irvin, R; Kalter, S; Kuhn, J; Rodriguez, G; Shaffer, D; Smith, L; Weiss, G | 1 |
| Arbuck, SG; Cheson, BD; Phillips, PH | 1 |
| Cohen, PR; Kavanagh, JJ; Kudelka, AP; Pazdur, R; Raber, MN | 1 |
| Eisenhauer, E | 1 |
| Pronk, LC; Stoter, G; Verweij, J | 1 |
| Guy, RK; Nicolaou, KC; Potier, P | 1 |
| Armand, JP; Couteau, C; Goncalves, E; Terret, C; Yakendji, K | 1 |
| Arioka, H; Eguchi, K; Fukuoka, K; Funayama, Y; Ishida, T; Kunito, H; Kurokawa, H; Nishio, K; Nomoto, T; Ohe, Y; Ohta, S; Ohtsu, T; Saijo, N; Sasaki, Y; Shinkai, T; Tamura, T; Yamamoto, N | 1 |
| Barnicle, M; Blendowski, C; Goodman, M; Lydon, J; Petersen, J; Stewart, I; Wickham, R | 1 |
| Halle, M | 1 |
| Aapro, M | 1 |
| Hilkens, PH; Pronk, LC; van den Bent, MJ; van Putten, WL; Vecht, CJ; Verweij, J | 1 |
| Rowinsky, EK | 1 |
| Blanc, C; Bruno, R; de Boer-Dennert, M; Harteveld, M; Hilkens, PH; Ma, J; Planting, AS; Pronk, LC; Schellens, JH; Stoter, G; van den Bent, MJ; van der Burg, ME; Verweij, J | 1 |
| Linsenmeyer, ME; Millward, MJ; Rischin, D; Urch, ME; Webster, LK; Woodcock, DM | 1 |
| MacConnachie, AM | 1 |
| Adamson, PC; Balis, FM; Berg, SL; Blaney, SM; Krailo, MD; Mosher, R; O'Brien, M; Poplack, DG; Reaman, GH; Seibel, NL | 1 |
| Loos, WJ; Nooter, K; Sparreboom, A; Stoter, G; Verweij, J | 2 |
| Valero, V | 2 |
| Chaitchik, S; Inbar, M; Merimsky, O | 1 |
| Burris, HA | 1 |
| Eckardt, JR | 1 |
| Kraynak, MA | 1 |
| Yee, GC | 1 |
| Bruno, R; Hille, D; Lebecq, A; Riva, A; Thomas, L | 1 |
| Bruno, R; Burris, HA; Chevallier, B; Fossella, FV; Fumoleau, P; Hille, D; Kaye, SB; Ravdin, PM; Rigas, JR; Riva, A; Seidman, AD; Sheiner, LB; ten Bokkel Huinnink, WW; Valero, V; van Oosterom, AT; Verweij, J; Vivier, N | 1 |
| Dörken, B; Köhne, CH; Kretzschmar, A | 1 |
| de Bruijn, EA; Groult, V; Locci-Tonelli, D; Planting, AS; Pronk, LC; Schellens, JH; Schrijvers, D; van Oosterom, AT; Verweij, J | 2 |
| Eisenhauer, EA; Vermorken, JB | 1 |
| Bontenbal, M; Hilkens, PH; Sillevis Smitt, PA; van den Bent, MJ; van Raaij-van den Aarssen, VJ; Verweij, J | 1 |
| Burris, HA; Erland, JB; Greco, FA; Hainsworth, JD; Thomas, M | 1 |
| Anderson, N; Lokich, J | 1 |
| Bruno, R; Kearns, CM; Kuhn, JG; McLeod, HL | 1 |
| Baille, P; Bruno, R; Millward, M; Montay, G; Schellens, JH; Verweij, J; Webster, LK | 1 |
| Hilkens, PH; Pronk, LC; Stoter, G; van den Bent, MJ; van Putten, WL; Verweij, J | 1 |
| Sparano, JA | 1 |
| Burris, H | 1 |
| Armand, JP; Couteau, C | 1 |
| Georgoulias, V; Giatromanolaki, A; Kakolyris, S; Koukourakis, MI; Schiza, S | 1 |
| Aylesworth, C; Bellet, R; Burris, H; Peacock, N; Petit, T; Ravdin, P; Rodriguez, G; Rowinsky, EK; Smetzer, L; Smith, L; Von Hoff, DD | 1 |
| Balis, FM; Blaney, SM; Hutchinson, R; Krailo, M; Mosher, RB; O'Brien, M; Reaman, GH; Seibel, NL | 1 |
| Candalh, E; Kramar, A; Lebecq, A | 1 |
| Anastasopoulos, D; Briasoulis, E; Fountzilas, G; Karavasilis, V; Kostadima, V; Pavlidis, N; Rammou, D; Tzamakou, E | 1 |
| Greco, FA | 1 |
| Choy, H | 3 |
| Evtushenko, OI | 1 |
| Miller, M | 1 |
| Baccala, P; Berg, D; Clark, JW; Finkelstein, D; Fuchs, CS; Grenon, N; Grossbard, ML; Lynch, TJ; Mayer, RJ; Ryan, DP; Seiden, MV | 1 |
| Ando, Y | 1 |
| Bartholomeus, S; Bleiberg, H; Brassinne, C; Cazenave, I; de Valeriola, D; Hennebert, P; Kerger, J; Kusenda, Z; Lefresne-Soulas, F; Piccart, M; Selleslags, J; Van Den Neste, E; Wythouck, H | 1 |
| Beijnen, JH; Bult, A; Huizing, MT; Lustig, V; Rodenhuis, S; Rosing, H; Schellens, JH; ten Bokkel Huinink, WW; van Warmerdam, LJ | 1 |
| Adjei, AA; Alberts, SR; Atherton, P; Erlichman, C; Goldberg, RM; Hanson, LJ; Kastrissios, H; Klein, CE; Pitot, HC; Reid, JM; Rubin, J; Sloan, JA | 1 |
| Hudis, CA; Münster, PN | 1 |
| Bamias, A; Katsimbri, P; Pavlidis, N | 1 |
| Collins, JM | 1 |
| Bol, CJ; Palmer, PA; Sparreboom, A; van Beurden, V; van der Burg, ME; van der Gaast, A; van Zuylen, L; Verweij, J; Woestenborghs, R | 1 |
| Bishop, J; Boyer, M; Davison, J; Emmett, E; McClure, B; Michael, M; Millward, M; Rischin, D; Smith, J; Zalcberg, J | 1 |
| Abad, A; Guillot, M; Martin, C; Plasencia, C; Taron, M | 1 |
| Bahlitzanakis, N; Froudarakis, M; Georgoulias, V; Giatromanolaki, A; Kakolyris, S; Koukourakis, MI; Retalis, G | 1 |
| Gordon, RJ; Osterwalder, B; Planting, AS; Pronk, LC; Reigner, B; Sparreboom, A; Twelves, C; Vasey, P; Verweij, J | 1 |
| Brouwer, E; Nooter, K; Sparreboom, A; Stoter, G; van Zuylen, L; Verweij, J | 1 |
| Brooks, SE; Day, RS; Dobson, JM; Doyle, LA; Egorin, MJ; Meisenberg, BR; Nemieboka, NN; Tait, NS; Tkaczuk, KH; Van Echo, DA; Zamboni, WC | 1 |
| Briasoulis, E; Karavasilis, V; Pavlidis, N | 1 |
| Apostolaki, S; Georgoulias, V; Kotsakis, A; Koukourakis, M; Mavromanomakis, E; Peraki, M; Sarra, E; Souglakos, J; Vlachonikolis, J | 1 |
| Armand, JP; Bruno, R; Couteau, C; Ducreux, M; Lebecq, A; Lefresne-Soulas, F; Lokiec, F; Risse, ML; Riva, A; Rougier, P; Ruffié, P | 1 |
| Hyman, W; Lawson, JM; Maples, PB; Nemunaitis, J; Ordonez, G; Richards, D; Seamour, B; Stein, L; Tong, AW; Vukelja, S | 1 |
| Doyle, LA; Edelman, MJ; Egorin, MJ; Hausner, PF; Meisenberg, BR; Tait, NS; Tkaczuk, KH; Van Echo, DA; Zamboni, WC | 1 |
| Agelaki, S; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Kalbakis, K; Kouroussis, C; Mavroudis, D; Reppa, D; Samonis, G; Souglakos, J; Vardakis, N | 1 |
| Iñiguez, C; Larrodé, P; Mauri, JA; Mayordomo, JI; Morales, F; Trés, A | 1 |
| Lokich, J | 1 |
| Beijnen, JH; Koopman, FJ; Malingré, MM; Richel, DJ; Rosing, H; Schellens, JH; Schot, ME; Ten Bokkel Huinink, WW | 1 |
| Brescia, FJ; Green, MR; Rocha Lima, CM; Sherman, CA; Urbanic, JJ | 1 |
| Aapro, M; Rowinsky, E | 1 |
| Prescott, LM | 1 |
| Beijnen, JH; Bouma, M; Nuijen, B; Schellens, JH | 1 |
| Beijnen, JH; Malingré, MM; Schellens, JH | 1 |
| Bruno, R; Montay, G; Rhodes, GR; Veyrat-Follet, C; Vivier, N | 1 |
| Ratain, MJ; Sawyer, M | 1 |
| Gianni, L; Grasselli, G; Locatelli, A; Vigano, L | 1 |
| Kuroi, K; Tanaka, C; Toi, M | 1 |
| Botwood, N | 1 |
| Beijnen, JH; Mackay, M; Malingré, MM; Schellens, JH; Ten Bokkel Huinink, WW | 1 |
| Bhargava, P; Dahut, W; Figuera, M; Fried, K; Gehan, E; Hanfelt, J; Hawkins, MJ; Lefebvre, P; Marshall, JL; Rizvi, NA; Williams, M | 1 |
| Markman, M; Zanotti, KM | 1 |
| Alexander, W; Chang, EH; Huang, CC; Pirollo, KF; Rait, A; Tang, WH; Xiang, LM; Xu, L | 1 |
| Banerjee, D | 1 |
| Wilke, H | 1 |
| de Wit, R; Loos, WJ; Louwerens, M; Smorenburg, C; Sparreboom, A; Verweij, J | 1 |
| Iimura, S; Ishiyama, T; Ohsuki, S; Soga, T; Terasawa, H; Uoto, K | 1 |
| Bol, CJ; Brouwer, E; de Vries, R; Eskens, FA; Nooter, K; Palmer, PA; Sparreboom, A; van der Gaast, A; van Zuylen, L; Verweij, J | 1 |
| Baker, SD; Brahmer, JR; Sparreboom, A; Verweij, J; Zhao, M | 1 |
| Clinton, S; Erdal, S; Hauger, M; Kraut, E; Monk, P; Nadella, P; Otterson, GA; Shah, M; Shapiro, C; Stanek, M; Villalona-Calero, MA | 1 |
| Marchettini, P; Mohamed, F; Stuart, OA; Sugarbaker, PH; Yoo, D | 1 |
| Amato, I | 1 |
| Bayssas, MM; Benvenuto, J; Bready, B; Fuentes, A; Jaiyesimi, I; Moore, D; Newman, BM; Newman, RA; Pazdur, R; Vreeland, F | 1 |
| Kaye, SB; Schwartsmann, G; Workman, P | 1 |
| Arbuck, SG; Canetta, RM; Onetto, N; Rowinsky, EK | 1 |
| Lavelle, F; Naudin, A; Riou, JF | 1 |
115 review(s) available for docetaxel anhydrous and Benign Neoplasms
| Article | Year |
|---|---|
Association between gene polymorphism and adverse effects in cancer patients receiving docetaxel treatment: a meta-analysis.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Cytochrome P-450 CYP3A; Docetaxel; Genotype; Humans; Neoplasms; Pharmacogenetics; Polymorphism, Single Nucleotide | 2022 |
Design, development and clinical translation of CriPec®-based core-crosslinked polymeric micelles.
Topics: Animals; Antineoplastic Agents; Docetaxel; Drug Carriers; Micelles; Neoplasms; Polyethylene Glycols; Polymers; Tissue Distribution | 2022 |
Paclitaxel resistance related to nuclear envelope structural sturdiness.
Topics: Apoptosis; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Humans; Neoplasms; Nuclear Envelope; Paclitaxel; Taxoids | 2022 |
Cell proliferation, drug distribution and therapeutic effects in relation to the vascular system of solid tumours.
Topics: Antineoplastic Agents; Cell Proliferation; Docetaxel; Doxorubicin; Humans; Neoplasms; Tumor Microenvironment | 2023 |
The interactions of docetaxel with tumor microenvironment.
Topics: Antineoplastic Agents; Docetaxel; Humans; Neoplasms; T-Lymphocytes, Cytotoxic; Tumor Microenvironment | 2023 |
Combination of chemotherapy and radiotherapy: A thirty years evolution.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chemoradiotherapy; Cisplatin; DNA Repair; Docetaxel; Drug Administration Schedule; Fluorouracil; Humans; Molecular Targeted Therapy; Neoplasms; Organs at Risk; Radiation Injuries; Time Factors | 2019 |
Chitosan-based advanced materials for docetaxel and paclitaxel delivery: Recent advances and future directions in cancer theranostics.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biological Availability; Chitosan; Docetaxel; Drug Carriers; Humans; Hydrogen-Ion Concentration; Molecular Targeted Therapy; Nanoparticles; Neoplasms; Oxidation-Reduction; Paclitaxel; Solubility; Static Electricity; Theranostic Nanomedicine | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
The Scope and Challenges of Vesicular Carrier-Mediated Delivery of Docetaxel for the Management of Cancer.
Topics: Docetaxel; Drug Carriers; Drug Delivery Systems; Humans; Liposomes; Neoplasms; Taxoids | 2020 |
Biomedical applications of methionine-based systems.
Topics: Cell Proliferation; COVID-19; COVID-19 Drug Treatment; Docetaxel; Humans; Liver Diseases; Methionine; Nanoparticles; Neoplasms; S-Adenosylmethionine; SARS-CoV-2 | 2021 |
Emerging nanotaxanes for cancer therapy.
Topics: Antineoplastic Agents; Docetaxel; Drug Delivery Systems; Humans; Immunotherapy; Neoplasms | 2021 |
New insight towards development of paclitaxel and docetaxel resistance in cancer cells: EMT as a novel molecular mechanism and therapeutic possibilities.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Neoplasms; Paclitaxel | 2021 |
Pharmacogenetic and Pharmacokinetic Dose Individualization of the Taxane Chemotherapeutic Drugs Paclitaxel and Docetaxel.
Topics: Animals; Antineoplastic Agents; Docetaxel; Dose-Response Relationship, Drug; Humans; Neoplasms; Paclitaxel; Pharmacogenetics; Taxoids | 2017 |
Quest for Efficacious Next-Generation Taxoid Anticancer Agents and Their Tumor-Targeted Delivery.
Topics: Animals; Antineoplastic Agents; Docetaxel; Drug Resistance, Neoplasm; Humans; Neoplasms; Paclitaxel; Taxoids | 2018 |
A Critical Review of Properties and Analytical Methods for the Determination of Docetaxel in Biological and Pharmaceutical Matrices.
Topics: Animals; Body Fluids; Chemistry, Pharmaceutical; Docetaxel; Drug Compounding; Drug Delivery Systems; Humans; Neoplasms; Pharmaceutical Preparations; Taxoids | 2018 |
Current advances in development of new docetaxel formulations.
Topics: Animals; Antineoplastic Agents; Docetaxel; Drug Compounding; Humans; Nanomedicine; Nanoparticles; Neoplasms; Technology, Pharmaceutical | 2019 |
Neutropenia and docetaxel exposure in metastatic castration-resistant prostate cancer patients: A meta-analysis and evaluation of a clinical cohort.
Topics: Area Under Curve; Clinical Trials as Topic; Docetaxel; Humans; Incidence; Logistic Models; Male; Neoplasm Metastasis; Neoplasms; Neutropenia; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2019 |
[Clinical Pharmaceutical Research Based on New Proteome Analysis Based on Chromatographic Separation].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antigen-Antibody Complex; Antigens; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Cardiotonic Agents; Chromatography, Liquid; Docetaxel; Doxorubicin; Humans; Mice; Neoplasms; Pharmaceutical Research; Proteome; Proteomics; Tandem Mass Spectrometry | 2019 |
Combined strategies for tumor immunotherapy with nanoparticles.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Dendritic Cells; Docetaxel; Doxorubicin; Galectin 1; Gold; Humans; Immunity, Cellular; Immunity, Humoral; Immunotherapy; Killer Cells, Natural; Lymphocyte Activation; Macrophage Activation; Nanoparticles; Neoplasms; Organ Specificity; Paclitaxel; Receptors, Chimeric Antigen | 2019 |
Prophylactic management for taxane-induced nail toxicity: A systematic review and meta-analysis.
Topics: Cryotherapy; Docetaxel; Humans; Nail Diseases; Neoplasms; Oils, Volatile; Onycholysis; Paclitaxel; Paronychia; Pigmentation Disorders; Plant Oils; Taxoids; Waxes | 2019 |
Defining risks of taxane neuropathy: insights from randomized clinical trials.
Topics: Axons; Bridged-Ring Compounds; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Humans; Nanoparticles; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Randomized Controlled Trials as Topic; Taxoids | 2013 |
How nanotechnology can enhance docetaxel therapy.
Topics: Animals; Antineoplastic Agents; Docetaxel; Drug Carriers; Humans; Mice; Nanomedicine; Nanoparticles; Neoplasms; Taxoids | 2013 |
Dosing considerations for obese patients receiving cancer chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Docetaxel; Humans; Neoplasms; Obesity; Paclitaxel; Taxoids; Vincristine | 2013 |
Targeted therapy using nanotechnology: focus on cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Aptamers, Nucleotide; Chemistry, Pharmaceutical; Delayed-Action Preparations; Docetaxel; Drug Delivery Systems; Endothelial Cells; Humans; Liposomes; Molecular Targeted Therapy; Nanomedicine; Nanoparticles; Nanotechnology; Neoplasms; Taxoids | 2014 |
Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel--a review.
Topics: Administration, Metronomic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Interactions; Humans; Maximum Tolerated Dose; Neoplasms; Paclitaxel; Taxoids | 2014 |
In vivo imaging as a pharmacodynamic marker.
Topics: Antineoplastic Agents; Carbon Radioisotopes; Docetaxel; Fluorine Radioisotopes; Humans; Neoplasms; Paclitaxel; Positron-Emission Tomography; Taxoids; Tissue Distribution; Treatment Outcome | 2014 |
Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review.
Topics: Antineoplastic Agents; Chemotherapy-Induced Febrile Neutropenia; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasms; Polyethylene Glycols; Recombinant Fusion Proteins; Recombinant Proteins; Serum Albumin; Serum Albumin, Human; Taxoids | 2015 |
Metabolism of the taxanes including nab-paclitaxel.
Topics: Albumins; Animals; Antineoplastic Agents; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Humans; Liver; Neoplasms; Paclitaxel; Taxoids | 2015 |
The risk of nail changes with taxane chemotherapy: a systematic review of the literature and meta-analysis.
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Nail Diseases; Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Tubulin Modulators | 2015 |
Inter-patient variability in docetaxel pharmacokinetics: A review.
Topics: Antineoplastic Agents; Docetaxel; Humans; Neoplasms; Taxoids | 2015 |
Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials as Topic; Docetaxel; Erlotinib Hydrochloride; Everolimus; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Sirolimus; Taxoids; TOR Serine-Threonine Kinases | 2015 |
Docetaxel-induced polyploidization may underlie chemoresistance and disease relapse.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cellular Senescence; Centrosome; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Giant Cells; Humans; Mitosis; Neoplasms; Polyploidy; Signal Transduction; Taxoids; Treatment Failure | 2015 |
Cucurbitacins: A Systematic Review of the Phytochemistry and Anticancer Activity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Cucurbitacins; Docetaxel; Drug Therapy, Combination; Humans; Methotrexate; Molecular Conformation; Neoplasm Invasiveness; Neoplasms; Phytotherapy; Signal Transduction; Structure-Activity Relationship; Taxoids | 2015 |
Treatment regimens of classical and newer taxanes.
Topics: Albumins; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Liver; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome; Tubulin Modulators | 2016 |
Taxane anticancer agents: a patent perspective.
Topics: Animals; Antineoplastic Agents; Docetaxel; Drug Delivery Systems; Drug Design; Female; Humans; Male; Nanostructures; Neoplasms; Paclitaxel; Patents as Topic; Taxoids | 2016 |
Recent advances in design, synthesis and bioactivity of paclitaxel-mimics.
Topics: Animals; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Resistance, Multiple; Humans; Mice; Molecular Structure; Neoplasms; Paclitaxel; Taxoids | 2016 |
Survivin Modulators: An Updated Patent Review (2011-2015).
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Docetaxel; Humans; Inhibitor of Apoptosis Proteins; Neoplasms; Patents as Topic; Protein Structure, Secondary; Survivin; Taxoids | 2016 |
Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: a comparative review.
Topics: Antineoplastic Agents; Asian People; ATP-Binding Cassette Transporters; Camptothecin; Docetaxel; Doxorubicin; Humans; Irinotecan; Neoplasms; Polymorphism, Genetic; Solute Carrier Proteins; Taxoids; Treatment Outcome; White People | 2016 |
Intelligent polymeric micelles: development and application as drug delivery for docetaxel.
Topics: Antineoplastic Agents; Biological Availability; Cell Line, Tumor; Docetaxel; Enzymes; Humans; Hydrogen-Ion Concentration; Light; Magnetic Resonance Imaging; Magnetics; Micelles; Neoplasms; Polymers; Taxoids; Temperature | 2017 |
Polymer decorated gold nanoparticles in nanomedicine conjugates.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Diagnostic Imaging; Docetaxel; Drug Delivery Systems; Gold; Humans; Hyperthermia, Induced; MCF-7 Cells; Metal Nanoparticles; Mice; Molecular Targeted Therapy; Neoplasms; Particle Size; Polyethylene Glycols; Taxoids; Xenograft Model Antitumor Assays | 2017 |
Lessons learned from development of docetaxel.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Drug Interactions; Female; Humans; Neoplasms; Pharmacogenetics; Taxoids | 2008 |
Taxanes in the elderly: can we gain as much and be less toxic?
Topics: Aged; Aged, 80 and over; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2009 |
Docetaxel-related side effects and their management.
Topics: Antineoplastic Agents; Asthenia; Docetaxel; Drug Administration Schedule; Drug Hypersensitivity; Drug Monitoring; Edema; Evidence-Based Practice; Humans; Nail Diseases; Neoplasms; Nervous System Diseases; Neutropenia; Nursing Assessment; Oncology Nursing; Patient Selection; Practice Guidelines as Topic; Quality of Life; Severity of Illness Index; Taxoids | 2009 |
Efficacy and safety of the combination of docetaxel (Taxotere) with targeted therapies in the treatment of solid malignancies.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Clinical Trials as Topic; Docetaxel; Drug Delivery Systems; Humans; Neoplasms; Phenotype; Taxoids | 2009 |
Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics.
Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Genetic Therapy; Humans; Male; Mitoxantrone; Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Taxoids; Virus Replication | 2009 |
Scheduling of taxanes: a review.
Topics: Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Docetaxel; Drug Administration Schedule; Humans; Neoplasms; Paclitaxel; Taxoids; Trastuzumab | 2010 |
Targeting Notch signaling pathway to overcome drug resistance for cancer therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; MicroRNAs; Neoplasms; Paclitaxel; Receptors, Notch; Signal Transduction; Tamoxifen; Taxoids; Trastuzumab | 2010 |
[Molecular mechanisms of antitumor activity of taxanes. I. Interaction of docetaxel with microtubules].
Topics: Antineoplastic Agents; Cell Cycle; Docetaxel; Humans; Microtubules; Neoplasms; Taxoids | 2010 |
[Non-pegylated doxorubicin (Myocet®) as the less cardiotoxic alternative of free doxorubicin].
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Doxorubicin; Heart Diseases; Humans; Neoplasms; Paclitaxel; Taxoids; Trastuzumab | 2010 |
Pulmonary toxicity among cancer patients treated with a combination of docetaxel and gemcitabine: a meta-analysis of clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung; Neoplasms; Regression Analysis; Taxoids | 2011 |
Albumin-bound paclitaxel: the benefit of this new formulation in the treatment of various cancers.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasms; Paclitaxel; Standard of Care; Taxoids | 2011 |
[Main treatment and preventive measures for hand-foot syndrome, a dermatologic side effect of cancer therapy].
Topics: Antineoplastic Agents; Capecitabine; Cytarabine; Deoxycytidine; Docetaxel; Doxorubicin; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Neoplasms; Peripheral Nervous System; Quality of Life; Severity of Illness Index; Skin; Syndrome; Taxoids | 2011 |
Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials.
Topics: Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Dose-Response Relationship, Drug; Ethnicity; Humans; Neoplasms; Neutropenia; Taxoids | 2013 |
Docetaxel nanotechnology in anticancer therapy.
Topics: Antineoplastic Agents; Dendrimers; Docetaxel; Drug Carriers; Gold; Humans; Metal Nanoparticles; Nanotechnology; Neoplasms; Polymers; Taxoids | 2012 |
Update on taxane development: new analogs and new formulations.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Approval; Drug Design; Humans; Neoplasms; Paclitaxel; Taxoids; United States; United States Food and Drug Administration | 2012 |
[Prevention and treatment for adverse events induced by chemotherapy].
Topics: Anaphylaxis; Antineoplastic Agents; Brain Diseases; Cisplatin; Docetaxel; Fluorouracil; Humans; Neoplasms; Neutropenia; Paclitaxel; Taxoids; Vomiting, Anticipatory | 2002 |
Potential for combined modality therapy of cyclooxygenase inhibitors and radiation.
Topics: Angiogenesis Inhibitors; Animals; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Docetaxel; Humans; Isoenzymes; Lung Neoplasms; Membrane Proteins; Neoplasms; Paclitaxel; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Radiation-Sensitizing Agents; Taxoids | 2003 |
Management of toxicities associated with the administration of taxanes.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 2003 |
Mode of action of docetaxel - a basis for combination with novel anticancer agents.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Female; Follow-Up Studies; Humans; Male; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Pharmacogenetics; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Preclinical pharmacology of the taxanes: implications of the differences.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Humans; Maximum Tolerated Dose; Neoplasms; Paclitaxel; Prognosis; Survival Rate; Taxoids | 2004 |
Pemetrexed: a novel antifolate agent enters clinical practice.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Glutamates; Guanine; Humans; Neoplasms; Pemetrexed; Taxoids | 2004 |
Practical aspects of weekly docetaxel administration schedules.
Topics: Age Factors; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Fatigue; Humans; Infusions, Intravenous; Neoplasms; Neutropenia; Palliative Care; Taxoids | 2004 |
[Association of taxanes and radiotherapy: preclinical and clinical studies].
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cells, Cultured; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Dosage; Taxoids; Time Factors; Tumor Cells, Cultured | 2004 |
[New microtubule stabilizers].
Topics: Animals; Antineoplastic Agents, Phytogenic; Docetaxel; Epothilones; Humans; Microtubules; Neoplasms; Taxoids | 2005 |
[Cost-benefit aspects of taxane therapy].
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Neoplasms; Quality of Life; Taxoids | 2005 |
[The action and toxicity of taxanes].
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Male; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Taxoids | 2005 |
Docetaxel for treatment of solid tumours: a systematic review of clinical data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Docetaxel; Female; Humans; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2005 |
Taxanes in paediatric oncology: and now?
Topics: Antineoplastic Agents, Phytogenic; Child; Clinical Trials as Topic; Docetaxel; Humans; Medical Oncology; Neoplasms; Paclitaxel; Pediatrics; Taxoids | 2006 |
Alternative drug formulations of docetaxel: a review.
Topics: Animals; Antineoplastic Agents, Phytogenic; Chemistry, Pharmaceutical; Docetaxel; Excipients; Humans; Neoplasms; Polysorbates; Taxoids | 2007 |
Catastrophic antiphospholipid syndrome associated with malignancies (case report and review of the literature).
Topics: Adenocarcinoma, Clear Cell; Adolescent; Adult; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Antiphospholipid Syndrome; Carboplatin; Cerebral Hemorrhage; Cerebral Infarction; Docetaxel; Fatal Outcome; Female; Humans; Male; Middle Aged; Neoplasms; Neoplasms, Unknown Primary; Ovarian Neoplasms; Palliative Care; Paraneoplastic Syndromes; Protein C Deficiency; Protein S Deficiency; Pulmonary Embolism; Taxoids; Thrombophilia; Thrombophlebitis; Warfarin | 2007 |
[Recent advances in the biosynthesis of Taxol].
Topics: Antineoplastic Agents, Phytogenic; Arteriosclerosis; Docetaxel; Genes, Plant; Genetic Engineering; Neoplasms; Paclitaxel; Taxoids; Taxus | 2007 |
Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents.
Topics: Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epothilones; Humans; Microtubules; Neoplasms; Paclitaxel; Taxoids; Tubulin Modulators | 2007 |
[Paclitaxel (Taxol) and docetaxel (Taxotere): results of phase II trials in monochemotherapy].
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Administration Schedule; Drug Hypersensitivity; Drug Tolerance; Female; Humans; Male; Neoplasms; Neutropenia; Organoplatinum Compounds; Paclitaxel; Taxoids | 1995 |
Early clinical studies with docetaxel. Docetaxel Investigators Group.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials, Phase I as Topic; Docetaxel; Drug Administration Schedule; Female; Humans; Male; Neoplasms; Paclitaxel; Taxoids | 1995 |
Docetaxel.
Topics: Adult; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 1995 |
Taxanes: a new class of antitumor agents.
Topics: Animals; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Drug Screening Assays, Antitumor; Humans; Mice; Neoplasms; Neoplasms, Experimental; Paclitaxel; Taxoids | 1995 |
[Taxenes: a new hope of clinical oncology in the 90-ies].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Paclitaxel; Taxoids | 1995 |
Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1995 |
Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: Clinical experience.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1995 |
Docetaxel (Taxotere) in the treatment of solid tumors other than breast and lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials, Phase II as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1995 |
Pharmacokinetics and metabolism of Taxotere (docetaxel).
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1993 |
Taxoids: a new class of cytotoxic agents.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Neoplasms; Paclitaxel; Taxoids | 1994 |
Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Arrhythmias, Cardiac; Cell Cycle; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Hypersensitivity; Drug Screening Assays, Antitumor; Gastrointestinal Diseases; Humans; Mice; Microtubules; Neoplasms; Neoplasms, Experimental; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Polyethylene Glycols; Taxoids; Tubulin | 1994 |
The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere).
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoplasms; Ovarian Neoplasms; Paclitaxel; Taxoids | 1993 |
Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effects.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lethal Dose 50; Lung Neoplasms; Microtubules; Neoplasms; Ovarian Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 1995 |
[Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials].
Topics: Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Humans; Irinotecan; Loperamide; Male; Neoplasms; Neutropenia; Paclitaxel; Remission Induction; Taxoids; Topoisomerase I Inhibitors | 1996 |
Progress in preclinical and clinical studies for the development of new anticancer drugs in Japan, with emphasis on taxanes.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Drug Evaluation, Preclinical; Humans; Japan; Microtubule-Associated Proteins; Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured; Vinblastine; Vindesine; Vinorelbine | 1996 |
The scientific rationale for developing taxoids.
Topics: Animals; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Therapy, Combination; Humans; Microtubules; Neoplasms; Paclitaxel; Taxoids | 1996 |
The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents.
Topics: Animals; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Humans; Microtubules; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 1997 |
Docetaxel (taxotere, Rhone-Poulenc Rorer).
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Drug Monitoring; Humans; Neoplasms; Paclitaxel; Taxoids | 1997 |
[Taxanes: a breakthrough in cancer chemotherapy].
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1997 |
Docetaxel in combination with fluorouracil for advanced solid tumors.
Topics: Adult; Aged; Animals; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Models, Animal; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Leucovorin; Mice; Middle Aged; Mucous Membrane; Neoplasms; Neutropenia; Paclitaxel; Taxoids | 1997 |
Antitumor activity of docetaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1997 |
Pharmaceutical aspects of docetaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1997 |
Cost-utility analysis of taxane therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cost-Benefit Analysis; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1997 |
Pharmacokinetic and pharmacodynamic properties of docetaxel: results of phase I and phase II trials.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1997 |
[Docetaxel in treatment of other solid tumors].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 1997 |
The taxoids. Comparative clinical pharmacology and therapeutic potential.
Topics: Alopecia; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Docetaxel; Female; Humans; Lung Neoplasms; Neoplasms; Neutropenia; Ovarian Neoplasms; Paclitaxel; Taxoids | 1998 |
[Irinotecan-containing combinations in solid tumors, except colonic carcinomas].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diarrhea; Docetaxel; Enzyme Inhibitors; Etoposide; Female; Genital Neoplasms, Female; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasm Proteins; Neoplasms; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids; Topoisomerase I Inhibitors; Treatment Outcome | 1998 |
Taxanes in combined-modality therapy for solid tumors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; Paclitaxel; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Stomach Neoplasms; Taxoids | 1999 |
[The administration of Docetaxel (taxoter): a new stage in chemotherapy of cancer].
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1999 |
Role of taxanes in adjuvant therapy.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 2000 |
Combining taxanes with radiation for solid tumors.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 2000 |
[Peripheral nervous system neurotoxicity secondary to chemotherapy treatment] .
Topics: Anti-HIV Agents; Antineoplastic Agents; Cyclosporine; Depsipeptides; Docetaxel; Doxorubicin; Humans; Neoplasms; Neuromuscular Diseases; Oligopeptides; Organoplatinum Compounds; Paclitaxel; Peripheral Nervous System Diseases; Procarbazine; Reverse Transcriptase Inhibitors; Suramin; Taxoids; Vinca Alkaloids | 2000 |
Docetaxel followed by gemcitabine and irinotecan in solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Survival Rate; Taxoids | 2001 |
Taxanes in combined modality therapy for solid tumors.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 2001 |
Docetaxel: assessing a range of activity.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 2001 |
Progress in the development of alternative pharmaceutical formulations of taxanes.
Topics: Animals; Antineoplastic Agents, Phytogenic; Chemistry, Pharmaceutical; Cyclodextrins; Docetaxel; Drug Compounding; Emulsions; Humans; Neoplasms; Paclitaxel; Prodrugs; Solvents; Surface-Active Agents; Taxoids | 2001 |
Oral delivery of taxanes.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Cyclosporine; Cyclosporins; Docetaxel; Humans; Mice; Mice, Knockout; Neoplasms; Paclitaxel; Taxoids | 2001 |
Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Computer Simulation; Docetaxel; Humans; Lung Neoplasms; Models, Statistical; Neoplasms; Nonlinear Dynamics; Paclitaxel; Prospective Studies; Research Design; Taxoids | 2001 |
Body surface area as a determinant of pharmacokinetics and drug dosing.
Topics: Adult; Animals; Anthropometry; Antineoplastic Agents; Area Under Curve; Body Surface Area; Carboplatin; Cardiac Output; Child; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Humans; Kidney; Liver; Medical Oncology; Neoplasms; Paclitaxel; Taxoids | 2001 |
Drug interactions of paclitaxel and docetaxel and their relevance for the design of combination therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Chemistry, Pharmaceutical; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Interactions; Glycerol; Humans; Neoplasms; Paclitaxel; Pharmaceutical Vehicles; Radiotherapy, Adjuvant; Taxoids; Vinca Alkaloids | 2001 |
Prevention and management of antineoplastic-induced hypersensitivity reactions.
Topics: Antineoplastic Agents; Asparaginase; Docetaxel; Drug Hypersensitivity; Humans; Neoplasms; Organoplatinum Compounds; Paclitaxel; Podophyllotoxin; Taxoids | 2001 |
Laboratory and phase I studies of new cancer drugs.
Topics: Antineoplastic Agents; Bryostatins; Camptothecin; Docetaxel; Humans; Lactones; Macrolides; Neoplasms; Paclitaxel; Taxoids | 1992 |
Taxol: the first of the taxanes, an important new class of antitumor agents.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Drug Evaluation; Drug Evaluation, Preclinical; Drugs, Investigational; Female; Forecasting; Humans; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Paclitaxel; Taxoids | 1992 |
192 trial(s) available for docetaxel anhydrous and Benign Neoplasms
| Article | Year |
|---|---|
Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Docetaxel-Induced Neutropenia in Patients With Solid Tumors: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Diketopiperazines; Docetaxel; Double-Blind Method; Female; Filgrastim; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Polyethylene Glycols; Prostatic Neoplasms; Treatment Outcome | 2022 |
Minimal added value of wetting hair before scalp cooling to prevent chemotherapy-induced alopecia in cancer patients - results from the Dutch Scalp Cooling Registry.
Topics: Alopecia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Hair; Humans; Hypothermia, Induced; Neoplasms; Paclitaxel; Registries; Scalp | 2023 |
Multicenter randomized controlled trial to evaluate the efficacy and tolerability of frozen gloves for the prevention of chemotherapy-induced peripheral neuropathy.
Topics: Antineoplastic Agents; Docetaxel; Freezing; Gloves, Protective; Humans; Hypothermia, Induced; Neoplasms; Peripheral Nervous System Diseases; Quality of Life; Surveys and Questionnaires | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Clinical application of the AUC-guided dosage adjustment of docetaxel-based chemotherapy for patients with solid tumours: a single centre, prospective and randomised control study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Docetaxel; Humans; Neoplasms; Prospective Studies | 2020 |
A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Docetaxel; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasms; Prognosis; Sunitinib; Survival Rate | 2020 |
A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Lymphoma; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Spermine; Sunitinib | 2021 |
Effect of Food on the Pharmacokinetics of the Oral Docetaxel Tablet Formulation ModraDoc006 Combined with Ritonavir (ModraDoc006/r) in Patients with Advanced Solid Tumours.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP3A Inhibitors; Diarrhea; Diet, High-Fat; Docetaxel; Drug Combinations; Fasting; Fatigue; Female; Food-Drug Interactions; Humans; Hypokalemia; Male; Middle Aged; Neoplasms; Ritonavir; Tablets; Therapeutic Equivalency | 2021 |
First-in-human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Delayed-Action Preparations; Docetaxel; Dose-Response Relationship, Drug; Drug Liberation; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nanoparticles; Neoplasms; Treatment Outcome | 2021 |
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Drug Eruptions; Fatigue; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Sarcoma; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2017 |
A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capsules; Docetaxel; Drug Administration Schedule; Drug Compounding; Drug Dosage Calculations; Female; Half-Life; Humans; Male; Maximum Tolerated Dose; Metabolic Clearance Rate; Middle Aged; Neoplasms; Netherlands; Ritonavir; Tablets; Taxoids; Treatment Outcome | 2017 |
Pharmacodynamic study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dideoxynucleosides; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasms; Oxindoles; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Radiopharmaceuticals; Vascular Endothelial Growth Factor A | 2018 |
Role of Skin Tests in the Diagnosis of Immediate Hypersensitivity Reactions to Taxanes: Results of a Multicenter Study.
Topics: Adult; Aged; Antineoplastic Agents; Docetaxel; Drug Hypersensitivity; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Skin Tests | 2019 |
Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Cyclopentanes; Cytochrome P-450 CYP3A Inhibitors; Docetaxel; Drug Interactions; Enzyme Inhibitors; Female; Fluconazole; Humans; Itraconazole; Male; Middle Aged; Neoplasms; Paclitaxel; Pyrimidines | 2019 |
Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; ErbB Receptors; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Quinazolines; Taxoids; Treatment Outcome | 2013 |
A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Double-Blind Method; Electrocardiography; Female; Heart Rate; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Prospective Studies; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Taxoids; Ventricular Function | 2013 |
A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Receptor, IGF Type 1; Sarcoma; Taxoids; Treatment Outcome; Vomiting; Young Adult | 2013 |
Efficacy and tolerability of two scalp cooling systems for the prevention of alopecia associated with docetaxel treatment.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Female; Humans; Hypothermia, Induced; Induction Chemotherapy; Male; Middle Aged; Neoplasms; Palliative Care; Prospective Studies; Risk Reduction Behavior; Scalp; Taxoids | 2013 |
The effect of Echinacea purpurea on the pharmacokinetics of docetaxel.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Cytochrome P-450 CYP3A; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Echinacea; Enzyme Induction; Female; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Plant Extracts; Taxoids | 2013 |
A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Drug Hypersensitivity; Female; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Severity of Illness Index; Taxoids; Tubulin Modulators | 2013 |
A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease-Free Survival; Docetaxel; Female; Gonanes; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Taxoids; Treatment Outcome | 2013 |
Risk-adapted, dose escalation study of weekly docetaxel in the first-line treatment of elderly patients with advanced cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Comorbidity; Docetaxel; Dose-Response Relationship, Drug; Female; Geriatric Assessment; Humans; Male; Multivariate Analysis; Neoplasms; Risk Assessment; Severity of Illness Index; Taxoids | 2013 |
Open-label, randomized, single-dose, crossover study to evaluate the pharmacokinetics and safety differences between two docetaxel products, CKD-810 and Taxotere injection, in patients with advanced solid cancer.
Topics: Adult; Aged; Antineoplastic Agents; Chemistry, Pharmaceutical; Cross-Over Studies; Docetaxel; Drug Delivery Systems; Female; Humans; Injections; Male; Middle Aged; Neoplasms; Neutropenia; Polysorbates; Taxoids | 2014 |
Cryotherapy for docetaxel-induced hand and nail toxicity: randomised control trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cryotherapy; Docetaxel; Female; Freezing; Gloves, Protective; Hand; Humans; Male; Middle Aged; Nail Diseases; Nails; Neoplasms; Single-Blind Method; Skin Diseases; Taxoids | 2014 |
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Exanthema; Fatigue; Febrile Neutropenia; Female; Heterocyclic Compounds, 3-Ring; Humans; Male; Middle Aged; Nausea; Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-akt; Quinazolines; Stomatitis; Taxoids; Tinnitus; Treatment Outcome; Young Adult | 2014 |
A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Interactions; Female; Humans; Male; Middle Aged; Neoplasms; Serine; Taxoids; Treatment Outcome; Young Adult | 2014 |
Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Deoxyuridine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Prodrugs; Taxoids; Treatment Outcome | 2014 |
Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Docetaxel; Drug Interactions; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Response Evaluation Criteria in Solid Tumors; Serine; Taxoids; Young Adult | 2014 |
Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antineoplastic Combined Chemotherapy Protocols; Broadly Neutralizing Antibodies; Carboplatin; Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Polyethylene Glycols; Taxoids | 2015 |
An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cisplatin; Dacarbazine; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines; Sulfonamides; Taxoids; Temozolomide; Young Adult | 2015 |
Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Taxoids; Treatment Outcome | 2014 |
A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors.
Topics: Administration, Intravenous; Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug Monitoring; Female; Florida; Humans; Immunologic Factors; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Taxoids; Time Factors; Treatment Outcome; Tryptophan | 2014 |
Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Interactions; Electrocardiography; Humans; Middle Aged; Neoplasm Metastasis; Neoplasms; Receptor, ErbB-2; Taxoids; Time Factors; Trastuzumab | 2014 |
Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Interactions; Female; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrimidines; Sulfonamides; Taxoids | 2015 |
Lack of a pharmacokinetic interaction between trastuzumab and carboplatin in the presence of docetaxel: results from a phase Ib study in patients with HER2-positive metastatic or locally advanced inoperable solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Interactions; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Receptor, ErbB-2; Taxoids; Trastuzumab | 2015 |
Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arginine; Docetaxel; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hydrolases; Male; Neoplasm Staging; Neoplasms; Polyethylene Glycols; Taxoids; Treatment Outcome | 2015 |
Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Docetaxel; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Taxoids; Tetrahydroisoquinolines; Trabectedin | 2015 |
4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Cytochrome P-450 CYP3A; Docetaxel; Female; Humans; Hydroxycholesterols; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Young Adult | 2015 |
Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors.
Topics: Adolescent; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; Child; Child, Preschool; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Male; Metabolic Clearance Rate; Neoplasms; Neutropenia; Quinolines; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2015 |
Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administration Schedule; Febrile Neutropenia; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Hypertension; Infusions, Intravenous; Male; Middle Aged; Molecular Targeted Therapy; Neoplasms; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Taxoids; Thrombocytopenia; Treatment Outcome; Vascular Endothelial Growth Factor A | 2016 |
A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Aurora Kinase A; Cross-Over Studies; Cyclohexanecarboxylic Acids; Docetaxel; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Taxoids; Thiazoles | 2016 |
Dose modifications in Asian cancer patients with hepatic dysfunction receiving weekly docetaxel: A prospective pharmacokinetic and safety study.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Asian People; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Liver; Liver Diseases; Male; Middle Aged; Neoplasms; ROC Curve; Taxoids | 2016 |
Results of 20- versus 45-min post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hypothermia, Induced; Male; Middle Aged; Neoplasms; Outcome Assessment, Health Care; Prospective Studies; Scalp; Taxoids | 2016 |
ASP9853, an inhibitor of inducible nitric oxide synthase dimerization, in combination with docetaxel: preclinical investigation and a Phase I study in advanced solid tumors.
Topics: Acrylamides; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dimerization; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Mice; Mice, Nude; Middle Aged; Neoplasms; Neutropenia; Nitric Oxide Synthase Type II; Pyrimidines; Taxoids; Xenograft Model Antitumor Assays | 2016 |
Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Surface; Docetaxel; Drug Administration Schedule; Drug Carriers; Female; Glutamate Carboxypeptidase II; Humans; Male; Middle Aged; Nanoparticles; Neoplasms; Taxoids | 2016 |
Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Azepines; Biomarkers; Docetaxel; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasm Grading; Neoplasm Staging; Neoplasms; Pyrimidines; Taxoids; Treatment Outcome | 2016 |
Safety and Efficacy in Advanced Solid Tumors of a Targeted Nanocomplex Carrying the p53 Gene Used in Combination with Docetaxel: A Phase 1b Study.
Topics: Adult; Aged; Cohort Studies; Combined Modality Therapy; Docetaxel; Drug Resistance, Neoplasm; Female; Genes, p53; Humans; Liposomes; Male; Middle Aged; Nanoparticles; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Retreatment; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Polymeric nanoparticle-docetaxel for the treatment of advanced solid tumors: phase I clinical trial and preclinical data from an orthotopic pancreatic cancer model.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; Docetaxel; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Humans; Male; Maximum Tolerated Dose; Mice; Middle Aged; Nanoparticles; Neoplasm Staging; Neoplasms; Pancreatic Neoplasms; Polymers; Taxoids; Treatment Outcome; Tubulin Modulators; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Polyethylene Glycols; Quinazolines; Recombinant Proteins; Taxoids | 2008 |
Phase I trial of weekly docetaxel and daily temozolomide in patients with metastatic disease.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Survival Rate; Taxoids; Temozolomide | 2008 |
Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prognosis; Taxoids; Thalidomide; Treatment Outcome; Young Adult | 2009 |
A phase I/II trial of fixed-dose docetaxel plus irinotecan and escalating doses of estramustine phosphate for second-line or greater treatment of selected advanced solid tumors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Estramustine; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Taxoids; Treatment Outcome | 2009 |
Phase I trial of weekly docetaxel, weekly doxorubicin, daily oral cyclophosphamide, and G-CSF (ConTAC regimen) in advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Taxoids | 2010 |
Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Cohort Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasms; Ritonavir; Taxoids | 2009 |
A double-blind randomized phase II study on the efficacy of topical eye treatment in the prevention of docetaxel-induced dacryostenosis.
Topics: Administration, Topical; Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents; Constriction, Pathologic; Docetaxel; Double-Blind Method; Female; Humans; Lacrimal Apparatus Diseases; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Ophthalmic Solutions; Taxoids; Treatment Outcome | 2010 |
A dose escalation study of docetaxel plus capecitabine in combination with oxaliplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Taxoids | 2010 |
Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endpoint Determination; Female; Half-Life; Humans; Indoles; Male; Middle Aged; Neoplasms; Pyrroles; Sunitinib; Taxoids | 2010 |
Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study.
Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Brain Injuries; Canada; Cerebral Infarction; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Ifosfamide; Male; Maximum Tolerated Dose; Mesna; Middle Aged; Neoplasms; Neutropenia; Taxoids; Thrombocytopenia | 2010 |
Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Polyethylene Glycols; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2011 |
A dose escalation trial of biweekly docetaxel and gemcitabine with filgrastim or pegfilgrastim for the treatment of patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Polyethylene Glycols; Recombinant Proteins; Taxoids | 2010 |
Biodistribution and radiation dosimetry of 11C-labelled docetaxel in cancer patients.
Topics: Aged; Biological Transport; Carbon Radioisotopes; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Metabolic Clearance Rate; Neoplasms; Positron-Emission Tomography; Radiation Dosage; Radiometry; Taxoids; Tomography, X-Ray Computed | 2010 |
Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer.
Topics: Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dexamethasone; Docetaxel; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Least-Squares Analysis; Leukocyte Count; Male; Middle Aged; Neoplasms; Neurokinin-1 Receptor Antagonists; Neutrophils; Ondansetron; Piperazines; Piperidines; Taxoids | 2011 |
Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Cytochrome P-450 CYP3A Inhibitors; Docetaxel; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Ritonavir; Taxoids | 2010 |
The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cellulitis; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Immunoglobulins, Intravenous; Lymphopenia; Male; Middle Aged; Neoplasms; Neutropenia; Prostatic Neoplasms; Receptor, IGF Type 1; Taxoids | 2010 |
Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Docetaxel; Drug Administration Schedule; Drug Interactions; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Michigan; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; New Jersey; Perfusion Imaging; Piperazines; Pyrimidines; Taxoids; Time Factors; Treatment Outcome | 2012 |
REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Agents; Docetaxel; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Immunohistochemistry; Injections, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Oncolytic Virotherapy; Oncolytic Viruses; Reoviridae; Taxoids | 2010 |
Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bilirubin; Creatinine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Imidazoles; Indazoles; Male; Middle Aged; Neoplasms; Patient Selection; Receptors, Vascular Endothelial Growth Factor; Taxoids | 2010 |
Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Deoxycytidine; Docetaxel; Endostatins; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Recombinant Proteins; Survival Rate; Taxoids; Treatment Outcome | 2010 |
The validity of neuropathy and neuropathic pain measures in patients with cancer receiving taxanes and platinums.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Cisplatin; Comorbidity; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasms; Neuralgia; Nursing Assessment; Oncology Nursing; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pain Measurement; Reproducibility of Results; Risk Factors; Taxoids | 2011 |
Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Male; Middle Aged; Neoplasms; Pilot Projects; Piperidines; Pyridines; Taxoids | 2011 |
Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Docetaxel; Gastrointestinal Stromal Tumors; Humans; Maximum Tolerated Dose; Melanoma; Neoplasms; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Research Design; Safety; Taxoids; Treatment Outcome | 2011 |
A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Castration; Docetaxel; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Organoplatinum Compounds; Prognosis; Prostatic Neoplasms; Taxoids | 2013 |
A phase I trial of bexarotene in combination with docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Docetaxel; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Survival Rate; Taxoids; Tetrahydronaphthalenes; Treatment Outcome; Young Adult | 2011 |
The safety and tolerability of intravenous ASA404 when administered in combination with docetaxel (60 or 75 mg/m²) in Japanese patients with advanced or recurrent solid tumors.
Topics: Aged; Alopecia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Appetite; Asian People; Constipation; Docetaxel; Drug Administration Schedule; Fatigue; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Neutropenia; Severity of Illness Index; Taxoids; Treatment Outcome; Xanthones | 2011 |
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Docetaxel; Drug Administration Schedule; Female; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Taxoids | 2012 |
Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antibodies; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Neutropenia; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Taxoids | 2012 |
Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cohort Studies; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Taxoids; Treatment Outcome | 2012 |
Short post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia.
Topics: Alopecia; Antineoplastic Agents; Cryotherapy; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasms; Patient Satisfaction; Scalp Dermatoses; Taxoids; Time Factors; Treatment Outcome | 2012 |
Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administration Schedule; Fatigue; Female; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Taxoids | 2012 |
Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Imidazoles; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Taxoids; Treatment Outcome | 2012 |
PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cell Hypoxia; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Half-Life; Humans; Male; Middle Aged; Neoplasms; Nitrogen Mustard Compounds; Prodrugs; Taxoids | 2012 |
Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines; Skin Diseases; Taxoids | 2013 |
A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Deoxyglucose; Docetaxel; Electrocardiography; Female; Humans; Male; Middle Aged; Neoplasms; Taxoids | 2013 |
A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Cohort Studies; Docetaxel; Drug Administration Schedule; Drug Carriers; Drug Compounding; Drug Resistance, Neoplasm; Excipients; Female; Freeze Drying; Half-Life; Humans; Infusions, Intravenous; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Taxoids; Treatment Outcome | 2013 |
A phase I study of weekly gemcitabine and docetaxel in patients with advanced cancer: a Hoosier Oncology Group Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Area Under Curve; Biotransformation; Chromatography, High Pressure Liquid; Deoxycytidine; Docetaxel; Drug Interactions; Female; Gemcitabine; Half-Life; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2002 |
Phase I study of docetaxel plus ifosfamide in patients with advanced cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Female; Gastrointestinal Diseases; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Ifosfamide; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2002 |
Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics.
Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Confidence Intervals; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Probability; Risk Assessment; Sensitivity and Specificity; Survival Rate; Taxoids; Treatment Outcome | 2002 |
Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2003 |
A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Darbepoetin alfa; Deoxycytidine; Docetaxel; Erythropoietin; Fatigue; Female; Gemcitabine; Humans; Injections, Subcutaneous; Male; Middle Aged; Neoplasms; Paclitaxel; Pilot Projects; Taxoids; Treatment Outcome | 2003 |
Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Recombinant Proteins; Salvage Therapy; Taxoids; Treatment Outcome | 2003 |
A phase I dose-escalation study of docetaxel with granulocyte colony-stimulating factor support in patients with solid tumours.
Topics: Adult; Aged; Docetaxel; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2003 |
A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms; Taxoids; Time Factors; Trastuzumab; Treatment Outcome | 2003 |
Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Polyethylene Glycols; Taxoids; Treatment Outcome | 2003 |
A phase I study of gemcitabine and docetaxel for advanced stage solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Patient Selection; Taxoids | 2003 |
Population pharmacokinetics of weekly docetaxel in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Humans; Male; Middle Aged; Models, Biological; Neoplasms; Taxoids | 2004 |
Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Taxoids | 2004 |
A phase I and pharmacokinetic study of docetaxel combined with Doxil (pegylated liposomal doxorubicin) without and with granulocyte colony stimulating factor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Clinical Trials, Phase I as Topic; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Half-Life; Hematologic Diseases; Humans; Infusions, Intravenous; Liposomes; Male; Middle Aged; Neoplasms; Taxoids | 2004 |
Dexamethasone as a probe for docetaxel clearance.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Biomarkers; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dexamethasone; Docetaxel; Female; Genes, MDR; Genotype; Humans; Male; Middle Aged; Neoplasms; Phenotype; Polymorphism, Single Nucleotide; Reproducibility of Results; Taxoids | 2004 |
Phase I evaluation of docetaxel and topotecan for patients with advanced solid tumors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasms; Taxoids; Topotecan; Treatment Outcome | 2004 |
A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cohort Studies; Diarrhea; Docetaxel; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neoplasms, Squamous Cell; Neutropenia; Organoplatinum Compounds; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2004 |
A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Neoplasms; Taxoids; Thionucleotides; Treatment Outcome | 2004 |
A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Quinazolines; Taxoids; Thymidylate Synthase; Time Factors; Treatment Outcome | 2004 |
Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093).
Topics: Administration, Oral; Aged; Antineoplastic Agents, Phytogenic; Biological Availability; Docetaxel; Drug Administration Schedule; Drug Resistance, Multiple; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Taxoids | 2005 |
Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Dibenzocycloheptenes; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinolines; Taxoids; Time Factors | 2004 |
Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Middle Aged; Neoplasms; Neutropenia; Taxoids | 2005 |
Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients.
Topics: Administration, Oral; Aged; Antiemetics; Antineoplastic Agents, Phytogenic; Aprepitant; Cross-Over Studies; Docetaxel; Female; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Morpholines; Nausea; Neoplasms; Taxoids | 2005 |
Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mucous Membrane; Neoplasms; Taxoids | 2005 |
Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly schedule.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Taxoids | 2005 |
Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Taxoids; Topotecan | 2005 |
A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Cyclooxygenase Inhibitors; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Pyrazoles; Sulfonamides; Taxoids; Treatment Outcome | 2005 |
Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Taxoids; Treatment Outcome; Vomiting | 2005 |
Phase I study of weekly docetaxel and liposomal doxorubicin in patients with advanced solid tumors.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Liposomes; Male; Middle Aged; Neoplasms; Neoplasms, Unknown Primary; Polyethylene Glycols; Prostatic Neoplasms; Stomach Neoplasms; Taxoids; Treatment Outcome | 2005 |
Phase I combining a P-glycoprotein inhibitor, MS209, in combination with docetaxel in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prospective Studies; Quinolines; Taxoids; Treatment Outcome | 2005 |
A randomized trial assessing the utility of a test-dose program with taxanes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Cost Control; Docetaxel; Drug Hypersensitivity; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2005 |
Phase I clinical trial of weekly docetaxel and exisulind, a novel inducer of apoptosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Sulindac; Taxoids | 2006 |
Breath alcohol concentrations in Japanese outpatients following paclitaxel and docetaxel infusion.
Topics: Adult; Aged; Alcoholic Intoxication; Antineoplastic Agents, Phytogenic; Asian People; Breast Neoplasms; Breath Tests; Carcinoma, Non-Small-Cell Lung; Docetaxel; Ethanol; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasms; Outpatients; Ovarian Neoplasms; Paclitaxel; Taxoids | 2005 |
Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Boronic Acids; Bortezomib; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Docetaxel; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Taxoids; Treatment Outcome | 2006 |
A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Half-Life; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Neutropenia; Taxoids; Treatment Outcome | 2006 |
Phase I study of docetaxel and topotecan in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Marrow Cells; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Taxoids; Thrombocytopenia; Topotecan; Treatment Outcome | 2005 |
Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Asthenia; Docetaxel; Dose-Response Relationship, Drug; Etanercept; Fatigue; Female; Humans; Immunoglobulin G; Immunologic Factors; Injections, Subcutaneous; Male; Middle Aged; Neoplasms; Receptors, Tumor Necrosis Factor; Taxoids; Treatment Outcome; Tumor Necrosis Factor-alpha | 2006 |
A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with advanced solid cancers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colorectal Neoplasms; Cyclic AMP-Dependent Protein Kinase RIalpha Subunit; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Oligonucleotides; Pancreatic Neoplasms; Prothrombin Time; Taxoids | 2006 |
Predicting the toxicity of weekly docetaxel in advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasms; Survival Analysis; Taxoids | 2006 |
Phase I and pharmacokinetic evaluation of the combination of orally administered docetaxel and cyclosporin A in tumor-bearing dogs.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cyclosporine; Docetaxel; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Male; Neoplasms; Taxoids | 2006 |
A phase I clinical and pharmacokinetic study of paclitaxel and docetaxel given in combination in patients with solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2006 |
Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme System; Docetaxel; Female; Humans; Ketoconazole; Male; Middle Aged; Neoplasms; Polymorphism, Single Nucleotide; Taxoids | 2006 |
A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Models, Chemical; Morpholines; Neoplasms; Neutropenia; Taxoids | 2006 |
A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasms; Quinazolines; Taxoids | 2007 |
Frequency and characteristics of docetaxel-induced radiation recall phenomenon.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Comorbidity; Docetaxel; Female; Humans; Incidence; Japan; Male; Middle Aged; Neoplasms; Radiation Injuries; Radiation Tolerance; Risk Assessment; Risk Factors; Taxoids | 2006 |
Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment.
Topics: Acetylcarnitine; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carnitine; Chromatography, High Pressure Liquid; Creatinine; Docetaxel; Female; Glucose; Humans; Infusions, Intravenous; Kidney; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Paclitaxel; Phosphates; Taxoids; Urea; Vinblastine; Vinorelbine | 2007 |
Phase I trial of three-weekly docetaxel, carboplatin and oral lenalidomide (Revlimid) in patients with advanced solid tumors.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Taxoids; Thalidomide; Treatment Outcome | 2007 |
A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Aminopterin; Antineoplastic Combined Chemotherapy Protocols; Dietary Supplements; Docetaxel; Female; Folic Acid Antagonists; Homocysteine; Humans; Male; Methylmalonic Acid; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Vitamins | 2007 |
A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pancreatic Neoplasms; Patient Compliance; Stomach Neoplasms; Taxoids; Treatment Outcome | 2006 |
A phase I clinical and pharmacokinetic study of tipifarnib in combination with docetaxel in patients with advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Drug Interactions; Female; Humans; Immune System; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinolones; Taxoids; Treatment Outcome | 2007 |
Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Flavonoids; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Piperidines; Taxoids; Treatment Outcome | 2007 |
A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers.
Topics: Antineoplastic Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Docetaxel; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Ketoconazole; Male; Maximum Tolerated Dose; Midazolam; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Neutropenia; Taxoids | 2008 |
Phase I and pharmacokinetic study of gemcitabine administered at fixed-dose rate, combined with docetaxel/melphalan/carboplatin, with autologous hematopoietic progenitor-cell support, in patients with advanced refractory tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Neoplasms; Taxoids; Transplantation, Autologous | 2007 |
A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cohort Studies; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Receptor, ErbB-2; Recombinant Proteins; Taxoids; Time Factors; Treatment Outcome | 2007 |
Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Mitomycin; Nausea; Neoplasms; Skin Diseases; Taxoids; Treatment Outcome; Vomiting | 2007 |
A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clusterin; Docetaxel; Humans; Neoplasms; Oligonucleotides, Antisense; Taxoids; Thionucleotides | 2008 |
A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines; Taxoids | 2008 |
Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Case-Control Studies; Cryotherapy; Docetaxel; Evaluation Studies as Topic; Female; Follow-Up Studies; Foot Diseases; Freezing; Humans; Male; Middle Aged; Nail Diseases; Neoplasm Invasiveness; Neoplasms; Onycholysis; Taxoids; Treatment Outcome | 2008 |
A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Female; Humans; Kinesins; Male; Middle Aged; Neoplasms; Quinazolines; Taxoids | 2008 |
A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Fatigue; Female; Fibroblast Growth Factor 2; Gastrointestinal Diseases; Glucuronidase; Heparin; Humans; Male; Maximum Allowable Concentration; Middle Aged; Neoplasm Proteins; Neoplasms; Oligosaccharides; Partial Thromboplastin Time; Platelet Factor 4; Taxoids; Vascular Endothelial Growth Factor A | 2008 |
A phase I study of docetaxel and bexarotene.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Docetaxel; Drug Administration Schedule; Fatigue; Female; Humans; Male; Middle Aged; Nausea; Neoplasms; Taxoids; Tetrahydronaphthalenes | 2008 |
Prevention of docetaxel- or paclitaxel-associated taste alterations in cancer patients with oral glutamine: a randomized, placebo-controlled, double-blind study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Double-Blind Method; Dysgeusia; Female; Glutamine; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Risk Factors; Taste; Taxoids; Treatment Outcome | 2008 |
Phase II studies of docetaxel in the treatment of various solid tumours. EORTC Early Clinical Trials Group and the EORTC Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Head and Neck Neoplasms; Humans; Melanoma; Middle Aged; Neoplasms; Paclitaxel; Sarcoma; Stomach Neoplasms; Taxoids | 1995 |
Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis.
Topics: Adult; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 1994 |
[Phase I clinical trial of RP 56976 (docetaxel) a new anticancer drug].
Topics: Adolescent; Adult; Aged; Alopecia; Anorexia; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Paclitaxel; Taxoids | 1994 |
Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 1993 |
Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 1993 |
[Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials].
Topics: Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Humans; Irinotecan; Loperamide; Male; Neoplasms; Neutropenia; Paclitaxel; Remission Induction; Taxoids; Topoisomerase I Inhibitors | 1996 |
Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Nervous System Diseases; Paclitaxel; Paresthesia; Taxoids | 1997 |
Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Feasibility Studies; Female; Follow-Up Studies; Humans; Leukopenia; Male; Middle Aged; Nausea; Neoplasms; Paclitaxel; Taxoids; Vomiting | 1997 |
Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Docetaxel; Drug Administration Schedule; Female; Humans; Incidence; Infant; Infusions, Intravenous; Male; Neoplasms; Neutropenia; Paclitaxel; Severity of Illness Index; Taxoids; Treatment Outcome | 1997 |
Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography.
Topics: Aged; Antineoplastic Agents, Phytogenic; Chromatography, High Pressure Liquid; Docetaxel; Female; Humans; Neoplasms; Paclitaxel; Reproducibility of Results; Sensitivity and Specificity; Taxoids | 1997 |
Docetaxel and cyclophosphamide in patients with advanced solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Humans; Neoplasms; Neutropenia; Paclitaxel; Taxoids | 1997 |
Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.
Topics: Adenocarcinoma; Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Cyclophosphamide; Dexamethasone; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fever; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Premedication; Remission Induction; Sarcoma; Taxoids | 1997 |
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Bayes Theorem; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Edema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Prospective Studies; Taxoids | 1998 |
Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Feasibility Studies; Female; Follow-Up Studies; Humans; Ifosfamide; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Paclitaxel; Taxoids; Vomiting | 1998 |
Lhermitte's sign following chemotherapy with docetaxel.
Topics: Adult; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Humans; Infusions, Intravenous; Magnetic Resonance Imaging; Middle Aged; Neoplasms; Paclitaxel; Spinal Cord; Spinal Cord Diseases; Taxoids | 1998 |
Docetaxel and ifosfamide in patients with advanced solid tumors: results of a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Feasibility Studies; Female; Humans; Ifosfamide; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 1998 |
Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Dexamethasone; Docetaxel; Drug Administration Schedule; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 1998 |
Optimal sampling strategies for bayesian estimation of docetaxel (Taxotere) clearance.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Infusions, Intravenous; Likelihood Functions; Lung Neoplasms; Metabolic Clearance Rate; Neoplasms; Paclitaxel; Prospective Studies; Sampling Studies; Specimen Handling; Taxoids | 1997 |
Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dexamethasone; Docetaxel; Female; Glucocorticoids; Humans; Male; Middle Aged; Neoplasms; Nervous System Diseases; Paclitaxel; Prospective Studies; Taxoids | 1998 |
Weekly schedules of docetaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 1998 |
Concurrent twice-a-week docetaxel and radiotherapy: a dose escalation trial with immunological toxicity evaluation.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Dose Fractionation, Radiation; Drug Administration Schedule; Feasibility Studies; Female; Glioblastoma; Humans; Lung Neoplasms; Lymphocytes; Lymphopenia; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Pelvic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy; Survival Analysis; Taxoids; Treatment Outcome | 1999 |
A phase I study of docetaxel and 5-fluorouracil in patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 1999 |
Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group trial.
Topics: Adolescent; Adult; Child; Child, Preschool; Docetaxel; Dose-Response Relationship, Drug; Drug Eruptions; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Infant; Male; Neoplasms; Neutropenia; Paclitaxel; Recombinant Proteins; Taxoids | 1999 |
Weekly docetaxel in minimally pretreated cancer patients: a dose-escalation study focused on feasibility and cumulative toxicity of long-term administration.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 1999 |
Docetaxel (Taxotere) administered in weekly schedules.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 1999 |
A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Taxoids; Thrombocytopenia; Treatment Outcome | 2000 |
A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Methylprednisolone; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Taxoids | 2000 |
Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion.
Topics: Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Alopecia; Antineoplastic Agents, Phytogenic; Area Under Curve; Aspartate Aminotransferases; Breast Neoplasms; Diarrhea; Docetaxel; Fatigue; Female; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Mouth Mucosa; Neoplasms; Neutropenia; Paclitaxel; Stomatitis; Taxoids; Time Factors | 2000 |
Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Humans; Infusions, Intravenous; Irinotecan; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
Prevention of chemotherapy-induced alopecia using an effective scalp cooling system.
Topics: Adult; Aged; Alopecia; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cryotherapy; Docetaxel; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Scalp; Taxoids | 2000 |
The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzazepines; Docetaxel; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Male; Middle Aged; Mouth Mucosa; Neoplasms; Neutropenia; Paclitaxel; Quinolines; Stomatitis; Taxoids; Vomiting | 2000 |
A phase I trial of docetaxel and gemcitabine in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
Phase I/II dose escalation study of docetaxel and carboplatin combination supported with amifostine and GM-CSF in patients with incomplete response following docetaxel chemo-radiotherapy: additional chemotherapy enhances regression of residual cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Docetaxel; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasm, Residual; Neoplasms; Paclitaxel; Taxoids | 2000 |
A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Biotransformation; Capecitabine; Carboxylic Ester Hydrolases; Deamination; Deoxycytidine; Dexamethasone; Docetaxel; Drug Administration Schedule; Female; Fever; Fluorouracil; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Liver; Male; Maximum Tolerated Dose; Methylprednisolone; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Paronychia; Prodrugs; Remission Induction; Taxoids; Treatment Outcome | 2000 |
Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug Interactions; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukocyte Count; Male; Middle Aged; Neoplasms; Paclitaxel; Platelet Count; Recombinant Proteins; Taxoids; Topotecan | 2000 |
Successful rechallenge with taxanes following prophylactic ketotifen in patients who had developed severe hypersensitivity reactions.
Topics: Adult; Aged; Anti-Allergic Agents; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Hypersensitivity; Female; Humans; Ketotifen; Male; Middle Aged; Neoplasms; Paclitaxel; Pilot Projects; Taxoids | 2000 |
Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2000 |
Phase I study of docetaxel and topotecan in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Topotecan | 2000 |
A dose escalation study of weekly docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Fever; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Taxoids | 2000 |
Phase I clinical trial of weekly combined paclitaxel plus docetaxel in patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Erythema; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2000 |
Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Cyclosporine; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2001 |
Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2001 |
Phase I pharmacokinetic and sequence finding study of the combination of docetaxel and methotrexate in patients with solid tumours.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Synergism; Female; Humans; Male; Methotrexate; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2002 |
Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Thymidine Phosphorylase | 2002 |
Phase I trial of Taxotere: five-day schedule.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Mouth Mucosa; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 1992 |
Laboratory and phase I studies of new cancer drugs.
Topics: Antineoplastic Agents; Bryostatins; Camptothecin; Docetaxel; Humans; Lactones; Macrolides; Neoplasms; Paclitaxel; Taxoids | 1992 |
310 other study(ies) available for docetaxel anhydrous and Benign Neoplasms
| Article | Year |
|---|---|
Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Neoplasms; Noscapine | 2015 |
Novel Benzo[a]quinolizidine Analogs Induce Cancer Cell Death through Paraptosis and Apoptosis.
Topics: Animals; Apoptosis; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Mice; Molecular Structure; Neoplasms; Quinolizidines; Structure-Activity Relationship; Tumor Cells, Cultured | 2016 |
Synthesis and biological evaluation of novel larotaxel analogues.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chemistry Techniques, Synthetic; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Mice, SCID; Molecular Docking Simulation; Neoplasms; Structure-Activity Relationship; Taxoids | 2018 |
Synthesis, anticancer activity and molecular modeling studies of 1,2,4-triazole derivatives as EGFR inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Molecular Docking Simulation; Neoplasms; Structure-Activity Relationship; Triazoles | 2018 |
Four new antitumor metabolites isolated from a mutant 3-f-31 strain derived from Penicillium purpurogenum G59.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biological Products; Cell Line, Tumor; HCT116 Cells; Humans; Mice; Models, Molecular; Mutation; Neoplasms; Penicillium | 2018 |
Polymorphs, co-crystal structure and pharmacodynamics study of MBRI-001, a deuterium-substituted plinabulin derivative as a tubulin polymerization inhibitor.
Topics: Animals; Binding Sites; Cell Line, Tumor; Cell Survival; Crystallography, X-Ray; Deuterium; Diketopiperazines; Humans; Mice; Mice, Nude; Molecular Conformation; Molecular Dynamics Simulation; Neoplasms; Protein Structure, Tertiary; Tubulin; Tubulin Modulators | 2019 |
Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models.
Topics: Animals; Antineoplastic Agents; Biological Availability; Cell Line, Tumor; Drug Discovery; Glutaminase; Humans; Male; Mice, SCID; Molecular Docking Simulation; Neoplasms; Pyridazines; Thiadiazoles | 2019 |
DTX@VTX NPs synergy PD-L1 immune checkpoint nanoinhibitor to reshape immunosuppressive tumor microenvironment for enhancing chemo-immunotherapy.
Topics: Animals; Antineoplastic Agents; B7-H1 Antigen; Benzazepines; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Docetaxel; Drug Synergism; Female; Immunologic Factors; Immunotherapy; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Small Molecule Libraries; Transplantation, Homologous; Tumor Microenvironment | 2021 |
Preparation and Characterization of Docetaxel-PLGA Nanoparticles Coated with Folic Acid-chitosan Conjugate for Cancer Treatment.
Topics: Chitosan; Docetaxel; Folic Acid; Humans; Lactic Acid; Nanoparticles; Neoplasms; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2022 |
Synergistic chemo-photothermal cancer therapy of pH-responsive polymeric nanoparticles loaded IR825 and DTX with charge-reversal property.
Topics: Animals; Cell Line, Tumor; Docetaxel; Doxorubicin; Humans; Hydrogen-Ion Concentration; Hyperthermia, Induced; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Phototherapy; Photothermal Therapy; Polymers; Tumor Microenvironment | 2022 |
Docetaxel-triggered SIDT2/NOX4/JNK/HuR signaling axis is associated with TNF-α-mediated apoptosis of cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Docetaxel; ELAV-Like Protein 1; Gene Expression Regulation; Humans; JNK Mitogen-Activated Protein Kinases; MCF-7 Cells; MicroRNAs; NADPH Oxidase 4; Neoplasms; Nucleotide Transport Proteins; Proteins; Reactive Oxygen Species; RNA Interference; Signal Transduction; Tumor Necrosis Factor-alpha; U937 Cells | 2022 |
A novel targeted multifunctional nanoplatform for visual chemo-hyperthermia synergy therapy on metastatic lymph nodes via lymphatic delivery.
Topics: Animals; Antibodies; Antineoplastic Agents; Apoptosis; Carbon; Cell Line, Tumor; Docetaxel; Female; Humans; Hyperthermia, Induced; Hypoxia-Inducible Factor 1, alpha Subunit; Infrared Rays; Lymph Nodes; Lymphatic Metastasis; Nanomedicine; Nanoparticles; Neoplasms; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Transplantation, Heterologous | 2021 |
Cancer cell membrane-coated nanoparticles for bimodal imaging-guided photothermal therapy and docetaxel-enhanced immunotherapy against cancer.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Membrane; Cell Survival; Docetaxel; Ferrocyanides; Humans; Imiquimod; Immunotherapy; Infrared Rays; Macrophages; Mice; Mice, Nude; Nanoparticles; Neoplasms; Optical Imaging; Photothermal Therapy; Polylactic Acid-Polyglycolic Acid Copolymer | 2021 |
Biodegradable nanoparticles combining cancer cell targeting and anti-angiogenic activity for synergistic chemotherapy in epithelial cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Carriers; Endothelial Cells; Folic Acid; Nanoparticles; Neoplasms; Zebrafish | 2022 |
Depleting Tumor Infiltrating B Cells to Boost Antitumor Immunity with Tumor Immune-Microenvironment Reshaped Hybrid Nanocage.
Topics: Cell Line, Tumor; Cytokines; Docetaxel; Humans; Immunotherapy; Neoplasms; Tumor Microenvironment | 2022 |
Development of poly(
Topics: Antineoplastic Agents; Cell Line, Tumor; Containment of Biohazards; Coumaric Acids; Docetaxel; Drug Carriers; Nanoparticles; Neoplasms | 2022 |
Multistage pH-responsive codelivery liposomal platform for synergistic cancer therapy.
Topics: Antineoplastic Agents; Docetaxel; Hydrogen-Ion Concentration; Liposomes; Neoplasms; RNA, Small Interfering | 2022 |
Monoglycocalix[4]arene-based nanoparticles for tumor selective drug delivery
Topics: Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Carriers; Drug Delivery Systems; Glucose Transporter Type 1; Humans; Nanoparticles; Neoplasms | 2022 |
Autophagy responsive intra-intercellular delivery nanoparticles for effective deep solid tumor penetration.
Topics: Autophagy; Cell Line, Tumor; Chloroquine; Docetaxel; Drug Delivery Systems; Humans; Nanoparticles; Neoplasms; Tumor Microenvironment | 2022 |
Docetaxel in combination with metformin enhances antitumour efficacy in metastatic breast carcinoma models: a promising cancer targeting based on PEGylated liposomes.
Topics: Ammonium Sulfate; Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Liposomes; Metformin; Mice; Mice, Inbred BALB C; Neoplasms; Phosphates; Polyethylene Glycols; Tissue Distribution | 2022 |
Novel Self-Assembled Micelles With Increased Tumor Penetration and Anti-Tumor Efficiency Against Breast Cancer.
Topics: Acitretin; Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Carriers; Excipients; Female; Methanol; Mice; Micelles; Neoplasms; Polysorbates; Rats; Surface-Active Agents; Taxoids; Tretinoin | 2022 |
Docetaxel-loaded M1 macrophage-derived exosomes for a safe and efficient chemoimmunotherapy of breast cancer.
Topics: Docetaxel; Exosomes; Humans; Immunotherapy; Macrophages; Neoplasms; Tumor Microenvironment | 2022 |
Enhanced phosphorylation of c-Jun by cisplatin treatment as a potential predictive biomarker for cisplatin response in combination with patient-derived tumor organoids.
Topics: Antineoplastic Agents; Biomarkers; Cisplatin; Docetaxel; Humans; Neoplasms; Organoids; Phosphorylation | 2022 |
Development of a liquid chromatography-tandem mass spectrometry method for the analysis of docetaxel-loaded Poly(lactic-co-glycolic acid) nanoparticles.
Topics: Chromatography, Liquid; Docetaxel; Glycols; Humans; Nanoparticles; Neoplasms; Polylactic Acid-Polyglycolic Acid Copolymer; Tandem Mass Spectrometry; United States | 2023 |
pH/Redox Dual-Responsive Drug Delivery System with on-Demand RGD Exposure for Photochemotherapy of Tumors.
Topics: Docetaxel; Drug Delivery Systems; Humans; Hydrogen-Ion Concentration; Micelles; Neoplasms; Oligopeptides; Oxidation-Reduction; Photochemotherapy; Tumor Microenvironment | 2022 |
Preclinical evaluation of albumin-bound docetaxel nanoparticles as potential anti-cancer products.
Topics: Albumins; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Carriers; Drug Delivery Systems; Humans; Nanoparticles; Neoplasms; Solvents | 2023 |
Pharmacological ascorbate potentiates combination nanomedicines and reduces cancer cell stemness to prevent post-surgery recurrence and systemic metastasis.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Mice; Nanomedicine; Neoplasms; Neoplastic Stem Cells; Oxaliplatin | 2023 |
A degradome-based prognostic signature that correlates with immune infiltration and tumor mutation burden in breast cancer.
Topics: Animals; Cyclophosphamide; Docetaxel; Female; Neoplasms; Nomograms; Phosphatidylinositol 3-Kinases; Prognosis | 2023 |
Targeting the IL1β Pathway for Cancer Immunotherapy Remodels the Tumor Microenvironment and Enhances Antitumor Immune Responses.
Topics: Animals; Cell Line, Tumor; Docetaxel; Immunity; Immunotherapy; Interleukin-1beta; Mice; Neoplasms; Tumor Microenvironment | 2023 |
Reduction-Responsive Docetaxel Prodrug Encapsulated within Human Serum Albumin Nanoparticles for Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Carriers; Humans; Mice; Nanoparticles; Neoplasms; Paclitaxel; Prodrugs; Serum Albumin, Human | 2023 |
Exploiting docetaxel-induced tumor cell necrosis with tumor targeted delivery of IL-12.
Topics: Animals; B7-H1 Antigen; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Docetaxel; Immunotherapy; Interleukin-12; Mice; Necrosis; Neoplasms; Tumor Microenvironment | 2023 |
Smart hydrothermally responsive microneedle for topical tumor treatment.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Delivery Systems; Drug Liberation; Micelles; Neoplasms | 2023 |
Biomimetic Nanoparticle with Glutathione Depletion and Amplified ROS Generation Capabilities for Synergistic Chemo-Sonodynamic Therapy in Squamous Cell Carcinomas.
Topics: Biomimetics; Carcinoma, Squamous Cell; Cell Line, Tumor; Docetaxel; Glutathione; Humans; Nanoparticles; Neoplasms; Reactive Oxygen Species; Ultrasonic Therapy | 2023 |
Semi-physiological Enriched Population Pharmacokinetic Modelling to Predict the Effects of Pregnancy on the Pharmacokinetics of Cytotoxic Drugs.
Topics: Antineoplastic Agents; Child; Docetaxel; Doxorubicin; Epirubicin; Female; Humans; Models, Biological; Neoplasms; Paclitaxel; Pregnancy | 2023 |
A Biomimetic Nanogel System Restores Macrophage Phagocytosis for Magnetic Resonance Imaging-Guided Synergistic Chemoimmunotherapy of Breast Cancer.
Topics: Animals; Biomimetics; Cell Line, Tumor; Docetaxel; Immunotherapy; Macrophages; Magnetic Resonance Imaging; Mice; Nanogels; Nanoparticles; Neoplasms; Phagocytosis; Polyethyleneimine; Tumor Microenvironment | 2023 |
Docetaxel-loaded pH/ROS dual-responsive nanoparticles with self-supplied ROS for inhibiting metastasis and enhancing immunotherapy of breast cancer.
Topics: Docetaxel; Hydrogen-Ion Concentration; Nanoparticles; Nanostructures; Neoplasms; Reactive Oxygen Species | 2023 |
Sialic acid-decorated liposomes enhance the anti-cancer efficacy of docetaxel in tumor-associated macrophages.
Topics: Animals; Docetaxel; Liposomes; Mice; N-Acetylneuraminic Acid; Neoplasms; NIH 3T3 Cells; Sialic Acid Binding Ig-like Lectin 1; Tissue Distribution; Tumor Microenvironment; Tumor-Associated Macrophages | 2023 |
Taxane chemotherapy induces stromal injury that leads to breast cancer dormancy escape.
Topics: Animals; Cytokines; Docetaxel; Granulocyte Colony-Stimulating Factor; Interleukin-6; Mice; Mitogen-Activated Protein Kinase Kinases; Neoplasms; Taxoids | 2023 |
Wounding the stroma: Docetaxel's role in dormant breast cancer escape.
Topics: Bridged-Ring Compounds; Cytokines; Docetaxel; Neoplasms; Taxoids | 2023 |
Immune-triggered cancer treatment by intestinal lymphatic delivery of docetaxel-loaded nanoparticle.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Chondroitin Sulfates; Docetaxel; Drug Liberation; Glycocholic Acid; Humans; Ileum; Lymphatic Vessels; Macrophages; Male; Mice, Inbred C57BL; Nanoparticles; Neoplasms; Rats, Sprague-Dawley; T-Lymphocytes, Cytotoxic | 2019 |
Keratin nanoparticles co-delivering Docetaxel and Chlorin e6 promote synergic interaction between chemo- and photo-dynamic therapies.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biocompatible Materials; Cell Membrane Permeability; Cell Survival; Chlorophyllides; Docetaxel; Drug Carriers; Drug Compounding; Drug Liberation; Drug Synergism; HeLa Cells; Humans; Keratins; Nanoparticles; Neoplasms; Photochemotherapy; Photosensitizing Agents; Porphyrins; Spheroids, Cellular | 2019 |
In Vivo Environment-Adaptive Nanocomplex with Tumor Cell-Specific Cytotoxicity Enhances T Cells Infiltration and Improves Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Aspirin; CD8-Positive T-Lymphocytes; Cell Death; Cell Line, Tumor; Docetaxel; Endocytosis; Heparitin Sulfate; Humans; MCF-7 Cells; Mice, Inbred BALB C; Nanoparticles; Neoplasm Metastasis; Neoplasms; Polyethylene Glycols; Polyethyleneimine; Tissue Distribution | 2019 |
Fatal neutropenic enterocolitis associated with docetaxel use: A review of cases reported to the United States Food and Drug Administration Adverse Event Reporting System.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Antineoplastic Agents; Docetaxel; Enterocolitis, Neutropenic; Female; Humans; Male; Middle Aged; Neoplasms; United States; United States Food and Drug Administration | 2020 |
A Population Pharmacokinetic Model of Oral Docetaxel Coadministered With Ritonavir to Support Early Clinical Development.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Clinical Trials, Phase I as Topic; Computer Simulation; Cytochrome P-450 CYP3A Inhibitors; Docetaxel; Dosage Forms; Drug Administration Schedule; Humans; Infusions, Intravenous; Models, Biological; Neoplasms; Ritonavir; Software | 2020 |
Exposure to Docetaxel in the Elderly Patient Population: a Population Pharmacokinetic Study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neoplasms; Treatment Outcome | 2019 |
Genetic associations of docetaxel-based chemotherapy-induced myelosuppression in Chinese Han population.
Topics: Aged; Antineoplastic Agents; Asian People; Biomarkers; Bone Marrow; Docetaxel; Female; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Neoplasms; Polymorphism, Single Nucleotide | 2020 |
Safety and tolerability of cryocompression as a method of enhanced limb hypothermia to reduce taxane-induced peripheral neuropathy.
Topics: Adult; Aged; Cryotherapy; Docetaxel; Extremities; Female; Humans; Hypothermia, Induced; Male; Middle Aged; Neoplasms; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Pilot Projects; Retrospective Studies; Treatment Outcome | 2020 |
Taxotere Induces Dephosphorylation of MET in Patient-derived Tumor Models.
Topics: Animals; Antineoplastic Agents; Biomarkers; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Docetaxel; Humans; Mice; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-met; Signal Transduction; Xenograft Model Antitumor Assays | 2020 |
Selective Intratumoral Drug Release and Simultaneous Inhibition of Oxidative Stress by a Highly Reductive Nanosystem and Its Application as an Anti-tumor Agent.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Carriers; Drug Liberation; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms; Oxidative Stress; Rats, Sprague-Dawley; Reactive Oxygen Species | 2020 |
An industrially viable technique for fabrication of docetaxel NLCs for oncotherapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Delayed-Action Preparations; Docetaxel; Drug Carriers; Drug Liberation; Drug Stability; Drug Storage; Humans; Humidity; Lipids; Male; Nanostructures; Neoplasms; Particle Size; Rats; Rats, Sprague-Dawley; Temperature; Thermodynamics | 2020 |
Usefulness of melatonin as complementary to chemotherapeutic agents at different stages of the angiogenic process.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Docetaxel; Drug Synergism; Gene Expression; Human Umbilical Vein Endothelial Cells; Humans; Insulin-Like Growth Factor I; Jagged-1 Protein; Melatonin; Neoplasms; Neovascularization, Pathologic; Receptor, Fibroblast Growth Factor, Type 3; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor D; Vinorelbine | 2020 |
Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Docetaxel; Drug Evaluation, Preclinical; Female; Humans; Mice; Mice, Nude; Neoplasms; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Enzymatic synthesis of PEG-poly(amine-co-thioether esters) as highly efficient pH and ROS dual-responsive nanocarriers for anticancer drug delivery.
Topics: Animals; Antineoplastic Agents; Docetaxel; Drug Carriers; Drug Delivery Systems; HeLa Cells; Humans; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Polyethylene Glycols; Xenograft Model Antitumor Assays | 2019 |
An improved LC-MS/MS method for determination of docetaxel and its application to population pharmacokinetic study in Chinese cancer patients.
Topics: Adult; Antineoplastic Agents; China; Chromatography, Liquid; Docetaxel; Humans; Linear Models; Neoplasms; Reproducibility of Results; Sensitivity and Specificity; Solid Phase Extraction; Tandem Mass Spectrometry; Young Adult | 2020 |
Engineering Thermo-pH Dual Responsive Hydrogel for Enhanced Tumor Accumulation, Penetration, and Chemo-Protein Combination Therapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Delivery Systems; Drug Liberation; Drug Synergism; Female; Granzymes; Humans; Hydrogels; Hydrogen-Ion Concentration; Injections; Mice, Inbred C57BL; Micelles; Neoplasms; Polyethylene Glycols; Temperature | 2020 |
Oxaliplatin- and docetaxel-induced polyneuropathy: clinical and neurophysiological characteristics.
Topics: Aged; Antineoplastic Agents; Diagnostic Techniques, Neurological; Docetaxel; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasms; Neuralgia; Oxaliplatin; Polyneuropathies; Prospective Studies; Quality of Life; Severity of Illness Index | 2020 |
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; Docetaxel; Endosomes; Female; Fibrinolytic Agents; Folate Receptor 1; Folic Acid; Heparin; Humans; In Vitro Techniques; Mice; Mice, Inbred BALB C; Micelles; Nanoparticles; Neoplasms; Patents as Topic | 2020 |
Bile Acid Tethered Docetaxel-Based Nanomicelles Mitigate Tumor Progression through Epigenetic Changes.
Topics: Animals; Antineoplastic Agents; Calcium-Binding Proteins; Cell Line, Tumor; CpG Islands; Demethylation; Disease Progression; Docetaxel; Epigenesis, Genetic; Extracellular Matrix Proteins; Female; Lithocholic Acid; Mice, Inbred BALB C; Micelles; Neoplasms; Surface-Active Agents | 2021 |
Population Pharmacokinetics of Docetaxel, Paclitaxel, Doxorubicin and Epirubicin in Pregnant Women with Cancer: A Study from the International Network of Cancer, Infertility and Pregnancy (INCIP).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Epirubicin; Female; Humans; Infertility; Neoplasms; Paclitaxel; Pregnancy; Pregnant Women; Taxoids | 2021 |
Single nucleotide polymorphisms to predict taxanes toxicities and effectiveness in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Albumins; ATP Binding Cassette Transporter, Subfamily B; Cytochrome P-450 CYP3A; Docetaxel; Female; Genotype; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Pharmacogenetics; Polymorphism, Single Nucleotide; Prospective Studies; Taxoids | 2021 |
Pressure-driven accumulation of Mn-doped mesoporous silica nanoparticles containing 5-aza-2-deoxycytidine and docetaxel at tumours with a dry cupping device.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Docetaxel; Drug Carriers; Drug Delivery Systems; Humans; Manganese; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Nanomedicine; Nanoparticles; Neoplasms; Porosity; Silicon Dioxide | 2021 |
Impact of Clinical Pharmacy Services on Patient Management in the Chemotherapy Infusion Clinics: A 5-Year Study at a Comprehensive Cancer Center.
Topics: Adult; Carboplatin; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Humans; Neoplasms; Pharmacists; Pharmacy Service, Hospital; Retrospective Studies; Zoledronic Acid | 2022 |
The Circadian Protein PER1 Modulates the Cellular Response to Anticancer Treatments.
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Carcinogenesis; Cell Cycle; Cell Line, Tumor; Circadian Rhythm; Cisplatin; Docetaxel; Drug Chronotherapy; Etoposide; Humans; Mice; Neoplasms; Period Circadian Proteins; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2021 |
Efficacy of S-1 plus docetaxel in the treatment of metastatic extramammary Paget's disease: a multicentre retrospective study.
Topics: Docetaxel; Genital Neoplasms, Male; Humans; Male; Neoplasms; Paget Disease, Extramammary; Retrospective Studies | 2021 |
Novel pegylated liposomal formulation of docetaxel with 3-n-pentadecylphenol derivative for cancer therapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Liberation; Humans; Liposomes; MCF-7 Cells; Mice; Neoplasms; Polyethylene Glycols | 2021 |
Natural history of nasal vestibulitis associated with paclitaxel, docetaxel, and other chemotherapy agents: a Minnesota Cancer Clinical Trials Network (MNCCTN) study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Minnesota; Neoplasms; Paclitaxel | 2021 |
Anti-Cancer Activity Based on the High Docetaxel Loaded Poly(2-Oxazoline)s Micelles.
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Carriers; Drug Liberation; Endocytosis; Humans; Hydrophobic and Hydrophilic Interactions; Male; Maximum Tolerated Dose; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Micelles; Neoplasms; Oxazoles; Particle Size; Surface-Active Agents; Tissue Distribution | 2021 |
Green surfactant-dendrimer aggreplexes: An ingenious way to launch dual attack on arch-enemy cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Dendrimers; Docetaxel; Drug Carriers; Nanoparticles; Neoplasms; Particle Size; Surface-Active Agents | 2021 |
Metformin alters therapeutic effects in the BALB/c tumor therapy model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BALB 3T3 Cells; Carcinogens; Cell Survival; Cell Transformation, Neoplastic; Culture Media; Docetaxel; Doxorubicin; Drug Evaluation, Preclinical; Drug Interactions; Fluorouracil; Glucose; Humans; Metformin; Methylcholanthrene; Mice; Mitomycin; Neoplasms | 2021 |
Plasmonic photothermal release of docetaxel by gold nanoparticles incorporated onto halloysite nanotubes with conjugated 2D8-E3 antibodies for selective cancer therapy.
Topics: Antineoplastic Agents; Cell Line, Tumor; Clay; Docetaxel; Drug Carriers; Drug Delivery Systems; Drug Liberation; Female; Gold; Humans; Metal Nanoparticles; Nanocomposites; Nanotubes; Neoplasms; Ovarian Neoplasms; Particle Size | 2021 |
Docetaxel-loaded RIPL peptide (IPLVVPLRRRRRRRRC)-conjugated liposomes: Drug release, cytotoxicity, and antitumor efficacy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Liberation; Female; Humans; Liposomes; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Peptides; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
A Smart Responsive Dual Aptamers-Targeted Bubble-Generating Nanosystem for Cancer Triplex Therapy and Ultrasound Imaging.
Topics: Animals; Aptamers, Nucleotide; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Docetaxel; Drug Liberation; Humans; Injections, Intravenous; Liposomes; MCF-7 Cells; Mice; Nanoparticles; Neoplasms; Temperature; Tissue Distribution; Ultrasonography | 2017 |
Novel Approach of Using Near-Infrared Responsive PEGylated Gold Nanorod Coated Poly(l-lactide) Microneedles to Enhance the Antitumor Efficiency of Docetaxel-Loaded MPEG-PDLLA Micelles for Treating an A431 Tumor.
Topics: Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Carriers; Gold; Humans; Micelles; Nanotubes; Neoplasms; Polyesters; Polyethylene Glycols | 2017 |
Cholic acid-based novel micellar nanoplatform for delivering FDA-approved taxanes.
Topics: Antineoplastic Agents; Bridged-Ring Compounds; Cell Line, Tumor; Cholic Acid; Docetaxel; Drug Carriers; Humans; Micelles; Nanoparticles; Neoplasms; Paclitaxel; Taxoids | 2017 |
Simultaneous sentinel lymph node computed tomography and locoregional chemotherapy for lymph node metastasis in rabbit using an iodine-docetaxel emulsion.
Topics: Animals; Disease Models, Animal; Docetaxel; Drug Stability; Emulsions; Iodine; Lymphatic Metastasis; Male; Neoplasm Staging; Neoplasms; Particle Size; Rabbits; Sentinel Lymph Node; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring.
Topics: Antineoplastic Agents; Computer Simulation; Docetaxel; Drug Monitoring; Humans; Leukocyte Count; Models, Biological; Neoplasms; Neutropenia; Neutrophils; Taxoids; Time Factors | 2017 |
Design of theranostic nanomedicine (II): synthesis and physicochemical properties of a biocompatible polyphosphazene-docetaxel conjugate.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chemistry Techniques, Synthetic; Docetaxel; Drug Delivery Systems; Drug Liberation; Half-Life; Humans; Mice, Inbred BALB C; Micelles; Neoplasms; Organophosphorus Compounds; Polyethylene Glycols; Polymers; Solubility; Taxoids; Theranostic Nanomedicine; Tissue Distribution; Xenograft Model Antitumor Assays | 2017 |
Ternary cocktail nanoparticles for sequential chemo-photodynamic therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Carriers; Gemcitabine; Humans; Nanoparticles; Neoplasms; Photochemotherapy; Taxoids | 2017 |
Inflammatory cytokine production in tumor cells upon chemotherapy drug exposure or upon selection for drug resistance.
Topics: Antineoplastic Agents; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation; Humans; Lipopolysaccharides; MCF-7 Cells; Myeloid Differentiation Factor 88; Neoplasm Proteins; Neoplasms; Taxoids; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2017 |
Identification of Angiogenesis Inhibitors Using a Co-culture Cell Model in a High-Content and High-Throughput Screening Platform.
Topics: Angiogenesis Inhibitors; Bortezomib; Cell Line, Transformed; Coculture Techniques; Docetaxel; Drug Evaluation, Preclinical; Endothelium, Vascular; High-Throughput Screening Assays; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mesenchymal Stem Cells; Neoplasms; Neovascularization, Pathologic; NF-kappa B; Signal Transduction; Telomerase; Topotecan | 2018 |
NGR-modified pH-sensitive liposomes for controlled release and tumor target delivery of docetaxel.
Topics: Animals; Cell Line, Tumor; Cholesterol Esters; Delayed-Action Preparations; Docetaxel; Drug Delivery Systems; Drug Liberation; Humans; Hydrogen-Ion Concentration; Liposomes; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Oligopeptides; Polyethylene Glycols; Taxoids; Xenograft Model Antitumor Assays | 2017 |
Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio.
Topics: Docetaxel; Endpoint Determination; Humans; Immunotherapy; Lung Neoplasms; Neoplasms; Nivolumab; Proportional Hazards Models; Randomized Controlled Trials as Topic; Research Design; Survival Analysis; Treatment Outcome | 2017 |
Facile Synthesis of Lipid-Perfluorocarbon Nanoemulsion Coated with Silica Shell as an Ultrasound Imaging Agent.
Topics: A549 Cells; Animals; Antineoplastic Agents; Cell Survival; Contrast Media; Docetaxel; Drug Carriers; Drug Liberation; Fluorocarbons; Humans; Hyaluronic Acid; Male; Mice; Nanoparticles; Neoplasms; Particle Size; Phosphatidylcholines; Silicon Dioxide; Transplantation, Heterologous; Ultrasonography | 2018 |
Docetaxel promotes the generation of anti-tumorigenic human macrophages.
Topics: Antineoplastic Agents; Carcinogenesis; Cell Differentiation; Dendritic Cells; Docetaxel; Female; Humans; Immunity, Innate; Macrophages; Monocytes; Myeloid Cells; Neoplasms; Paclitaxel; T-Lymphocytes; Taxoids | 2018 |
A long non-coding RNA inside the type 2 transglutaminase gene tightly correlates with the expression of its transcriptional variants.
Topics: Carcinogenesis; Docetaxel; Doxorubicin; Exons; Female; Gene Expression Regulation, Enzymologic; GTP-Binding Proteins; Humans; K562 Cells; Male; Neoplasms; Oligonucleotide Array Sequence Analysis; Phorbol Esters; Protein Glutamine gamma Glutamyltransferase 2; RNA, Long Noncoding; Transglutaminases; U937 Cells | 2018 |
Triphenylphosphine-docetaxel conjugate-incorporated albumin nanoparticles for cancer treatment.
Topics: Albumins; Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Delivery Systems; Humans; Mice; Mitochondria; Nanoparticles; Neoplasms; Organophosphorus Compounds; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2018 |
Salutaxel, a Conjugate of Docetaxel and a Muramyl Dipeptide (MDP) Analogue, Acts as Multifunctional Prodrug That Inhibits Tumor Growth and Metastasis.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Animals; Antineoplastic Agents; Cell Line; Cytokines; Docetaxel; Humans; Mice; Myeloid-Derived Suppressor Cells; Neoplasm Metastasis; Neoplasms; Nod1 Signaling Adaptor Protein; Prodrugs | 2018 |
Dual tumor-targeted multifunctional magnetic hyaluronic acid micelles for enhanced MR imaging and combined photothermal-chemotherapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Docetaxel; Drug Liberation; Humans; Hyaluronic Acid; Hyperthermia, Induced; Magnetic Resonance Imaging; Magnetics; Mice; Micelles; Neoplasms; NIH 3T3 Cells; Phototherapy; Taxoids | 2018 |
Effective deactivation of A549 tumor cells in vitro and in vivo by RGD-decorated chitosan-functionalized single-walled carbon nanotube loading docetaxel.
Topics: A549 Cells; Animals; Antineoplastic Agents; Cell Survival; Chitosan; Docetaxel; Drug Carriers; Drug Liberation; Female; Humans; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Nanotubes, Carbon; Neoplasms; Oligopeptides; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Enterocolitis in Patients with Cancer Treated with Docetaxel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Enterocolitis; Female; Humans; Incidence; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Retrospective Studies; Taxoids; Vomiting; Young Adult | 2018 |
Mps1 inhibitors synergise with low doses of taxanes in promoting tumour cell death by enhancement of errors in cell division.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Cell Cycle Proteins; Cell Death; Cell Division; Cell Line, Tumor; Docetaxel; Drug Synergism; Female; Humans; MCF-7 Cells; Mice; Mitosis; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2018 |
Pre-clinical evaluation of EC1456, a folate-tubulysin anti-cancer therapeutic.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cell Line, Tumor; Cisplatin; Docetaxel; Drug Evaluation, Preclinical; Folic Acid; Humans; Mice, Nude; Neoplasms; Oligopeptides; Paclitaxel; Pipecolic Acids; Topotecan; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Primary prophylactic granulocyte colony-stimulating factor according to ASCO guidelines has no preventive effect on febrile neutropenia in patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Febrile Neutropenia; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Japan; Male; Middle Aged; Neoplasms; Practice Guidelines as Topic; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2018 |
A new method for the determination of total and released docetaxel from docetaxel-entrapped core-crosslinked polymeric micelles (CriPec®) by LC-MS/MS and its clinical application in plasma and tissues in patients with various tumours.
Topics: Antineoplastic Agents, Phytogenic; Chromatography, High Pressure Liquid; Docetaxel; Drug Liberation; Humans; Liquid-Liquid Extraction; Micelles; Nanoparticles; Neoplasms; Tandem Mass Spectrometry; Tissue Distribution | 2018 |
Distinct phenotypes and 'bystander' effects of senescent tumour cells induced by docetaxel or immunomodulatory cytokines.
Topics: Animals; Antineoplastic Agents; Bystander Effect; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Disease Models, Animal; Docetaxel; Humans; Interferon-gamma; Male; Mice; Mice, Inbred C57BL; Neoplasms; Phenotype; Tumor Necrosis Factor-alpha | 2018 |
Synthesis and Characterization of Cetuximab-Docetaxel and Panitumumab-Docetaxel Antibody-Drug Conjugates for EGFR-Overexpressing Cancer Therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cetuximab; Cross-Linking Reagents; Docetaxel; ErbB Receptors; Humans; Immunoconjugates; Mice; Mice, Nude; Neoplasms; Panitumumab; Survival Analysis; Tissue Distribution; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
Development of novel PLGA nanoparticles with co-encapsulation of docetaxel and abiraterone acetate for a highly efficient delivery into tumor cells.
Topics: A549 Cells; Androstenes; Delayed-Action Preparations; Docetaxel; Drug Carriers; Humans; Nanoparticles; Neoplasms; Polylactic Acid-Polyglycolic Acid Copolymer | 2019 |
Prior anti-CAFs break down the CAFs barrier and improve accumulation of docetaxel micelles in tumor.
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cancer-Associated Fibroblasts; Cell Line, Tumor; Cell Movement; Cell Proliferation; Docetaxel; Extracellular Fluid; Female; Humans; Mice; Mice, Inbred BALB C; Micelles; Microvessels; Neoplasm Metastasis; Neoplasms; Organ Specificity; ortho-Aminobenzoates; Spheroids, Cellular; Taxoids; Tissue Distribution; Tumor Microenvironment | 2018 |
Mathematical modeling in scheduling cancer treatment with combination of VEGF inhibitor and chemotherapy drugs.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Docetaxel; Drug Administration Schedule; Humans; Models, Theoretical; Neoplasms; Vascular Endothelial Growth Factor A | 2019 |
Enhancing solid tumor therapy with sequential delivery of dexamethasone and docetaxel engineered in a single carrier to overcome stromal resistance to drug delivery.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dexamethasone; Docetaxel; Drug Liberation; Female; Humans; Liposomes; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms | 2019 |
A benzoxazole compound as a novel MEK inhibitor for the treatment of RAS/RAF mutant cancer.
Topics: Animals; Benzoxazoles; Biological Availability; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Drug Synergism; Female; HT29 Cells; Humans; Mice; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Vemurafenib; Xenograft Model Antitumor Assays | 2019 |
Evaluating dose of cisplatin responsible for causing nephrotoxicity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Electronic Health Records; Female; Fluorouracil; Humans; Incidence; Male; Middle Aged; Neoplasms; Renal Insufficiency; Retrospective Studies | 2019 |
Arginine Starvation and Docetaxel Induce c-Myc-Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors.
Topics: Animals; Arginine; Argininosuccinate Synthase; Cell Line, Tumor; Cell Membrane; Deoxycytidine; Disease Models, Animal; Docetaxel; Equilibrative Nucleoside Transporter 1; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Models, Biological; Neoplasms; Protein Binding; Protein Transport; Proto-Oncogene Proteins c-myc; Xenograft Model Antitumor Assays | 2019 |
Treatment with melatonin and selenium attenuates docetaxel-induced apoptosis and oxidative injury in kidney and testes of mice.
Topics: Animals; Antineoplastic Agents; Antioxidants; Apoptosis; Disease Models, Animal; Docetaxel; Drug Therapy, Combination; Humans; Kidney; Kidney Diseases; Male; Melatonin; Mice; Neoplasms; Oxidative Stress; Reactive Oxygen Species; Selenium; Testicular Diseases; Testis; Treatment Outcome | 2019 |
An innovative in situ method of creating hybrid dendrimer nano-assembly: An efficient next generation dendritic platform for drug delivery.
Topics: Administration, Oral; Animals; Cell Line, Tumor; Dendrimers; Docetaxel; Drug Delivery Systems; Heterografts; Humans; Mice; Nanocomposites; Nanomedicine; Neoplasms; Nylons | 2019 |
NIR-guided dendritic nanoplatform for improving antitumor efficacy by combining chemo-phototherapy.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Combined Modality Therapy; Dendrimers; Docetaxel; Endocytosis; Fluorescence; Hep G2 Cells; Hot Temperature; Humans; Indoles; Infrared Rays; Mice, Nude; Nanoparticles; Neoplasms; Oligopeptides; Photochemotherapy; Phototherapy; Propionates; Reactive Oxygen Species; Theranostic Nanomedicine | 2019 |
High-resolution computed tomography findings for patients with drug-induced pulmonary toxicity, with special reference to hypersensitivity pneumonitis-like patterns in gemcitabine-induced cases.
Topics: Adult; Aged; Aged, 80 and over; Alveolitis, Extrinsic Allergic; Antineoplastic Agents; Biopsy; Docetaxel; Female; Gefitinib; Granuloma; Humans; Lung; Male; Middle Aged; Neoplasms; Quinazolines; Retrospective Studies; Taxoids; Thoracic Surgery, Video-Assisted; Tomography, X-Ray Computed | 2013 |
Chemotherapeutic drug delivery to cancer cells using a combination of folate targeting and tumor microenvironment-sensitive polypeptides.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Survival; Cell-Penetrating Peptides; Docetaxel; Drug Carriers; Drug Delivery Systems; Female; Folate Receptors, GPI-Anchored; Folic Acid; Humans; Ligands; Matrix Metalloproteinases; Mice; Mice, Nude; Molecular Sequence Data; Nanostructures; Neoplasms; Phosphatidylethanolamines; Polyethylene Glycols; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Spheroids, Cellular; Taxoids; Tumor Microenvironment | 2013 |
The use of nanoparticulate delivery systems in metronomic chemotherapy.
Topics: Administration, Metronomic; Animals; Antineoplastic Agents; Bone Marrow; Cell Line, Tumor; Cell Movement; Cell Proliferation; Docetaxel; Drug Delivery Systems; Endocytosis; Female; Human Umbilical Vein Endothelial Cells; Humans; Mice; Mice, Inbred BALB C; Models, Molecular; Mucous Membrane; Nanoparticles; Neoplasms; Neovascularization, Physiologic; Peptides; Platelet Endothelial Cell Adhesion Molecule-1; Taxoids; Tissue Distribution; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1 | 2013 |
Docetaxel-loaded thermosensitive and bioadhesive nanomicelles as a rectal drug delivery system for enhanced chemotherapeutic effect.
Topics: Administration, Rectal; Animals; Antineoplastic Agents; Docetaxel; Drug Delivery Systems; Female; Male; Mice, Nude; Micelles; Neoplasms; Rats; Rats, Sprague-Dawley; Rectum; Taxoids | 2013 |
Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Docetaxel; Drug Monitoring; Female; Humans; Neoplasms; Paclitaxel; Pharmacogenetics; Precision Medicine; Taxoids | 2013 |
Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Humans; Melanoma, Experimental; Mice; Microtubule Proteins; Neoplasms; Protein Stability; Taxoids | 2013 |
Synergistic enhancement of cancer therapy using a combination of heat shock protein targeted HPMA copolymer-drug conjugates and gold nanorod induced hyperthermia.
Topics: Animals; Antineoplastic Agents; Benzoquinones; Cell Line, Tumor; Cell Survival; Cisplatin; Combined Modality Therapy; Docetaxel; Endoplasmic Reticulum Chaperone BiP; Gold; Heat-Shock Proteins; Humans; Hyperthermia, Induced; Lactams, Macrocyclic; Methacrylates; Mice; Mice, Nude; Nanotubes; Neoplasms; Oligopeptides; Taxoids | 2013 |
Two novel nanoscale preparations of micelle and thermosensitive hydrogel for docetaxel to treat malignant tumor.
Topics: Animals; Antineoplastic Agents; Body Weight; Cell Death; Cell Survival; Docetaxel; Female; Hemolysis; Hydrogel, Polyethylene Glycol Dimethacrylate; Mice; Mice, Inbred BALB C; Micelles; Nanotechnology; Neoplasms; Polyesters; Polyethylene Glycols; Rabbits; Survival Analysis; Taxoids; Temperature | 2013 |
Differential scanning calorimetry as a tool to investigate the transfer of anticancer drugs to biomembrane model.
Topics: Antineoplastic Agents; Biological Transport; Calorimetry, Differential Scanning; Cell Membrane; Cold Temperature; Dimyristoylphosphatidylcholine; Docetaxel; Drug Delivery Systems; Hot Temperature; Injections; Lapatinib; Liposomes; Membranes, Artificial; Neoplasms; Phospholipids; Quinazolines; Tamoxifen; Taxoids | 2013 |
Oral delivery of taurocholic acid linked heparin-docetaxel conjugates for cancer therapy.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Delivery Systems; Female; Heparin, Low-Molecular-Weight; Humans; Mice; Mice, Nude; Neoplasms; Taurocholic Acid; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
20(S)-Protopanaxadiol (PPD) analogues chemosensitize multidrug-resistant cancer cells to clinical anticancer drugs.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Design; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Neoplasms; Sapogenins; Taxoids; Verapamil | 2013 |
Synthesis and biological evaluation of new paclitaxel analogs and discovery of potent antitumor agents.
Topics: Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Screening Assays, Antitumor; Halogenation; Humans; Models, Molecular; Neoplasms; Paclitaxel; Structure-Activity Relationship; Taxoids; Taxus | 2013 |
Development of docetaxel-loaded solid self-nanoemulsifying drug delivery system (SNEDDS) for enhanced chemotherapeutic effect.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Delivery Systems; Emulsions; Female; Glycerides; Male; Mice; Mice, Nude; Microscopy, Electron, Scanning; Nanoparticles; Neoplasms; Rats; Rats, Sprague-Dawley; Solubility; Surface-Active Agents; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Modelling of tumour growth and cytotoxic effect of docetaxel in xenografts.
Topics: Algorithms; Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Proliferation; Docetaxel; Drug Screening Assays, Antitumor; Humans; Mice; Models, Biological; Neoplasm Transplantation; Neoplasms; Software; Taxoids; Time Factors | 2014 |
Cost comparison and economic implications of commonly used originator and generic chemotherapy drugs in India.
Topics: Camptothecin; Cost Savings; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Drugs, Generic; Gemcitabine; Humans; India; Irinotecan; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Poverty; Taxoids | 2013 |
Taking a break from chemotherapy to fight drug-resistance: The cases of cancer and HIV/AIDS.
Topics: Acquired Immunodeficiency Syndrome; Animals; Anti-HIV Agents; Antineoplastic Agents; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Drug Resistance, Viral; Humans; Mice; Models, Theoretical; Neoplasms; T-Lymphocytes; Taxoids; Tumor Burden | 2013 |
MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors.
Topics: Animals; Antibodies, Bispecific; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Docetaxel; Everolimus; Female; Gemcitabine; Humans; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptor, ErbB-3; Receptor, IGF Type 1; Signal Transduction; Sirolimus; Taxoids; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Interaction of standardized mistletoe (Viscum album) extracts with chemotherapeutic drugs regarding cytostatic and cytotoxic effects in vitro.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cytostatic Agents; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Herb-Drug Interactions; Humans; Male; Mitoxantrone; Neoplasms; Plant Extracts; Plants, Medicinal; Taxoids; Viscum album | 2014 |
Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Folic Acid; HeLa Cells; Humans; Irinotecan; Mice, Inbred BALB C; Mice, Inbred DBA; Mice, Nude; Neoplasms; Neoplasms, Experimental; Paclitaxel; Taxoids; Topotecan; Treatment Outcome; Vinca Alkaloids; Xenograft Model Antitumor Assays | 2014 |
The potential of pH-responsive PEG-hyperbranched polyacylhydrazone micelles for cancer therapy.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line; Delayed-Action Preparations; Docetaxel; Doxorubicin; Extracellular Space; Humans; Hydrazones; Hydrogen-Ion Concentration; Intracellular Space; Male; Mice; Mice, Nude; Micelles; Neoplasms; Polyethylene Glycols; Polymers; Taxoids; Tissue Distribution | 2014 |
Characterization and diagnostic evaluation of chronic polyneuropathies induced by oxaliplatin and docetaxel comparing skin biopsy to quantitative sensory testing and nerve conduction studies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Docetaxel; Humans; Middle Aged; Neoplasms; Neural Conduction; Organoplatinum Compounds; Oxaliplatin; Polyneuropathies; Sensation; Skin; Taxoids | 2014 |
Synthesis and therapeutic evaluation of an aptide-docetaxel conjugate targeting tumor-associated fibronectin.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Female; Fibronectins; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Neoplasms; Peptides; Protein Structure, Tertiary; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Star-shaped cyclodextrin-poly(l-lysine) derivative co-delivering docetaxel and MMP-9 siRNA plasmid in cancer therapy.
Topics: Antineoplastic Agents, Phytogenic; Base Sequence; Cell Line, Tumor; Cyclodextrins; DNA Primers; Docetaxel; Humans; Matrix Metalloproteinase 9; Neoplasms; Plasmids; Polylysine; RNA, Small Interfering; Taxoids | 2014 |
Particle replication in nonwetting templates nanoparticles with tumor selective alkyl silyl ether docetaxel prodrug reduces toxicity.
Topics: Animals; Docetaxel; Drug Carriers; Humans; Mice; Nanoparticles; Neoplasms; Prodrugs; Taxoids; Wettability; Xenograft Model Antitumor Assays | 2014 |
Synergistic enhancement of cancer therapy using a combination of ceramide and docetaxel.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Ceramides; Cytoskeleton; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Female; G2 Phase Cell Cycle Checkpoints; Hep G2 Cells; Humans; MCF-7 Cells; Melanoma, Experimental; Mice; Neoplasms; Taxoids; Tumor Burden | 2014 |
Pretreatment with chemotherapeutics for enhanced nanoparticles accumulation in tumor: the potential role of G2 cycle retention effect.
Topics: Animals; Antineoplastic Agents; Biological Transport; Cell Line, Tumor; Docetaxel; G2 Phase Cell Cycle Checkpoints; Humans; Mice; Nanoparticles; Neoplasms; Taxoids; Tissue Distribution | 2014 |
Introduction: why a supplement on taxanes?
Topics: Antineoplastic Agents; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 2014 |
Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel.
Topics: Adult; Docetaxel; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Female; Humans; Neoplasms; Paclitaxel; Pregnancy; Taxoids | 2014 |
Biocompatible amphiphilic pentablock copolymeric nanoparticles for anti-cancer drug delivery.
Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Cells, Cultured; Docetaxel; Drug Delivery Systems; Drug Evaluation, Preclinical; HeLa Cells; Humans; Lactic Acid; Materials Testing; Mice; Nanoparticles; Neoplasms; Poloxamer; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Propylene Glycols; Taxoids | 2014 |
Evaluation of the Semmes-Weinstein filaments and a questionnaire to assess chemotherapy-induced peripheral neuropathy.
Topics: Adult; Antineoplastic Agents; Brazil; Cross-Sectional Studies; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasms; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Psychometrics; Severity of Illness Index; Surveys and Questionnaires; Taxoids | 2014 |
Drug selection and dosing in pregnant cancer patients: insights from clinical pharmacokinetics.
Topics: Docetaxel; Doxorubicin; Epirubicin; Female; Humans; Neoplasms; Paclitaxel; Pregnancy; Taxoids | 2014 |
Carotidynia after anticancer chemotherapy.
Topics: Antineoplastic Agents; Carotid Artery, Common; Docetaxel; Granulocyte Colony-Stimulating Factor; Humans; Inflammation; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Taxoids; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2014 |
Tumor homing cell penetrating peptide decorated nanoparticles used for enhancing tumor targeting delivery and therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell-Penetrating Peptides; Docetaxel; Drug Delivery Systems; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms; Polyesters; Polyethylene Glycols; Taxoids; Tumor Burden | 2015 |
Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Antineoplastic Agents; Autophagy; Biomarkers, Tumor; Cell Line, Tumor; Docetaxel; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mice; Neoplasm Transplantation; Neoplasms; Pantoprazole; Single-Cell Analysis; Taxoids; Xenograft Model Antitumor Assays | 2015 |
Docetaxel enhances CD3+ CD56+ cytokine-induced killer cells-mediated killing through inducing tumor cells phenotype modulation.
Topics: Calreticulin; CD3 Complex; CD56 Antigen; Cell Line, Tumor; Cytokine-Induced Killer Cells; Cytotoxicity, Immunologic; Docetaxel; Humans; Intercellular Adhesion Molecule-1; Kinetics; Neoplasms; Phenotype; Taxoids; Up-Regulation | 2015 |
Predictive role of neutrophil gelatinase-associated lipocalin in early diagnosis of platin-induced renal injury.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carboplatin; Cisplatin; Creatinine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lipocalin-2; Lipocalins; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Proto-Oncogene Proteins; Taxoids | 2015 |
The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax).
Topics: Aged; Antineoplastic Agents; Diarrhea; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Germany; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neoplasms; Patient Selection; Prospective Studies; Quality of Life; Risk Factors; Severity of Illness Index; Surveys and Questionnaires; Taxoids; Time Factors; Treatment Outcome; Vomiting | 2015 |
Optimal standard regimen and predicting response to docetaxel therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Hep G2 Cells; Humans; Mice; Neoplasms; Prognosis; Reference Standards; Taxoids; Treatment Outcome; Xenograft Model Antitumor Assays | 2014 |
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.
Topics: Administration, Oral; Aniline Compounds; Animals; Antineoplastic Agents; bcl-X Protein; Benzothiazoles; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Survival; Docetaxel; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Granulocytes; Humans; Isoquinolines; Kinetics; Mice; Neoplasm Transplantation; Neoplasms; Neutropenia; Neutrophils; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; Taxoids; Thrombocytopenia | 2015 |
Design and Synthesis of New α-Naphthoflavones as Cytochrome P450 (CYP) 1B1 Inhibitors To Overcome Docetaxel-Resistance Associated with CYP1B1 Overexpression.
Topics: Antineoplastic Agents; Benzoflavones; Cell Line, Tumor; Cytochrome P-450 CYP1B1; Docetaxel; Drug Resistance, Neoplasm; Humans; Molecular Docking Simulation; Neoplasms; Taxoids | 2015 |
Blended nanoparticle system based on miscible structurally similar polymers: a safe, simple, targeted, and surprisingly high efficiency vehicle for cancer therapy.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biocompatible Materials; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Delivery Systems; Drug Resistance, Neoplasm; Endocytosis; Female; Folic Acid; HeLa Cells; Humans; MCF-7 Cells; Mice; Mice, SCID; Nanoparticles; Neoplasms; Particle Size; Polyethylene Glycols; Polyglactin 910; Polyglycolic Acid; Polymers; Taxoids; Vitamin E | 2015 |
Adenosine conjugated lipidic nanoparticles for enhanced tumor targeting.
Topics: Adenosine; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Docetaxel; Humans; Lipids; Mice; Nanoparticles; Neoplasms; Taxoids | 2015 |
Investigation of hydrophobically derivatized hyperbranched polyglycerol with PEGylated shell as a nanocarrier for systemic delivery of chemotherapeutics.
Topics: Animals; Docetaxel; Drug Carriers; Drug Delivery Systems; Female; Glycerol; HT29 Cells; Humans; Hydrophobic and Hydrophilic Interactions; Mice; Nanoparticles; Neoplasms; Polymers; Taxoids; Tissue Distribution; Xenograft Model Antitumor Assays | 2015 |
Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents; Child; Child, Preschool; Clinical Trials as Topic; Computer Simulation; Docetaxel; Drug Discovery; Humans; Infant; Models, Biological; Neoplasms; Predictive Value of Tests; Taxoids; Tissue Distribution | 2015 |
Hydrophobic Cysteine Poly(disulfide)-based Redox-Hypersensitive Nanoparticle Platform for Cancer Theranostics.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cysteine; Disulfides; Docetaxel; Drug Carriers; Fluorescence Resonance Energy Transfer; HeLa Cells; Humans; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Nanoparticles; Neoplasms; Oxidation-Reduction; Particle Size; Polyethylene Glycols; Polymers; Taxoids; Theranostic Nanomedicine | 2015 |
Innovative use of the taxol binding peptide overcomes key challenges of stable and high drug loading in polymeric nanomicelles.
Topics: Amino Acid Sequence; Antineoplastic Agents; Binding Sites; Bridged-Ring Compounds; Cell Line, Tumor; Docetaxel; Drug Carriers; Drug Delivery Systems; Humans; Micelles; Molecular Sequence Data; Neoplasms; Paclitaxel; Peptides; Polyethylene Glycols; Taxoids | 2015 |
A clinical pharmacokinetic microdosing study of docetaxel with Japanese patients with cancer.
Topics: Adult; Aged; Antineoplastic Agents; Docetaxel; Dose-Response Relationship, Drug; Drug Evaluation; Drugs, Investigational; Female; Half-Life; Humans; Infusions, Intravenous; Japan; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Neoplasms; Orosomucoid; Taxoids; Tubulin Modulators | 2015 |
Ceramide and N,N,N-Trimethylphytosphingosine-Iodide (TMP-I)-Based Lipid Nanoparticles for Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Ceramides; Chemistry, Pharmaceutical; Delayed-Action Preparations; Docetaxel; Excipients; Male; Mice; Nanoparticles; Neoplasms; Particle Size; Phosphatidylcholines; Poloxalene; Quaternary Ammonium Compounds; Rats; Rats, Sprague-Dawley; Sphingosine; Taxoids | 2016 |
Engineering of Biocompatible pH-Responsive Nanovehicles from Acetalated Cyclodextrins as Effective Delivery Systems for Tumor Therapy.
Topics: Animals; Antineoplastic Agents; beta-Cyclodextrins; Biocompatible Materials; Cells, Cultured; Docetaxel; Drug Carriers; Drug Delivery Systems; Hep G2 Cells; Humans; Hydrogen-Ion Concentration; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms; Polymers; Taxoids | 2015 |
Characterization and evaluation of a folic acid receptor-targeted cyclodextrin complex as an anticancer drug delivery system.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cyclodextrins; Docetaxel; Drug Carriers; Female; Folic Acid; Folic Acid Transporters; Humans; Mice, Inbred BALB C; Molecular Targeted Therapy; Neoplasms; Solubility; Taxoids; Tissue Distribution | 2016 |
What potential is there for the use of ZrO2 nanostructures for image-guided thermotherapy?
Topics: Docetaxel; Humans; Hyperthermia, Induced; Nanoparticles; Neoplasms; Taxoids; Tomography, X-Ray Computed; Zirconium | 2015 |
Reactive Oxygen Species-Manipulated Drug Release from a Smart Envelope-Type Mesoporous Titanium Nanovehicle for Tumor Sonodynamic-Chemotherapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Carriers; Drug Delivery Systems; Female; Humans; Mice; Mice, Inbred BALB C; Neoplasms; Reactive Oxygen Species; Taxoids; Titanium | 2015 |
Radiosensitization of TPGS-emulsified docetaxel-loaded poly(lactic-co-glycolic acid) nanoparticles in CNE-1 and A549 cells.
Topics: A549 Cells; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Docetaxel; Drug Carriers; Humans; Lactic Acid; Nanoparticles; Neoplasms; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Radiation-Sensitizing Agents; Taxoids | 2016 |
Reduction-Sensitive Polymeric Micelles Based on Docetaxel-Polymer Conjugates Via Disulfide Linker for Efficient Cancer Therapy.
Topics: Animals; Disulfides; Docetaxel; Drug Carriers; Female; Humans; MCF-7 Cells; Mice; Micelles; Neoplasms; Taxoids | 2016 |
Evaluation of glycosylated docetaxel-encapsulated liposomes prepared by remote loading under solubility gradient.
Topics: Acetylation; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Compounding; Glycosylation; Humans; Liposomes; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Solubility; Taxoids | 2016 |
Design, Synthesis, and Biological Evaluation of a Novel Water-soluble Prodrug of Docetaxel with Amino Acid as a Linker.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Design; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Prodrugs; Rats, Sprague-Dawley; Solubility; Taxoids; Water | 2016 |
Time-staggered delivery of docetaxel and H1-S6A,F8A peptide for sequential dual-strike chemotherapy through tumor priming and nuclear targeting.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Survival; Docetaxel; Female; HeLa Cells; Humans; Mice, Nude; Neoplasms; Peptides; Polymethacrylic Acids; Proto-Oncogene Proteins c-myc; Taxoids; Tumor Burden | 2016 |
Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: indicators of suspected adverse reactions.
Topics: Antineoplastic Agents; Capecitabine; Docetaxel; Drug Administration Schedule; Humans; Neoplasms; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Pharmacovigilance; Phenylurea Compounds; Retrospective Studies; Sorafenib; Taxoids; Treatment Outcome | 2016 |
Star-Shaped Amphiphilic Hyperbranched Polyglycerol Conjugated with Dendritic Poly(l-lysine) for the Codelivery of Docetaxel and MMP-9 siRNA in Cancer Therapy.
Topics: Cell Line, Tumor; Docetaxel; Drug Delivery Systems; Glycerol; Humans; MCF-7 Cells; Neoplasms; Polylysine; Polymers; RNA, Small Interfering; Taxoids | 2016 |
Chromatin Regulators as a Guide for Cancer Treatment Choice.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Chromatin; Chromatin Assembly and Disassembly; Cluster Analysis; Computational Biology; Databases, Genetic; Docetaxel; Gene Expression Profiling; Genes, Essential; Humans; Models, Biological; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Pharmacogenomic Testing; Protein Interaction Mapping; Protein Interaction Maps; Taxoids; Tubulin Modulators | 2016 |
Matrix metalloproteinases-2/9-sensitive peptide-conjugated polymer micelles for site-specific release of drugs and enhancing tumor accumulation: preparation and in vitro and in vivo evaluation.
Topics: alpha-Tocopherol; Animals; Cell Death; Cell Line, Tumor; Diagnostic Imaging; Docetaxel; Drug Delivery Systems; Drug Liberation; Endocytosis; Fluorescence Resonance Energy Transfer; Humans; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice, Inbred BALB C; Mice, Nude; Micelles; Neoplasms; Peptides; Polyethylene Glycols; Polymers; Proton Magnetic Resonance Spectroscopy; Subcellular Fractions; Taxoids; Vitamin E | 2016 |
Synergistic active targeting of dually integrin αvβ3/CD44-targeted nanoparticles to B16F10 tumors located at different sites of mouse bodies.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Liberation; Female; Humans; Hyaluronan Receptors; Hyaluronic Acid; Integrin alphaVbeta3; MCF-7 Cells; Mice, Inbred C57BL; Nanoparticles; Neoplasms; Taxoids; Thyroxine; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Docetaxel induced-JNK2/PHD1 signaling pathway increases degradation of HIF-1α and causes cancer cell death under hypoxia.
Topics: Amino Acid Sequence; Antineoplastic Agents, Phytogenic; Cell Death; Cell Hypoxia; Cell Line, Tumor; Docetaxel; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Hypoxia-Inducible Factor-Proline Dioxygenases; Mitogen-Activated Protein Kinase 9; Neoplasms; Proteolysis; Signal Transduction; Taxoids; Ubiquitination | 2016 |
Utilizing G2/M retention effect to enhance tumor accumulation of active targeting nanoparticles.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Disease Models, Animal; Docetaxel; Folic Acid; G2 Phase Cell Cycle Checkpoints; Humans; Ligands; Male; Mice; Molecular Imaging; Molecular Targeted Therapy; Nanoparticles; Neoplasms; Polyethylene Glycols; Polymers; Taxoids; Xenograft Model Antitumor Assays | 2016 |
Influence of Chemotherapy on the Antioxidant Status of Human Skin.
Topics: Adult; Aged; Antineoplastic Agents; Antioxidants; Carotenoids; Docetaxel; Doxorubicin; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Skin; Taxoids | 2016 |
Nephrotoxicity of epigenetic inhibitors used for the treatment of cancer.
Topics: Acetylation; Animals; Antineoplastic Agents; Azacitidine; Cell Death; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cyclin-Dependent Kinase Inhibitor p21; Docetaxel; Epigenesis, Genetic; HEK293 Cells; Histones; Humans; Hydroxamic Acids; Kidney; Male; Methylation; Neoplasms; Oligopeptides; Prostatic Neoplasms; Rats; Taxoids | 2016 |
Synergistic Anticancer Effect of Peptide-Docetaxel Nanoassembly Targeted to Tubulin: Toward Development of Dual Warhead Containing Nanomedicine.
Topics: Antineoplastic Agents; Docetaxel; Drug Delivery Systems; Humans; MCF-7 Cells; Mucin-1; Nanomedicine; Nanoparticles; Neoplasm Metastasis; Neoplasms; Peptides; Taxoids; Tubulin | 2017 |
Docetaxel-Loaded Self-Assembly Stearic Acid-Modified Bletilla striata Polysaccharide Micelles and Their Anticancer Effect: Preparation, Characterization, Cellular Uptake and In Vitro Evaluation.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Docetaxel; Drug Carriers; Drug Liberation; HeLa Cells; Hep G2 Cells; Humans; Hydrophobic and Hydrophilic Interactions; MCF-7 Cells; Micelles; Neoplasms; Nuclear Magnetic Resonance, Biomolecular; Particle Size; Plant Roots; Polysaccharides; Solubility; Stearic Acids; Taxoids | 2016 |
The structure of polymer carriers controls the efficacy of the experimental combination treatment of tumors with HPMA copolymer conjugates carrying doxorubicin and docetaxel.
Topics: Acrylamides; Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Doxorubicin; Drug Carriers; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms; Taxoids | 2017 |
Long-circulating polyhydroxybutyrate-co-hydroxyvalerate nanoparticles for tumor targeted docetaxel delivery: Formulation, optimization and in vitro characterization.
Topics: Cell Line, Tumor; Chemistry, Pharmaceutical; Docetaxel; Drug Carriers; Drug Delivery Systems; Drug Liberation; Humans; MCF-7 Cells; Nanoparticles; Neoplasms; Particle Size; Polyesters; Taxoids | 2017 |
Subcellular co-delivery of two different site-oriented payloads for tumor therapy.
Topics: Acrylamides; Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; DNA Damage; Docetaxel; Drug Delivery Systems; Humans; Male; Mice; Mice, Inbred BALB C; Micelles; Neoplasms; NIH 3T3 Cells; Organosilicon Compounds; Polymers; Taxoids; Tretinoin; Xenograft Model Antitumor Assays | 2017 |
Paclitaxel-resistant cancer cell-derived secretomes elicit ABCB1-associated docetaxel cross-resistance and escape from apoptosis through FOXO3a-driven glycolytic regulation.
Topics: Adenosine Triphosphate; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Cell-Derived Microparticles; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Forkhead Box Protein O3; Gene Silencing; Glucose; Glycolysis; Humans; Interferon-alpha; Interferons; Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-akt; RNA Interference; Secretory Vesicles; Signal Transduction; Taxoids; TNF-Related Apoptosis-Inducing Ligand | 2017 |
Nanosomal Docetaxel Lipid Suspension: A Guide to Its Use in Cancer.
Topics: Antineoplastic Agents; Docetaxel; Female; Humans; Lipids; Male; Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2017 |
Highly efficient system to deliver taxanes into tumor cells: docetaxel-loaded chitosan oligomer colloidal carriers.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmaceutical; Chitosan; Colloids; Docetaxel; Drug Delivery Systems; Fluorescent Dyes; Humans; Nanocapsules; Nanoparticles; Nanotechnology; Neoplasms; Taxoids; Time Factors | 2008 |
Cutaneous reaction associated with weekly docetaxel administration.
Topics: Adult; Antineoplastic Agents; Docetaxel; Drug Administration Schedule; Drug Eruptions; Female; Humans; Hyperpigmentation; Hypopigmentation; Male; Middle Aged; Neoplasms; Taxoids; Time Factors | 2009 |
Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antineoplastic Agents; Aspartate Aminotransferases; Docetaxel; Female; Humans; Liver Diseases; Male; Middle Aged; Neoplasms; Taxoids | 2009 |
The antitumor effects of CIK cells combined with docetaxel against drug-resistant lung adenocarcinoma cell line SPC-A1/DTX in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Immunotherapy; Killer Cells, Natural; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms; Taxoids; Tetrazolium Salts; Thiazoles | 2009 |
Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antioxidants; Bentonite; Cell Line; Coumarins; Docetaxel; Drug Carriers; Drug Delivery Systems; Drug Therapy; Humans; Lactic Acid; Male; Nanoparticles; Neoplasms; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Sprague-Dawley; Taxoids; Thiazoles; Vitamin E | 2009 |
Preparation, characterization and pharmacokinetics of folate receptor-targeted liposomes for docetaxel delivery.
Topics: Animals; Antineoplastic Agents; Carrier Proteins; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Delivery Systems; Drug Stability; Female; Fluoresceins; Fluorescent Dyes; Folate Receptors, GPI-Anchored; Freeze Drying; Half-Life; Humans; Liposomes; Metabolic Clearance Rate; Mice; Mice, Inbred ICR; Neoplasms; Receptors, Cell Surface; Taxoids | 2009 |
The effect of poloxamer 188 on nanoparticle morphology, size, cancer cell uptake, and cytotoxicity.
Topics: Calorimetry, Differential Scanning; Cell Death; Cell Line, Tumor; Cell Survival; Coumarins; Docetaxel; Humans; Inhibitory Concentration 50; Lactic Acid; Microscopy, Confocal; Nanoparticles; Neoplasms; Particle Size; Poloxamer; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Spectroscopy, Fourier Transform Infrared; Taxoids | 2010 |
A spatial model of tumor-host interaction: application of chemotherapy.
Topics: Antineoplastic Agents; Computer Simulation; Docetaxel; Endothelial Cells; Humans; Models, Immunological; Neoplasms; Neovascularization, Pathologic; Taxoids; Vascular Endothelial Growth Factor A | 2009 |
PF-00477736 mediates checkpoint kinase 1 signaling pathway and potentiates docetaxel-induced efficacy in xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzodiazepinones; cdc25 Phosphatases; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Dideoxynucleosides; Docetaxel; Drug Synergism; Fluorine Radioisotopes; Histones; Humans; Mice; Mice, Nude; Neoplasms; Phosphorylation; Protein Kinases; Pyrazoles; Signal Transduction; Taxoids; Tomography, Emission-Computed; Tumor Burden; Xenograft Model Antitumor Assays | 2009 |
Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Count; Cell Enlargement; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Etoposide; Fluorouracil; Humans; Models, Biological; Myelopoiesis; Neoplasms; Neutrophils; Observation; Paclitaxel; Precision Medicine; Taxoids; Topotecan | 2010 |
Feasibility of chemohyperthermia with docetaxel-embedded magnetoliposomes as minimally invasive local treatment for cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Combined Modality Therapy; Docetaxel; Electromagnetic Phenomena; Feasibility Studies; Female; Ferrosoferric Oxide; Humans; Hyperthermia, Induced; Liposomes; Mice; Mice, Nude; Neoplasms; Taxoids; Xenograft Model Antitumor Assays | 2010 |
FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cell Line; Cell Line, Tumor; Cytarabine; Docetaxel; Drug Therapy; Humans; Kidney; Neoplasms; Nuclear Proteins; Paclitaxel; Pancreatic Neoplasms; Phosphoprotein Phosphatases; Proto-Oncogene Proteins c-akt; Tacrolimus Binding Proteins; Taxoids | 2009 |
Effects of taxane-based chemotherapy on inhibin B and gonadotropins as biomarkers of spermatogenesis.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carboplatin; Deoxycytidine; Docetaxel; Fertility; Follicle Stimulating Hormone; Gemcitabine; Humans; Infertility, Male; Inhibins; Luteinizing Hormone; Male; Middle Aged; Neoplasms; Paclitaxel; Spermatogenesis; Taxoids; Testis; Ultrasonography; Young Adult | 2010 |
[Clinical analysis of premedication regimen with dexamethasone at different doses for docetaxel-induced hypersensitivity reaction].
Topics: Aged; Antineoplastic Agents; Dexamethasone; Docetaxel; Dose-Response Relationship, Drug; Drug Hypersensitivity; Exanthema; Fever; Humans; Middle Aged; Neoplasms; Premedication; Taxoids | 2009 |
Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival.
Topics: Animals; Apoptosis; Biphenyl Compounds; Cell Line; Cell Line, Tumor; Cell Survival; DNA Damage; Docetaxel; Etoposide; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Half-Life; Humans; Lysine; Mice; Mice, SCID; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms; Nitrophenols; Phosphorylation; Piperazines; Polyubiquitin; Prognosis; Protein Binding; Protein Stability; Proto-Oncogene Proteins c-bcl-2; RNA Interference; Sulfonamides; Taxoids; Ubiquitin Thiolesterase; Ubiquitination; Ultraviolet Rays; Xenograft Model Antitumor Assays | 2010 |
Pulmonary toxicity in patients receiving docetaxel chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Docetaxel; Female; Humans; Lung Diseases; Male; Middle Aged; Neoplasms; Prognosis; Prospective Studies; Radiation-Sensitizing Agents; Respiratory Function Tests; Spirometry; Survival Rate; Taxoids; Tomography, X-Ray Computed | 2010 |
Noninvasive molecular imaging of apoptosis in vivo using a modified firefly luciferase substrate, Z-DEVD-aminoluciferin.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Docetaxel; Female; Firefly Luciferin; Humans; Luminescent Agents; Mice; Mice, SCID; Molecular Imaging; Neoplasms; Oligopeptides; Taxoids | 2010 |
Chemosensitization of cancer cells by siRNA using targeted nanogel delivery.
Topics: Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Delivery Systems; ErbB Receptors; Female; Gels; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Nanotechnology; Neoplasms; Ovarian Neoplasms; Peptides; RNA, Small Interfering; Taxoids | 2010 |
Evidence for the conversion of docetaxel into 7'-epidocetaxel in patients receiving Taxotere-based conventional chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Neoplasms; Taxoids | 2010 |
A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers.
Topics: Animals; Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Cytotoxicity, Immunologic; Docetaxel; Female; Immune Tolerance; Immunomodulation; Immunosuppressive Agents; Lymphocyte Activation; Mice; Mice, Inbred BALB C; Mice, Transgenic; Myeloid Cells; Neoplasm Transplantation; Neoplasms; T-Lymphocytes; Taxoids | 2010 |
A strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug delivery.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biocompatible Materials; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Carriers; Humans; Microscopy, Confocal; Nanomedicine; Nanoparticles; Nanotechnology; Neoplasms; Polymers; Taxoids; Trastuzumab | 2010 |
Targeting the oncogenic protein beta-catenin to enhance chemotherapy outcome against solid human cancers.
Topics: Antineoplastic Agents; beta Catenin; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Docetaxel; Humans; Neoplasms; Organoplatinum Compounds; Organoselenium Compounds; Oxaliplatin; Paclitaxel; RNA Interference; Taxoids; Topotecan | 2010 |
A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model.
Topics: Antineoplastic Agents; Bone Marrow; Docetaxel; Drug Administration Schedule; Humans; Infusions, Intravenous; Leukocyte Count; Leukocytes; Models, Immunological; Models, Statistical; Neoplasms; Neutrophils; Nonlinear Dynamics; Taxoids; Time Factors; Treatment Outcome | 2012 |
Octreotide-modified polymeric micelles as potential carriers for targeted docetaxel delivery to somatostatin receptor overexpressing tumor cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Delivery Systems; Humans; Lactates; Male; Mice; Mice, Inbred BALB C; Micelles; Neoplasms; Octreotide; Polyethylene Glycols; Taxoids | 2011 |
FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism.
Topics: Angiogenesis Inhibitors; Animals; Blotting, Western; Cell Line; Cell Movement; Cell Proliferation; Docetaxel; Endothelial Cells; Hyaluronan Receptors; Immunophilins; Immunoprecipitation; Mice; Mice, Inbred BALB C; Mice, SCID; Neoplasms; Neovascularization, Pathologic; Neovascularization, Physiologic; Peptide Fragments; Rats; Recombinant Proteins; RNA, Small Interfering; Signal Transduction; Tacrolimus Binding Proteins; Taxoids; Xenograft Model Antitumor Assays | 2011 |
Falls in persons with chemotherapy-induced peripheral neuropathy.
Topics: Accidental Falls; Antineoplastic Combined Chemotherapy Protocols; Causality; Comorbidity; Docetaxel; Female; Humans; Logistic Models; Male; Middle Aged; Muscle Weakness; Neoplasm Staging; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Population Surveillance; Postural Balance; Prospective Studies; Risk Factors; Sensation Disorders; Severity of Illness Index; Surveys and Questionnaires; Taxoids | 2012 |
Permanent alopecia after systemic chemotherapy: a clinicopathological study of 10 cases.
Topics: Alopecia; Antineoplastic Agents; Busulfan; Cisplatin; Dermis; Diagnosis, Differential; Docetaxel; Etoposide; Female; Hair; Humans; Male; Neoplasms; Taxoids | 2011 |
Docetaxel-loaded-lipid-based-nanosuspensions (DTX-LNS): preparation, pharmacokinetics, tissue distribution and antitumor activity.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Carriers; Drug Compounding; Drug Delivery Systems; Excipients; Female; Formazans; Humans; Lecithins; Lipids; Melanoma; Mice; Nanoparticles; Neoplasms; Ovarian Neoplasms; Particle Size; Suspensions; Taxoids; Tetrazolium Salts; Tissue Distribution | 2011 |
Pharmacokinetics, efficacy, and safety evaluation of docetaxel/hydroxypropyl-sulfobutyl-β-cyclodextrin inclusion complex.
Topics: Animals; beta-Cyclodextrins; Docetaxel; Drug Delivery Systems; HCT116 Cells; Hep G2 Cells; Humans; Male; Mice; Neoplasms; Rabbits; Random Allocation; Rats; Rats, Wistar; Taxoids; Treatment Outcome; Xenograft Model Antitumor Assays | 2011 |
Dual docetaxel/superparamagnetic iron oxide loaded nanoparticles for both targeting magnetic resonance imaging and cancer therapy.
Topics: Cell Line, Tumor; Docetaxel; Drug Carriers; Drug Delivery Systems; Fluorescent Dyes; Humans; Magnetic Resonance Imaging; Magnetite Nanoparticles; Materials Testing; Neoplasms; Particle Size; Spectroscopy, Fourier Transform Infrared; Taxoids; X-Ray Diffraction | 2011 |
Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and Pluronic® for tumor-targeted delivery of docetaxel.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Ceramides; Docetaxel; Drug Carriers; Drug Delivery Systems; Hyaluronic Acid; Materials Testing; Mice; Molecular Structure; Nanoparticles; Neoplasms; Poloxalene; Taxoids | 2011 |
Precise evaluation of chemotherapy-induced peripheral neuropathy using the visual analogue scale: a quantitative and comparative analysis of neuropathy occurring with paclitaxel-carboplatin and docetaxel-carboplatin therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Pain Measurement; Peripheral Nervous System Diseases; Surveys and Questionnaires; Taxoids | 2012 |
Low-molecular-weight methylcellulose-based thermo-reversible gel/pluronic micelle combination system for local and sustained docetaxel delivery.
Topics: Animals; Antineoplastic Agents; Delayed-Action Preparations; Docetaxel; Male; Methylcellulose; Mice; Mice, Inbred C57BL; Micelles; Neoplasms; Poloxamer; Taxoids | 2012 |
A sensitive combined assay for the quantification of paclitaxel, docetaxel and ritonavir in human plasma using liquid chromatography coupled with tandem mass spectrometry.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Docetaxel; Humans; Neoplasms; Paclitaxel; Ritonavir; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Taxoids | 2011 |
Systemic inflammation and prediction of chemotherapy outcomes in patients receiving docetaxel for advanced cancer.
Topics: Acute-Phase Reaction; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; C-Reactive Protein; Cytokines; Docetaxel; Female; Humans; Inflammation; Leukocyte Count; Male; Middle Aged; Neoplasms; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Serum Albumin; Statistics, Nonparametric; Survival Rate; Taxoids | 2012 |
Synthetic modification of carboxymethylcellulose and use thereof to prepare a nanoparticle forming conjugate of docetaxel for enhanced cytotoxicity against cancer cells.
Topics: Animals; Antineoplastic Agents; Carboxymethylcellulose Sodium; Cell Line, Tumor; Docetaxel; Drug Carriers; Humans; Inhibitory Concentration 50; Mice; Nanoparticles; Neoplasms; Polyethylene Glycols; Taxoids | 2011 |
Preclinical pharmacokinetic, biodistribution, and anti-cancer efficacy studies of a docetaxel-carboxymethylcellulose nanoparticle in mouse models.
Topics: Animals; Antineoplastic Agents; Carboxymethylcellulose Sodium; Disease Models, Animal; Docetaxel; Drug Screening Assays, Antitumor; Intracellular Space; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasm Metastasis; Neoplasms; Polyethylene Glycols; Polymers; Taxoids; Tissue Distribution; Treatment Outcome | 2012 |
Tumor accumulation and antitumor efficacy of docetaxel-loaded core-shell-corona micelles with shell-specific redox-responsive cross-links.
Topics: Animals; Antineoplastic Agents; Carbocyanines; Cell Line, Tumor; Cross-Linking Reagents; Diagnostic Imaging; Disulfides; Docetaxel; Humans; In Situ Nick-End Labeling; Mice; Micelles; Neoplasms; Oxidation-Reduction; Particle Size; Peptides; Polyethylene Glycols; Polylysine; Taxoids; Time Factors; Tissue Distribution; Treatment Outcome | 2012 |
Intraepidermal nerve fibre density in cancer patients receiving adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Biopsy; Chemotherapy, Adjuvant; Docetaxel; Epidermis; Female; Humans; Male; Middle Aged; Neoplasms; Nerve Fibers; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Prospective Studies; Skin; Taxoids | 2011 |
[The role of nanotechnology in creating novel antitumor agents].
Topics: Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Design; Female; Humans; Liposomes; Nanoparticles; Nanostructures; Nanotechnology; Neoplasms; Paclitaxel; Tamoxifen; Taxoids | 2011 |
Association and correlation of different chemotherapeutic regimens and doses with onset and severity of anemia among solid cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Erythrocyte Count; Female; Fluorouracil; Hemoglobins; Humans; Male; Middle Aged; Neoplasms; Piperidines; Pyridines; Retrospective Studies; Taxoids; Young Adult | 2011 |
Tumor-targeted drug delivery using MR-contrasted docetaxel - carboxymethylcellulose nanoparticles.
Topics: Animals; Carboxymethylcellulose Sodium; Cell Line, Tumor; Contrast Media; Disease Models, Animal; Docetaxel; Dose-Response Relationship, Drug; Drug Delivery Systems; Female; Humans; Magnetic Resonance Imaging; Male; Mice; Nanoparticles; Neoplasms; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Staining and Labeling; Subcutaneous Tissue; Taxoids; Tissue Distribution; Treatment Outcome | 2012 |
[Support of hematological homeostasis during chemotherapy with taxanes].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Caproates; Docetaxel; Female; Fever; Follow-Up Studies; Homeostasis; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Protective Agents; Severity of Illness Index; Stomach Neoplasms; Taxoids; Tongue Neoplasms | 2011 |
Docetaxel and 5-fluorouracil induce human p53 tumor suppressor gene transcription via a short sequence at core promoter element.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Survival; Docetaxel; Fluorouracil; Genes, p53; Humans; Neoplasms; Promoter Regions, Genetic; Taxoids; Transcription, Genetic | 2012 |
Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Paclitaxel; Retrospective Studies; Smoking; Taxoids; Young Adult | 2012 |
Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Cell Line; Cricetinae; Docetaxel; Female; Genotype; Hepatocytes; Humans; Inactivation, Metabolic; Liver; Liver-Specific Organic Anion Transporter 1; Male; Mice; Mice, Knockout; Middle Aged; Neoplasms; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Polymorphism, Genetic; Solute Carrier Organic Anion Transporter Family Member 1B3; Taxoids | 2012 |
Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Binding Sites; Biological Availability; Caco-2 Cells; Cell Line, Tumor; Colchicine; Docetaxel; Dogs; Drug Interactions; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Indoles; Male; Mice; Mice, Inbred ICR; Mice, Nude; Neoplasms; Paclitaxel; Polymerization; Rats; Rats, Sprague-Dawley; Taxoids; Tubulin; Tubulin Modulators | 2012 |
Multimodality treatment of cancer with herceptin conjugated, thermomagnetic iron oxides and docetaxel loaded nanoparticles of biodegradable polymers.
Topics: Antibodies, Monoclonal, Humanized; Biocompatible Materials; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Docetaxel; Electricity; Ferric Compounds; Humans; Hyperthermia, Induced; Inhibitory Concentration 50; Magnetics; Nanoparticles; Neoplasms; Photoelectron Spectroscopy; Polyethylene Glycols; Succinates; Taxoids; Temperature; Trastuzumab | 2012 |
Personalising docetaxel and G-CSF schedules in cancer patients by a clinically validated computational model.
Topics: Adult; Aged; Aged, 80 and over; Computer Simulation; Docetaxel; Drug Administration Schedule; Granulocyte Colony-Stimulating Factor; Granulocytes; Humans; Middle Aged; Models, Biological; Neoplasms; Neutropenia; Reproducibility of Results; Taxoids | 2012 |
First trial tests targeted nanoparticles in patients.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Docetaxel; Humans; Nanoparticles; Neoplasms; Oncology Nursing; Taxoids | 2012 |
Involvement of hypothalamic cyclooxygenase-2, interleukin-1β and melanocortin in the development of docetaxel-induced anorexia in rats.
Topics: Animals; Anorexia; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Docetaxel; Hypothalamus; Indomethacin; Interleukin-1beta; Male; Neoplasms; Nitrobenzenes; Pro-Opiomelanocortin; Pyrazoles; Rats; Rats, Wistar; Sulfonamides; Taxoids | 2012 |
A docetaxel-carboxymethylcellulose nanoparticle outperforms the approved taxane nanoformulation, Abraxane, in mouse tumor models with significant control of metastases.
Topics: Albumin-Bound Paclitaxel; Albumins; Animals; Antineoplastic Agents; Carboxymethylcellulose Sodium; Cell Line, Tumor; Delayed-Action Preparations; Docetaxel; Female; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, SCID; Nanoparticles; Neoplasms; Paclitaxel; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
PEI-derivatized fullerene drug delivery using folate as a homing device targeting to tumor.
Topics: Administration, Intravenous; Animals; Apoptosis; Body Weight; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Delivery Systems; Endocytosis; Female; Folic Acid; Fullerenes; Humans; Male; Mice; Mice, Inbred BALB C; Neoplasms; Particle Size; Polyethyleneimine; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Taxoids; Tissue Distribution; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Intracellular delivery of docetaxel using freeze-dried polysaccharide nanocapsules.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chitosan; Docetaxel; Drug Delivery Systems; Freeze Drying; Humans; Nanocapsules; Neoplasms; Poloxamer; Taxoids | 2013 |
The multilayer nanoparticles formed by layer by layer approach for cancer-targeting therapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Carriers; Ferric Compounds; Gold; Male; Mice; Mice, Inbred C3H; Nanoparticles; Neoplasms; Particle Size; Poloxamer; Surface-Active Agents; Taxoids; Tumor Burden | 2013 |
Eccrine squamous syringometaplasia secondary to cutaneous extravasation of docetaxel: report of three cases.
Topics: Adult; Antineoplastic Agents; Docetaxel; Drug Eruptions; Female; Humans; Male; Metaplasia; Middle Aged; Neoplasms; Skin; Sweat Gland Diseases; Taxoids | 2013 |
Comparative transplacental transfer of taxanes using the human perfused cotyledon placental model.
Topics: Adult; Antineoplastic Agents; Docetaxel; Female; Humans; Maternal-Fetal Exchange; Neoplasms; Paclitaxel; Placenta; Pregnancy; Taxoids | 2012 |
The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance).
Topics: Adult; Aged; Antineoplastic Agents; Docetaxel; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasms; Neutropenia; Organic Anion Transporters, Sodium-Independent; Pharmacogenetics; Polymorphism, Single Nucleotide; Retrospective Studies; Solute Carrier Organic Anion Transporter Family Member 1B3; Taxoids; Tissue Distribution | 2013 |
Self-assembled methoxy poly(ethylene glycol)-cholesterol micelles for hydrophobic drug delivery.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cholesterol; Docetaxel; Drug Carriers; Drug Delivery Systems; Humans; Hydrophobic and Hydrophilic Interactions; Micelles; Neoplasms; Polyethylene Glycols; Taxoids | 2013 |
Raman spectroscopic imaging for the real-time detection of chemical changes associated with docetaxel exposure.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Docetaxel; Humans; Neoplasms; Spectrum Analysis, Raman; Taxoids; Time Factors | 2013 |
Polypeptide cationic micelles mediated co-delivery of docetaxel and siRNA for synergistic tumor therapy.
Topics: Animals; Antineoplastic Agents; Cations; Cell Proliferation; Colloids; Docetaxel; Drug Delivery Systems; Gene Expression Regulation, Neoplastic; Gene Transfer Techniques; Humans; Magnetic Resonance Spectroscopy; MCF-7 Cells; Mice; Mice, Inbred BALB C; Micelles; Nanoparticles; Neoplasms; Peptides; Polymers; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Small Interfering; Taxoids; Tissue Distribution; Transfection | 2013 |
The current status of docetaxel in solid tumors. An M. D. Anderson Cancer Center Review.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoadjuvant Therapy; Neoplasms; Paclitaxel; Taxoids | 2002 |
Nonneutropenic febrile episodes associated with docetaxel-based chemotherapy in patients with solid tumors.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Candidiasis; Cytomegalovirus Infections; Docetaxel; Fever; Herpesviridae Infections; Humans; Infections; Lung Diseases; Lymphopenia; Neoplasms; Paclitaxel; Pneumonia, Pneumocystis; Prospective Studies; T-Lymphocytopenia, Idiopathic CD4-Positive; Taxoids | 2002 |
Mobilization of dendritic cells in cancer patients treated with granulocyte colony-stimulating factor and chemotherapy.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Dendritic Cells; Docetaxel; Epirubicin; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Leukapheresis; Leukocyte Count; Leukocytes, Mononuclear; Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 2002 |
Measurement of volumetric and vascular changes with dynamic contrast enhanced MRI for cancer therapy monitoring.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Contrast Media; Docetaxel; Female; Gadolinium; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms; Paclitaxel; Radiography; Rats; Rats, Inbred F344; Taxoids; Time Factors; Treatment Outcome | 2002 |
Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Chromatography, Liquid; Docetaxel; Half-Life; Humans; Infusions, Intravenous; Mass Spectrometry; Models, Biological; Neoplasms; Paclitaxel; Reproducibility of Results; Specimen Handling; Taxoids; Time Factors | 2003 |
Predictive cancer genomics--what do we need?
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Screening Assays, Antitumor; Female; Gene Expression Regulation, Neoplastic; Genomics; Humans; Neoadjuvant Therapy; Neoplasms; Oligonucleotide Array Sequence Analysis; Paclitaxel; Sequence Analysis, DNA; Taxoids | 2003 |
Inhibitory effects of docetaxel on expression of VEGF, bFGF and MMPs of LS174T cell.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Docetaxel; Endothelial Growth Factors; Fibroblast Growth Factor 2; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Blood Proteins; Chemistry, Pharmaceutical; Docetaxel; Excipients; Female; Humans; Infusions, Intravenous; Linear Models; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Orosomucoid; Paclitaxel; Polysorbates; Taxoids | 2003 |
C225 antiepidermal growth factor receptor antibody enhances the efficacy of docetaxel chemoradiotherapy.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Docetaxel; Drug Synergism; Female; Humans; Mice; Mice, Nude; Neoplasms; Radiation-Sensitizing Agents; Taxoids; Transplantation, Heterologous | 2004 |
Effects of paclitaxel and docetaxel on EGFR-expressing human carcinoma cells under normoxic versus hypoxic conditions in vitro.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Hypoxia; Male; Neoplasms; Paclitaxel; Probability; Reference Values; Sensitivity and Specificity; Taxoids; Tumor Cells, Cultured | 2004 |
Relationship of systemic exposure to unbound docetaxel and neutropenia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Area Under Curve; Docetaxel; Female; Humans; Liver Function Tests; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Severity of Illness Index; Taxoids | 2005 |
Role of cytochrome P450 phenotyping in cancer treatment.
Topics: Antineoplastic Agents, Phytogenic; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Docetaxel; Humans; Neoplasms; Phenotype; Taxoids | 2005 |
Effects of docetaxel on antigen presentation-related functions of human monocyte-derived dendritic cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Survival; Dendritic Cells; Docetaxel; Dose-Response Relationship, Drug; Humans; Immunotherapy; Microtubules; Monocytes; Neoplasms; Phagocytosis; Taxoids | 2005 |
NHS76/PEP2, a fully human vasopermeability-enhancing agent to increase the uptake and efficacy of cancer chemotherapy.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Capillary Permeability; Cell Line, Tumor; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Fluorouracil; Humans; Injections, Intravenous; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Paclitaxel; Peptide Fragments; Taxoids; Time Factors; Tissue Distribution; Treatment Outcome; Vinblastine; Xenograft Model Antitumor Assays | 2005 |
Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Docetaxel; Doxorubicin; Drug Synergism; Genistein; Humans; Lung Neoplasms; Male; Neoplasms; NF-kappa B; Pancreatic Neoplasms; Prostatic Neoplasms; Taxoids | 2005 |
Quantification of [3H]docetaxel in feces and urine: development and validation of a combustion method.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Feces; Humans; Infusions, Intravenous; Neoplasms; Reproducibility of Results; Scintillation Counting; Taxoids; Tritium | 2006 |
Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: preclinical evaluation of chemovirotherapy.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Colorectal Neoplasms; Docetaxel; Drug Carriers; Esophageal Neoplasms; Feasibility Studies; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasms; Polymerase Chain Reaction; Stomach Neoplasms; Taxoids; Telomerase; Transplantation, Heterologous; Vinblastine; Vinorelbine | 2006 |
Pharmacokinetics and pharmacodynamics of protein-unbound docetaxel in cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Blood Proteins; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Taxoids | 2006 |
Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Disease Models, Animal; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Gene Expression Profiling; Humans; Mice; Mice, Nude; Neoplasms; Oligodeoxyribonucleotides, Antisense; Oligonucleotides; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sensitivity and Specificity; Structure-Activity Relationship; Taxoids; TNF-Related Apoptosis-Inducing Ligand; Transplantation, Heterologous; X-Linked Inhibitor of Apoptosis Protein; Xenograft Model Antitumor Assays | 2006 |
Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Docetaxel; Female; Genotype; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Metastasis; Neoplasms; Organic Anion Transporters; Pharmacogenetics; Polymorphism, Genetic; Taxoids | 2006 |
Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Cytochrome P-450 CYP3A; Docetaxel; Female; Ferritins; Humans; Lymphocyte Count; Male; Midazolam; Middle Aged; Neoplasms; Neutropenia; Prospective Studies; Radiation-Sensitizing Agents; Risk Factors; Taxoids | 2007 |
Dexamethasone as a probe for CYP3A4 metabolism: evidence of gender effect.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dexamethasone; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasms; Prospective Studies; Sex Factors; Taxoids | 2007 |
Influence of ketoconazole on the fecal and urinary disposition of docetaxel.
Topics: Administration, Oral; Adult; Aged; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Docetaxel; Feces; Female; Humans; Ketoconazole; Male; Middle Aged; Neoplasms; Taxoids; Tritium | 2007 |
Grb2-SH3 ligand inhibits the growth of HER2+ cancer cells and has antitumor effects in human cancer xenografts alone and in combination with docetaxel.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Female; GRB2 Adaptor Protein; Humans; Ligands; Male; Mice; Mice, Nude; Molecular Sequence Data; Neoplasms; Oligopeptides; Receptor, ErbB-2; Signal Transduction; src Homology Domains; Taxoids; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2007 |
Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Biomarkers, Tumor; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Insulin-Like Growth Factor Binding Protein 2; Lactams, Macrocyclic; Male; Mice; Neoplasms; Receptor, ErbB-2; Taxoids | 2007 |
Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Cannabinoids; Cytochrome P-450 CYP3A; Docetaxel; Drug Interactions; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Statistics, Nonparametric; Taxoids | 2007 |
Combination silencer RNA (siRNA) targeting Bcl-2 antagonizes siRNA against thymidylate synthase in human tumor cell lines.
Topics: Cell Line, Tumor; Cell Proliferation; Docetaxel; Floxuridine; G1 Phase; Humans; Neoplasms; Proto-Oncogene Proteins c-bcl-2; Quinazolines; RNA, Messenger; RNA, Small Interfering; Taxoids; Thiophenes; Thymidylate Synthase | 2007 |
Limited tissue penetration of taxanes: a mechanism for resistance in solid tumors.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Humans; Mice; Mice, Inbred Strains; Neoplasms; Paclitaxel; S Phase; Taxoids; Xenograft Model Antitumor Assays | 2007 |
Increased expression of cyclin B1 sensitizes prostate cancer cells to apoptosis induced by chemotherapy.
Topics: 2-Methoxyestradiol; Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Line, Tumor; Cyclin B; Cyclin B1; Docetaxel; Estradiol; Gene Expression Regulation, Neoplastic; Humans; Male; Mitosis; Neoplasms; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Taxoids | 2007 |
A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Black or African American; Black People; Cohort Studies; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasms; Organic Anion Transporters; Taxoids; White People; Xenobiotics | 2007 |
Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells.
Topics: 5'-Nucleotidase; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Cytarabine; Cytosine; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Equilibrative Nucleoside Transporter 1; Gemcitabine; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Inhibitory Concentration 50; Molecular Structure; Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Taxoids | 2007 |
Impact of hypoxic and acidic extracellular conditions on cytotoxicity of chemotherapeutic drugs.
Topics: Acidosis; Animals; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Daunorubicin; Docetaxel; Extracellular Space; Humans; Hydrogen-Ion Concentration; Hypoxia; Neoplasms; Rats; Taxoids | 2007 |
Population pharmacokinetic and pharmacodynamic analysis for time courses of docetaxel-induced neutropenia in Japanese cancer patients.
Topics: Adult; Antineoplastic Agents; Docetaxel; Humans; Infusions, Intravenous; Japan; Kinetics; Models, Biological; Neoplasms; Neutropenia; Reproducibility of Results; Taxoids | 2007 |
AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Docetaxel; Hepatocyte Growth Factor; Humans; Mice; Mice, Inbred Strains; Neoplasms; Taxoids; Temozolomide; Xenograft Model Antitumor Assays | 2007 |
Logistic regression analysis for febrile neutropenia (FN) induced by docetaxel in Japanese cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Data Interpretation, Statistical; Docetaxel; Female; Fever; Humans; Japan; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoplasms; Neutropenia; Taxoids | 2008 |
Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chitosan; Docetaxel; Drug Carriers; Drug Stability; Humans; Hydrophobic and Hydrophilic Interactions; Male; Mice; Mice, Nude; Nanoparticles; Neoplasms; Particle Size; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays | 2008 |
ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Cisplatin; DNA-Binding Proteins; Docetaxel; Drug Screening Assays, Antitumor; Endonucleases; Exudates and Transudates; Humans; Neoplasms; RNA, Messenger; Taxoids | 2008 |
In the clinic: where paclitaxel and docetaxel stand.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1995 |
Docetaxel (Taxotere): a new anti-cancer drug with promising potential?
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1994 |
Clinical trials referral resource. Clinical trials with Docetaxel (Taxotere).
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1993 |
Docetaxel: current status and future prospects.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Forecasting; Humans; Lung Neoplasms; Neoplasms; Paclitaxel; Taxoids | 1995 |
Taxoids: new weapons against cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Microtubules; Molecular Structure; Neoplasms; Ovarian Neoplasms; Paclitaxel; Phytotherapy; Taxoids; Trees | 1996 |
Use caution when managing paclitaxel and taxotere infiltrations.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Drug Eruptions; Humans; Infusions, Intravenous; Neoplasms; Nursing Assessment; Paclitaxel; Taxoids | 1996 |
Cancer treatments rationed by authority.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Drug Costs; England; Health Care Rationing; Humans; Neoplasms; Paclitaxel; Taxoids | 1996 |
Plasma concentrations of polysorbate 80 measured in patients following administration of docetaxel or etoposide.
Topics: Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Polysorbates; Surface-Active Agents; Taxoids | 1997 |
Paclitaxel hypersensitivity reactions: a role for docetaxel substitution.
Topics: Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Hypersensitivity; Female; Glycerol; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 1998 |
Evaluation of the linearity of docetaxel pharmacokinetics.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials, Phase I as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1998 |
Compilation of phase I and II trial data of docetaxel and doxorubicin in the treatment of advanced breast cancer and other malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Neoplasms; Paclitaxel; Taxoids | 1998 |
Continual reassessment methods in phase I trials of the combination of two drugs in oncology.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Camptothecin; Clinical Trials, Phase I as Topic; Computer Simulation; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Humans; Irinotecan; Likelihood Functions; Neoplasms; Neutropenia; Paclitaxel; Retrospective Studies; Taxoids | 1999 |
Taxing the taxanes: overused or undersold?
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Synergism; Estramustine; Female; Humans; Neoplasms; Ovarian Neoplasms; Paclitaxel; Taxoids | 1999 |
Liquid chromatographic analysis and preliminary pharmacokinetics of methotrexate in cancer patients co-treated with docetaxel.
Topics: Acetone; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemical Precipitation; Chromatography, High Pressure Liquid; Docetaxel; Humans; Hydroxylation; Kinetics; Methanol; Methotrexate; Neoplasms; Paclitaxel; Rats; Rats, Wistar; Sensitivity and Specificity; Taxoids | 1999 |
Possible metabolic interaction between docetaxel and ifosfamide.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Humans; Ifosfamide; Liver; Microsomes; Neoplasms; Paclitaxel; Taxoids | 2000 |
Cytochrome P-450 and other determinants of pharmacokinetics, toxicity, and efficacy in humans.
Topics: Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; Breath Tests; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Docetaxel; Erythromycin; Humans; Neoplasms; Oxidoreductases, N-Demethylating; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
Cytotoxic effects of topotecan combined with various active G2/M-phase anticancer drugs in human tumor-derived cell lines.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Bleomycin; Cell Cycle; Cell Survival; Docetaxel; Drug Interactions; Enzyme Inhibitors; Humans; Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 2000 |
Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzazepines; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Daunorubicin; Docetaxel; Drug Resistance, Multiple; Feces; Half-Life; Humans; Intestinal Mucosa; Metabolic Clearance Rate; Mixed Function Oxygenases; Neoplasms; Paclitaxel; Quinolines; Taxoids; Tumor Cells, Cultured | 2000 |
Docetaxel-induced lymphopenia in patients with solid tumors: a prospective phenotypic analysis.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Female; Humans; Immunophenotyping; Infections; Lymphocyte Count; Lymphocyte Subsets; Lymphocytes; Lymphopenia; Male; Middle Aged; Neoplasms; Neutropenia; Neutrophils; Paclitaxel; Prospective Studies; Taxoids | 2000 |
Cellular immune profile of patients with advanced cancer before and after taxane treatment.
Topics: Aged; Antineoplastic Agents, Phytogenic; Cytokines; Cytotoxicity, Immunologic; Docetaxel; Female; Humans; Immunity, Cellular; Immunophenotyping; Killer Cells, Lymphokine-Activated; Killer Cells, Natural; Lymphocyte Activation; Lymphocyte Subsets; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2000 |
Highlights of the Eighth European Cancer Conference.
Topics: Amifostine; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Docetaxel; Head and Neck Neoplasms; Humans; Irinotecan; Neoplasms; Paclitaxel; Radiation Injuries; Radiation-Protective Agents; Taxoids; Vinblastine; Vinorelbine | 1995 |
Clinical significance of plasma nucleosome levels in cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Docetaxel; Enzyme-Linked Immunosorbent Assay; Female; Humans; Leukocyte Count; Male; Mastectomy; Middle Aged; Neoplasms; Nucleosomes; Paclitaxel; Receptors, Estrogen; Receptors, Progesterone; Taxoids | 2001 |
Evaluating new treatments for advanced cancer.
Topics: Antineoplastic Agents; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2001 |
Pharmacokinetics of oral cyclosporin A when co-administered to enhance the absorption of orally administered docetaxel.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Area Under Curve; Cyclosporine; Docetaxel; Drug Interactions; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2001 |
Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv.
Topics: Animals; Antineoplastic Agents, Phytogenic; DNA Primers; Docetaxel; Enzyme-Linked Immunosorbent Assay; Female; Gene Targeting; Genetic Therapy; Genetic Vectors; Humans; Liposomes; Male; Mice; Mice, Nude; Neoplasms; Paclitaxel; Polymerase Chain Reaction; Receptors, Transferrin; Taxoids; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2001 |
Technology evaluation: G-3139.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cancer Care Facilities; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Dacarbazine; Docetaxel; Female; Genes, bcl-2; Genetic Therapy; Humans; Male; Mice; Mice, Inbred BALB C; National Institutes of Health (U.S.); Neoplasm Proteins; Neoplasms; Paclitaxel; Patents as Topic; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Neoplasm; Safety; Structure-Activity Relationship; Taxoids; Thionucleotides; Treatment Outcome; United States | 1999 |
Future treatment options with capecitabine in solid tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Fluorouracil; Forecasting; Humans; Irinotecan; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Taxoids | 2002 |
New highly active taxoids from 9 beta-dihydrobaccatin-9,10-acetals.
Topics: Acetals; Antineoplastic Agents; Docetaxel; Drug Screening Assays, Antitumor; Humans; Neoplasms; Paclitaxel; Structure-Activity Relationship; Taxoids; Tumor Cells, Cultured | 2002 |
Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Biological Availability; Cohort Studies; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Female; Follow-Up Studies; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel; Quinolines; Taxoids | 2002 |
Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometry.
Topics: Antineoplastic Agents, Phytogenic; Calibration; Docetaxel; Humans; Neoplasms; Paclitaxel; Pharmaceutical Vehicles; Polysorbates; Reproducibility of Results; Sensitivity and Specificity; Taxoids | 2002 |
Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model.
Topics: Absorption; Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Docetaxel; Dose-Response Relationship, Drug; Injections, Intraperitoneal; Injections, Intravenous; Male; Models, Animal; Neoplasms; Paclitaxel; Rats; Rats, Sprague-Dawley; Taxoids; Tissue Distribution | 2002 |
Chemists vie to make a better taxol.
Topics: Alkaloids; Docetaxel; Drug Design; Neoplasms; Paclitaxel; Taxoids | 1992 |
Effects of Taxotere on murine and human tumor cell lines.
Topics: Alkaloids; Animals; Cell Division; DNA; Docetaxel; Drug Resistance; Humans; Leukemia P388; Mice; Molecular Structure; Neoplasms; Paclitaxel; Protein Biosynthesis; RNA; Taxoids; Tumor Cells, Cultured | 1992 |